Genetic and Dietary Determinants of Homocysteine in Relation to Bone Health by Yazdan Panah, N. (Nahid)
Genetic and Dietary Determinants of 
Homocysteine in Relation to Bone Health
Nahid Yazdan Panah
Nahid BW.indd   1 31-Oct-07   15:31:16 PM
Acknowledgements
The work presented in this thesis was conducted at the Department of Internal 
Medicine, Department of Clinical Chemistry and Departments of Epidemiology & 
Biostatistics, Erasmus Medical Center, Rotterdam, The Netherlands.
The studies described in this thesis were supported the Netherlands Organization 
for Scientifi c Research grant (NOW 903-46-178) and the European Commission under 
grant “GENOMOS” (OLK6-CT-2002-02629).
The Rotterdam Study is supported by the Erasmus Medical Center and Erasmus 
University Rotterdam, the Netherlands Organization for Scientifi c Research (NWO), 
the Netherlands Organization for Health Research and Development (ZonMw), the 
Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, 
Culture and Science, the Ministry of Health, Welfare and Sports, the European Com-
mission (DG XII), the Municipality of Rotterdam.
The outstanding contributions of the general practitioners and pharmacists of the 
Ommoord district to the Rotterdam Study are greatly appreciated.
ISBN: 978-90-8559-331-1
Cover: Tree of Knowledge, Mojgan Yazdan Panah, 2007 
Layout and printing: Optima Grafi sche Communicatie, Rotterdam, The Netherlands
Nahid BW.indd   2 31-Oct-07   15:31:17 PM
Genetic and Dietary Determinants of 
Homocysteine in Relation to Bone Health
Genetische en dieetgerelateerde determinanten van 
homocysteïne in relatie tot de conditie van het bot
Proefschrift
ter verkrijging van de graad van Doctor aan de
Erasmus Universiteit Rotterdam
op gezag van de rector magnifi cus
Prof.dr. S.W.J. Lamberts
en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op
woensdag 5 december 2007 om 11.45 uur
door
Nahid Yazdan Panah
geboren te Teheran, Iran
Nahid BW.indd   3 31-Oct-07   15:31:17 PM
Promotiecommissie
Promotoren : Prof.dr. H.A.P. Pols
  Prof.dr. J.Lindemans
Overige leden : Prof.dr. P. Lips
  Prof.dr. C.M. van Duijn
  Prof.dr. C.P.G.M. de Groot
Copromotor : Dr. J.B.J. van Meurs
Nahid BW.indd   4 31-Oct-07   15:31:17 PM
All we know is still infi nitely less than all 
that remains unknown.
William Harvey (1578-1657)
To my beloved mother,
 and to the loving memory of my father
Nahid BW.indd   5 31-Oct-07   15:31:17 PM
Nahid BW.indd   6 31-Oct-07   15:31:17 PM
C
o
n
te
n
ts
7
CONTENTS
Chapter 1 General Introduction 11
Chapter 2 The association between homocysteine and related B 
vitamins with osteoporosis: a systematic review and meta-
analysis
29
Chapter 3 The effect of dietary B vitamins on BMD and risk of 
fracture in elderly men and women: The Rotterdam Study
53
Chapter 4 The association between polymorphisms involved in 
homocysteine remethylation with bone phenotypes
4.1 Low dietary ribofl avin but not folate predicts increased 
fracture risk in postmenopausal women homozygous for 
the MTHFR 677TT allele
73
4.2 Association of Methionine synthase A 2756G polymorphism 
with low dietary cobalamin intake and osteoporosis in 
elderly Caucasian
93
Chapter 5 Genetic and dietary determinants of homocysteine levels in 
elderly Caucasians
107
Chapter 6 Gene polymorphisms determining bone phenotypes
The -1997 G/T and the Sp1 polymorphisms in the Collagen 
Type I alpha 1 (COLIA1) gene in relation to changes in 
femoral neck BMD and the risk of fracture in the elderly: 
The Rotterdam Study
125
Chapter 7 General discussion 139
Summary Summary/Samenvatting 161
Acknowledgments 167
Curriculum Vitae 171
List of publications 173
Nahid BW.indd   7 31-Oct-07   15:31:18 PM
Nahid BW.indd   8 31-Oct-07   15:31:18 PM
M
an
u
sc
ri
p
ts
9
Publications and manuscripts based on the studies described in 
this thesis 
Chapter 2
Nahid Yazdanpanah, André G. Uitterlinden, Jan Lindemans, Huibert A.P. Pols, John 
P. A. Ioannidis, and Joyce B.J. van Meurs. The association between homocysteine, 
related B vitamins and bone health: a systematic review and meta-analysis.
To be submitted.
Chapter 3
Nahid Yazdanpanah, M. Carola Zillikens, Fernando Rivadeneira, Robert de Jong, Jan 
Lindemans, André G. Uitterlinden, Huibert A.P. Pols, Joyce B.J. van Meurs. Effect 
of dietary B vitamins on BMD and risk of fracture in elderly men and women: The 
Rotterdam Study.
Bone. In press
Chapter 4.1
Nahid Yazdanpanah, André G. Uitterlinden, M. Carola Zillikens, Mila Jhamai, Fernan-
do Rivadeneira, Albert Hofman, Robert de Jonge, Jan Lindemans, Huibert A.P. Pols, 
and Joyce B.J. van Meurs. Low dietary ribofl avin but not folate predicts increased 
fracture risk in postmenopausal women homozygous for the MTHFR TT allele.
J Bone Miner Res. 2007 In press.
Chapter 4.2
Nahid Yazdanpanah André G. Uitterlinden, Fernando Rivadeneira, Jan Lindemans, 
Huibert A.P. Pols, and Joyce B.J. van Meurs. Association of Methionine synthase 
A2756G polymorphism with low dietary cobalamin intake and osteoporosis in el-
derly Caucasian men and women.
To be submitted.
Chapter 5
Nahid Yazdanpanah, André G Uitterlinden, Fernando Rivadeneira, Monique M.B. 
Breteler, Jan Lindemans, Robert De Jong, Huibert AP Pols, Joyce B.J. van Meurs. 
Genetic and dietary determinants of homocysteine levels in elderly Caucasians.
To be submitted.
Chapter 6
Nahid Yazdanpanah, Fernando Rivadeneira, Joyce B.J. van Meurs, M Carola. Zil-
likens, Pascal P. Arp, Albert Hofman, Cornelia.M. van Duijn, Huibert A P. Pols, André 
Nahid BW.indd   9 31-Oct-07   15:31:18 PM
Manuscripts10
G. Uitterlinden. The -1997 G/T and Sp1 polymorphisms in the collagen type I alpha1 
(COLIA1) gene in relation to changes in femoral neck bone mineral density and the 
risk of fracture in the elderly: the Rotterdam study.
Calcif Tissue Int. 2007 Jul;81(1):18-25. Epub 2007 Jun 7.
Nahid BW.indd   10 31-Oct-07   15:31:18 PM
CHAPTER 1
General Introduction
Nahid BW.indd   11 31-Oct-07   15:31:18 PM
Nahid BW.indd   12 31-Oct-07   15:31:21 PM
C
h
ap
te
r 
1
13
Osteoporosis is characterized by low bone mineral density (BMD), and deterioration 
of the bone microarchitecture leading to an increased risk of fracture 1. Osteoporotic 
fractures are a major health problem in the western society; they are associated 
with increased morbidity and mortality and with substantial economic costs. In the 
coming years, the number of fractures will increase throughout the world as the 
population ages, so prevention of fractures with inexpensive and well-established 
interventions is becoming increasingly important.
Determinants of osteoporosis
Several studies have investigated risk factors for incident fractures, with most of the 
studies focusing on hip fractures 2. One of the most important risk factors for incident 
fractures is a low BMD 3. With decreasing BMD, the risk of an incident fracture 
increases rapidly, both in men and women. Besides BMD, the most important risk 
factors for fractures are age, female gender, low body weight, a personal history of 
prior fractures and a family history of fractures.
Evidence from twin and family studies indicates that genetic factors play an im-
portant role in the regulation of BMD and other skeletal phenotypes relevant to the 
pathogenesis of fragility fractures. For example, the heritability of BMD at the spine 
and hip has been estimated to lie between 70 and 85% 4-6. Many gene polymorphisms 
have been proposed to be involved in BMD 7. One of the most prominent candidate 
genes, which has been associated with osteoporosis in different populations is the 
collagen type I Alpha 1 gene 8, which encodes the alpha chain of collagen type 
I. COL1AI is the most abundant structural protein in the bone matrix. One of the 
most widely studied polymorphisms in the COL1AI gene is the Sp1 binding site 
polymorphism. This polymorphism has been examined for its association with BMD 
and osteoporotic fracture in several studies, but the results have been confl icting. 
This polymorphism was also studied in the Genetic Markers for Osteoporosis 9 Study 
(GENOMOS), which is Eu-sponsored collaborative effort to identify genetic variants 
for osteoporosis. In a total sample of 20,786 subjects, GENOMOS found a very 
modest association between the Sp1 polymorphism and incident risk of vertebral 
fractures mainly in the TT homozygotes 9. In the work presented in this thesis, 
we have attempted to clarify the association of this polymorphism in relation to 
another nearby polymorphism with BMD and osteoporotic fracture in the Rotterdam 
Study 10.
Recently, a new and potentially modifi able biochemical risk factor for osteoporotic 
fracture was identifi ed: a mildly increased circulating homocysteine level 11,12. These 
observational studies showed that a relatively high Hcy level predicts a higher frac-
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ture risk, independent of other known risk factors for fracture. Since this fi nding, 
numerous studies have investigated different nutritional determinants of Hcy, i.e., 
the vitamins B11 (folate), B6 (pyridoxine), B12 (cobalamin), and/or genetic poly-
morphisms involved in the Hcy metabolism. The overall results from these studies 
are inconclusive. In Chapter 2 we performed a systematic review and meta-analysis 
on studies that investigated the association of Hcy and related B vitamins with os-
teoporosis.
Homocysteine metabolism
Homocysteine is a highly reactive amino-acid, which is produced as an intermediate 
in the metabolism of methionine. The biochemistry of Hcy and related pathways, 
also referred to as the one-carbon metabolism, is illustrated in Figure 1. As shown, 
the control of the methionine metabolism is complex, as a result of the very basic 
and important need to satisfy the requirements of the individual for protein synthesis, 
DNA synthesis and methylation of DNA, RNA and proteins.
THF
Vit-B12
METHIONINE
cystathionine
Vit-B6
HOMOCYSTEINE
cysteine
SAH
SAM
betaine
DMG
5-CH3THF
5,10-CH2THF
Methyl-group
DNA 
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THYMS
MTRR/MTR
SAHH
CBS
Vitamin B11/Folate 
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Figure 1: Summary of homocysteine metabolism and relevant enzymes (boxed) and cofactors 
(circled) SAHH:s-adenosylhomocysteine hydrolase, CBS:cystathionine β-synthase, MTR: methionine 
synthase; MTRR: methionine synthase reductase, MTHFR:methylenetetrahydro folate reductase, 
MTHFD: methylenetetrahydro folate dehydrogenase,THYMS: thymidylate synthase, RFC1: reduced 
folate carrier, THF: terahydrofolate
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Methionine is fi rst converted to its active form S-adenosylmethionine (SAM). This 
converts to S-adenosyl-homocysteine (SAH) by donating a methyl group for cel-
lular methylation, and is then hydrolysed to Hcy. Further metabolism of Hcy occurs 
through two pathways: transsulfuration to cysteine, or remethylation to methionine. 
Several B vitamins are important for Hcy metabolism (Table 1): transsulfuration is 
dependent on vitamin B6 (pyridoxine), while remethylation is dependent on vitamin 
B11 (folate), vitamin B2 (ribofl avin) and B12 (cobalamin). Remethylation of Hcy 
is performed by methionine synthase (MTR), and methionine synthase reductase 
(MTRR) is necessary to keep MS in its activation form. Cystathionine β synthase 
(CBS) is essential for transulfuration of Hcy.
Defi ciencies in a number of essential enzymes in the one-carbon metabolism 
causes the rare (frequency:1/344000) classical metabolic disorder homocysteinuria 
which is characterized by very high Hcy levels (>200 μmol/l) 13. In addition to mental 
retardation and thromboembolic events, this metabolic disorder is characterized by 
symptoms related to connective tissue such as subluxation of the ocular lens, genu 
valgum, pes cavus, long extremities and early osteoporosis. If untreated, 80% of the 
patients will develop osteoporosis by the age of 30 years 13.
Determinants of homocysteine level
Determinants of plasma Hcy in the normal population include genetic, nutritional, 
and lifestyle factors, but also different disease conditions and certain drugs can affect 
the Hcy metabolism 14-18. Many of these factors cause a change in Hcy concentrations 
thereby infl uencing enzyme activity or modifying the function or blood concentra-
tions of the B vitamins involved in the Hcy metabolism.
Suboptimal nutritional status is acknowledged to result in moderately elevated Hcy 
levels (hyperhomocysteinemia) which is prevalent in approximately 19% of people 
older than 60 years 19. Elderly are at high risk for developing hyperhomocysteinemia, 
because especially in this group nutrition is often suboptimal, while absorption of 
certain nutrients is also impaired. For example, vitamin B12 defi ciency is present 
Table 1. B vitamins involved in homocysteine metabolism
Name Code Present in
Ribofl avin B2 Milk and other dairy products, enriched bread, cereal and other grain products; 
eggs, meat, green leafy vegetables, nuts, liver, kidney, and heart
pyridoxine B6 chicken, fi sh, pork, liver, kidney, whole grains, nuts and legumes
Folate B11 leafy vegetables, orange juice and some fruits, legumes, liver, yeast breads, wheat 
germ and some fortifi ed cereals
Cobalamin B12 Animal products and some fortifi ed foods
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in 20-25% of the Dutch elderly population 20 mainly due to malabsorption. Dietary 
determinants of Hcy levels include the B vitamins (B2, 6, 12, and folate), but also 
betaine, choline and protein intakes.
Hcy levels are strongly determined by genetic variation, and studies have sug-
gested a high heritability (47-57%) for Hcy levels 21,22. Therefore, Hcy concentrations 
are determined by environmental and genetic factors and the interaction between 
the two. In healthy well-nourished individuals the Hcy metabolism is well regulated 
and the plasma concentration is usually less than 12 µM. However, genetic variants 
and/ or nutritional defi ciencies lead to elevation of the levels of Hcy.
Genetic determinants of homocysteine
Table 2 shows the best characterized genetic variants in the Hcy metabolism at the time 
the work on this thesis was started. The most widely studied polymorphism in the Hcy 
metabolism is the MTHFR C677T (Ala222Val), which has been identifi ed as an impor-
tant determinant of Hcy levels 23. It is established that both vitamin B2 and folate play 
a critical role in modulating the Hcy level of 222 ValVal homozygotes 24,25. A second 
variant in this gene, the A1298C polymorphism (Glu429Ala) 26, was found associated 
with decreased enzyme activity together with the MTHFR 222ValVal homozygous 27. 
No effect of this variant alone on Hcy was observed 28,29, except for one study which 
reported increased Hcy in 429AlaAla compared to 429Glu carriers individuals 30.
Table 2. Genetic variants studied for their effect on plasma homocysteine levels
Gene name
 
Chromo-
somal 
location
Variant Amino acid
substitution
Abbre-
viation
Risk 
allele fre-
quency
Effect on Hcy level
Methylenetetrahydrofo-
late reductase
1p36.3 C677T Ala222Val MTHFR T=0.33 Increased 81, 82
Methylenetetrahydrofo-
late reductase
1p36.3 A1298C Glu429Ala MTHFR C=0.32 No effect 28, 29
Methionine synthase 1q43 A2756G Asp919Gly MTR G=0.17 Decreased- no effect-32, 33, 81, 83
Methionine synthase 
reductase
5p15.31 A66G Ile22Met MTRR G=0.43 Increased- no effect 35, 36
Reduced folate carrier 21q22.3 G80A Arg27His RFC1 A=0.40 Decreased- no effect- 38
Transcobalamin 22q12.2 C776G Pro259Arg TCN G=0.45 Increased- no effect 39, 40
Thymidylate Synthase 18p11.32 28bp 28 bp 
repeat3R/2R
THYMS 3R=0.52 No effect, interaction with 
MTHFR C677T
cystathionine 
β-synthase
21q22.3 844ins68 68-bp insertion CBS 2=0.10 Increased- no effect 44
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Both methionine synthase (MTR) and methionine synthase reductase (MTRR) 
enzymes are involved in Hcy remethylation, and the common MTR A2756G (As-
p919Gly) and MTRR A66G (Ile22Met) variants were found to be associated with 
Hcy. Several studies reported that the MTR 919GlyGly genotype was associated with 
higher Hcy levels 31-33. The MTRR A66G variant was fi rst described by Leclerc et al. 34. 
There are also several studies that could not show this, so results are inconclusive. 
In vitro studies showed that this transition mildly decreases enzyme activity 35, but 
only one study showed the MTRR A66G polymorphism to be a determinant of Hcy 
in the general population 36.
The reduced folate carrier RFC1 protein is involved in cellular uptake of reduced 
folate. The variant G80A (Arg27His) is thought to affect carrier function 37. Chango et 
al. found a trend towards higher Hcy in 27ArgArg individuals, which increased and 
inversely affected RBC folate in the MTHFR 222ValVal individuals 38.
Transcobalamin (TCN) is essential in the cellular uptake of vitamin B12. Vitamin 
B12 binds to TCN which accounts for 10-20% of the total cellular B12 uptake. Several 
polymorphisms have been identifi ed in the TCN gene, including a C776G (Pro259Arg) 
transition which results in an altered binding of vitamin B12 39. Heterozygosity for 
this variant was associated with signifi cantly higher Hcy compared with both ho-
mozygous genotypes 40.
Thymidine synthase (THYMS) catalyzes the reductive methylation and competes 
with MTHFR for the one-carbon unit of 5,10-methylenTHF. One of the polymorphisms 
in this enzyme is a 28-bp repeat in the 5’ UTR (resulting in the common genotypes 
2/2, 2/3, 3/3) 41. In a Chinese population, reduced plasma folate and increased Hcy 
levels were found in 3/3 individuals; this effect became more pronounced in MTHFR 
222ValVal individuals 42.
Homocysteine is irreversibly converted by CBS to cystationine, which is the fi rst 
step in the transulfuration of Hcy. The CBS gene harbors many polymorphisms, 
including a common 68 bp insertion (844ins68) 43. De Stefano et al. reported that this 
polymorphism, although by itself having no effect on Hcy level, did seem to abolish 
the Hcy raising effect of homozygosity for the MTHFR 222ValVal individuals 44.
Most of the described polymorphisms, (except for the MTHFR Ala222Val variant), 
have been studied sporadically and have yielded inconclusive results. This could 
partly be due to the small sample size of most of the studies, while many studies 
also ignore gene-gene and gene-environment interaction. Since we expect relatively 
modest effect sizes for each individual polymorphism (according to the common 
variant – common disease hypothesis), large sample sizes are needed to study this 
properly.
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Homocysteine and disease associations
Increased Hcy levels have been linked to the risk for a wide range of adverse 
health conditions throughout life, from birth defects to cardiovascular disease, can-
cer and cognitive dysfunction in the elderly. The cause of these associations is not 
yet known. Several mechanisms have been proposed to explain how Hcy may lead 
to disease. Regarding cardiovascular disease these include impaired (nitric oxide-
mediated) vasodilatation due to endothelial dysfunction 45 and oxidative stress 46. 
A more general mechanism was recently reviewed by Jacobsen et al. who suggest 
that molecular targeting of proteins by Hcy (called homocysteinylation) may disrupt 
protein function and contribute to the pathogenesis of cardiovascular disease 47.
Although hyperhomocysteinemia has been associated with several diseases, the 
mechanism of homocysteine induced deleterious effects is not fully elucidated. 
Prominent among the various mechanisms proposed for the harmful effects of Hcy 
is its ability to modulate the expression of certain genes that may either directly or 
indirectly lead to several pathological conditions 48. Homocysteine-induced modu-
lation of gene expression may be due to altered methylation status, because the 
levels of intracellular S-adenosylhomocysteine (SAH), an inhibitor of many S-ade-
nosylmethionine-dependent (SAM) methyl transferases (Mtase), are elevated during 
hyperhomocysteinemic conditions 49.
Homocysteine and osteoporosis
A few years ago a mildly elevated Hcy was identifi ed as a risk factor for osteoporotic 
fracture in both men and women 11,12. Hcy level in the highest 25% of the population 
resulted in an increased risk for fracture of approximately two-fold. In addition, a 
randomized, double-blinded study showed that folate and cobalamin supplementa-
tion is effective in preventing hip fracture in Japanese stroke patients 50,51. However, 
this observation needs to be replicated in other (larger) intervention studies. In order 
to prove a causal relationship we need intervention studies directed at lowering Hcy 
levels. Nevertheless, it is possible that the higher risk of fracture is not caused by 
higher Hcy levels, but by other factors related to a higher Hcy level.
Mendelian randomization
Mendelian randomization is the term that has been given to studies that use genetic 
variants in observational epidemiology to make causal inferences about modifi able 
(i.e. Hcy levels) risk factors for disease (i.e. osteoporosis) 52 53. Such studies ex-
ploit what is known as Mendel’s second law or the law of independent assortment: 
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The independent distribution of alleles (or blocks of alleles in linkage disequilib-
rium) from parents to their offspring means that a study relating health outcomes in 
the offspring to genetic variation transmitted from the parents will not suffer from 
confounding. This holds true for full siblings who are not monozygotic twins. De-
spite the actual random allocation of groups of alleles being at the level of parents to 
their offspring yoke, at a population level—when relating genetic variants to disease 
outcome—alleles are generally unrelated to those confounding factors (in particular, 
socio-economic position and lifestyle factors) that distort the interpretations of fi nd-
ings from observational epidemiology.
Furthermore, genetic variants that are related to a modifi able exposure will gener-
ally be related to it throughout life from birth to adulthood and therefore their use 
in causal inference can also avoid attenuation by errors (regression dilution bias). 
Mendelian randomization studies are therefore defi ned as any study that uses genetic 
variation that serves as a robust proxy for an environmentally modifi able exposure 
in order to make causal inferences about the outcomes of the modifi able exposure. 
Therefore, we have utilized the Mendelian randomization approach to determine 
the magnitude of causal relationships between elevated Hcy levels and fracture risk. 
Mendelian randomization provides a method to assess the causal nature of some 
environmental exposures, by studying an association between a disease and a DNA 
polymorphism that mimics the biological link between a proposed exposure (such 
as increasing Hcy levels) and disease (such as fracture risk) 54. This approach was 
applied to explore the association between Hcy and stroke. A consistent increased 
risk of stroke was found in the 222ValVal homozygotes of the MTHFR Ala222Val 
polymorphism 55.
Observational studies have shown that ribofl avin and folate modify the association 
between the MTHFR Ala222Val polymorphism and disease. It has been shown that 
222ValVal individuals had signifi cantly lower BMD than the AlaVal or AlaAla geno-
type group, but only when dietary ribofl avin and/or folate intake was low 56. In order 
to be active, MTHFR needs to bind to a cofactor, fl avin adenine dinucleotide (FAD), a 
derivative of ribofl avin. The 222Val allele encodes the valine (Val) amino acid instead 
of alanine (Ala) amino acid and this slightly changes the binding site for FAD, result-
ing in a lower affi nity for FAD than the 222Ala allele 57,58. Yet, this binding can be 
stabilized by the addition of folate 57,58. Therefore, low ribofl avin or folate status may 
reduce MTHFR activity, especially in individuals with the 222ValVal genotype, which 
results in increased Hcy levels. Indeed, ribofl avin and folate levels were shown to 
be predictors of Hcy levels in individuals homozygous for the MTHFR T677, and it is 
thought that higher ribofl avin and folate intake are required in 222Val-homozygous 
individuals to maintain low Hcy levels 24,57,58.
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Mechanisms explaining the relationship between Hcy and bone
A possible biological mechanism underlying the deleterious effect of Hcy on bone 
quality might involve the inhibition of collagen cross-linking by high Hcy concentra-
tions 5,59-62. This hypothesis is based on observations in homocystenuria patients. In 
vivo evidence for this hypothesis is limited, and it remains to be determined whether 
collagen cross-linking is disturbed when Hcy levels are only mildly elevated. Recent 
evidence does not corroborate this hypothesis, since higher levels of Hcy were 
found to be correlated with excretion of higher levels of collagen cross-links 63. In a 
pilot study of 100 individuals, we also found that high Hcy levels are not associated 
with lower levels of collagen cross-links per excreted collagen molecule; instead we 
found a tendency towards higher number of collagen cross-links (Table 3). However, 
these markers are related mainly to resorbed bone, and one expects the Hcy effect 
(if it exists) to be on the quality of the newly formed bone, something that is not 
monitored effectively by any of the markers studied so far. In addition, the exact 
local concentration of Hcy at the tissue level of the active osteoid, and whether it is 
suffi cient to interfere with collagen cross-links is not known. Interestingly, Paschalis 
et al. observed altered cross-links in fragile bone of osteoporotic patients specifi cally 
in the microenvironment of the bone-forming surfaces, which would support this 
hypothesis 64.
The association between Hcy and fracture could also be explained by other factors 
accompanying higher Hcy and not caused by Hcy itself. Higher Hcy could refl ect a 
poor vitamin B status, which could directly affect bone metabolism. Patients with vi-
tamin B12 defi ciency have a higher risk for fracture 65, while recent population-based 
studies suggest that vitamin B12 status is important for maintenance of BMD 63,66. 
Table 3. Collage cross link markers across the highest and lowest quartile of homocysteine levels
Collagen cross link markers Low homocysteine High homocysteine p-value*
Number N=50 N=50
HP/Creat 51.6 ± 20.1 49.5 ± 15.5 0.51
LP/Creat 14.8 ± 5.9 14.5 ± 5.9 0.75
Hyp/Creat 24.7 ± 8.2 20.7 ± 8.2 0.02
Pro/Creat 49.9 ± 12.8 50.6 ± 12.8 0.89
HP/Col 0.68 ± 0.28 0.79 ± 0.29 0.08
LP/Col 0.19 ± 0.09 0.23 ± 0.09 0.09
Pro/Hyp 2.16 ± 0.73 2.63 ± 0.73 0.003
* p-values were calculated with ANCOVA, measures were adjusted for age, quartiles are sex adjusted. Urine 
measurements (HPLC):
HydroxylysylPyridinoline (HP) cross-links
LysylPyridinoline (LP) crosslinks
Hydroxyproline (Hyp, total amount of collagen)
Proline (Pro, total amount of protein).
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Vitamin B12 has also been found to affect osteoblast activity and bone formation 67. 
Furthermore, Hcy or related B vitamins could affect the bone resorbing cells directly, 
as suggested by Herrmann et al., who observed direct effects of Hcy on osteoclast 
activity 68.
Alternatively, Hcy is produced as a result of methylation reactions, higher Hcy lev-
els could refl ect the methylation status of the individual as reviewed above. Recent 
studies on DNA have revealed that DNA methylation is one of the age-associated 
changes. Chronic elevation in Hcy levels results in parallel increases in intracellular 
SAH, which is a potent inhibitor of DNA methyltransferases. It was shown that higher 
SAH levels lead to decreased methylation of lymphocyte DNA 69,70. In addition, folate 
treatment could restore DNA methylation to normal levels and correct the patterns of 
abnormal gene expression both in animal models 71 and well as in humans 72.
These results suggest that elevated Hcy levels may be an indirect indicator of 
elevated intracellular SAH and compromised cellular methylation capacity. In this 
light, this hypothesis was supported by studying a gene, PASG (Proliferation As-
sociated SNF2-like Gene). They demonstrated that the disruption of a protein that 
facilitates DNA methylation (PASG), causes global hypomethylation, developmental 
growth retardation and a premature aging phenotype, including osteoporosis 73,74.
Thus, the decreased methylation associated with high Hcy levels may alter gene 
regulation, which could eventually lead to disease. Such “epigenetic” infl uence on 
disease has been studied intensely, in particular in cancer and arteriosclerosis 75-79. 
Studies also indicate that the relation between Hcy and dementia might in part be 
explained by a lower methylation level in the brain leading to a lower activity of key 
methyltransferases, which is important in neurotransmitter metabolism 80.
Scope of this thesis
The general aim of this thesis is to study the association between Hcy and osteoporo-
sis by examining genetic and dietary determinants of Hcy status on bone health. All 
the studies were performed within the Rotterdam Study, a population-based cohort 
study among 7,983 individuals aged 55 years and older.
In chapter 2 we performed a systematic review and meta-analysis to gain insight 
in the current state of knowledge on the association between B vitamins related to 
Hcy metabolism and bone health.
In chapter 3 we examined an effect of dietary B vitamins on BMD and risk of 
fracture in elderly men and women in the Rotterdam Study.
In chapter 4 we examined the association between polymorphisms involved in 
homocysteine remethylation with bone phenotypes.
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In the fi rst part of this chapter, we aimed to examine the infl uence of ribofl avin 
and/ or folate status on the relation between the MTHFR Ala222Val variant and Hcy 
levels, BMD, bone loss and risk of fracture.
In the second part of this chapter, we evaluated an association between the MTR 
Arg919Gly variant with BMD, bone loss and fracture risk. Furthermore, we also 
examined whether the dietary cobalamin intake infl uences the relationship of MTR 
Arg919Gly variant with bone end points.
In chapter 5 we examined a possible association of Hcy levels with eight polymor-
phisms involved in Hcy metabolism. Moreover, we studied gene-nutrient interactions 
to address all genetic and dietary determinants of Hcy levels in one analysis.
In chapter 6 we investigated the infl uence of both COLIA1 polymorphisms inde-
pendently and in the form of haplotypes in relation to baseline femoral neck BMD, 
change in BMD with follow-up, and risk of vertebral and non-vertebral fractures.
Finally in the general discussion (chapter 7) the main fi ndings of this thesis are 
addressed and suggestions are made for further research.
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related B vitamins and bone health: 
a systematic review and meta-analysis
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Abstract
Many studies have examined the relation between Homocysteine (Hcy) level and 
B-vitamins in relation to bone metabolism, bone quality and fracture risk. This sys-
tematic review of observational studies investigates the association between Hcy or 
B vitamin status and bone health, defi ned as fracture risk or bone mineral density 
(BMD), in a comprehensive way.
A literature search was conducted in PubMed and Web of science up to 27 July 
2007. We included longitudinal cohorts and cross-sectional studies of Hcy and re-
lated B vitamins in relation to BMD and fracture risk. The quality and heterogeneity 
of the study outcomes were assessed and graded.
Studies varied in the method of analysis precluding statistically pooling the data, 
therefore we used a best-evidence synthesis. Eight studies (all prospective cohorts), 
with a sample size ranging from 199 to 4766 subjects (four graded as good and four 
graded as fair) evaluated the association between Hcy levels and fracture risk. These 
studies show strong evidence for such an association between elevated Hcy levels 
and fracture risk, 75% of the studies reported this effect. A meta-analysis on studies 
which examined an association between Hcy levels and fracture shows 1.78 times an 
increased risk of fracture (95% CI: 1.43-2.23, p<0.0001). Thirteen studies (all cross-
sectional in design), examined the effect of Hcy levels on BMD; but with confl icting 
evidence. Sixteen studies (14 cross-sectional design, and two with a prospective 
design), evaluated the association between B vitamins and BMD. There is moderate 
evidence for an association between folate and vitamin B12 and BMD reporting on 
the effect of folate and one large good-quality study that reports on the effect of 
vitamin B12. Seven prospective cohort studies tested an association between B12 
and/ or folate and fracture risk; but with confl icting evidence.
In conclusion, the heterogeneity in assessment methodology, and a lack of stan-
dardized threshold levels for categorizing low B vitamin status precluded defi nite 
conclusions to be drawn for relating B vitamins and bone health. However, there is 
convincing data to support a positive association between Hcy levels and fracture 
risk, while the data also suggest a positive association between BMD and vitamin 
B12 and folate status.
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Introduction
Osteoporosis is a skeletal disorder characterized by compromised bone strength, 
which predisposes a person to increased risk of fracture 1. Osteoporotic fractures 
are a major health problem in the western society; they are associated with in-
creased morbidity, mortality, and substantial economic costs. In the coming years, 
the number of fractures will increase throughout the world as the population ages, 
so prevention of fractures with inexpensive and well-established interventions is 
becoming increasingly important.
Homocysteine (Hcy) is a sulfur amino acid produced as an intermediate in the 
metabolism of methionine. Recent studies suggest that elevated Hcy may affect bone 
metabolism and bone quality, as well as fracture risk in humans 2,3. This suggests 
that circulating Hcy may be used as a modifi able risk indicator for osteoporosis, but 
a cause and effect relationship remains to be proven 2,3.
Since the fi rst description many studies have investigated the relation between 
Hcy levels or nutritional determinants of Hcy levels and bone mineral density (BMD) 
and/or fracture risk 3-14. The results of these studies however, are not consistent 
and a complete and systematic overview on the present level of knowledge on 
this relationship is lacking. More information on the association between high Hcy 
concentrations and/or the associated B vitamins that contribute to the risk of osteo-
porosis is needed.
Therefore, the aim of this systematic review is to gain insight into the current state 
of knowledge on the association between Hcy levels and bone health.
Materials and methods
Study Eligibility
The articles were identifi ed by systematically searching Web of Science and PubMed, 
up to 27 July 2007. Osteoporosis, fracture, BMD, B vitamins (limited to B2, B6, B12 
and folate), Hcy levels and equivalents of these words were used as keywords (see 
Appendix I).
A study was included when all of the following criteria were fulfi lled. First, the 
article presents original data on a human study population. Second, the trait of inter-
est is fracture, BMD at femoral neck (FN) and/ or lumbar spine (LS), or bone loss. 
We covered studies which examined either Hcy levels or one of the four B vitamins 
involved in Hcy metabolism (ribofl avin, pyridoxine, folate and cobalamin) in relation 
to the above mentioned traits of interest. Third, the report was written in English.
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Two independent researchers checked the abstracts regarding the above-men-
tioned criteria. We divided the studies into those dealing with Hcy associated with 
BMD or fracture, and those exploring Hcy-related B vitamins associated with BMD or 
fracture. Studies were excluded if the measured relevant data (results of the analysis) 
were unavailable or incomplete.
Methodological quality
A three-category grading system (good, fair, and poor) was used to denote the qual-
ity of each study included in our review. Each study was graded by two reviewers, 
and disagreements were resolved through consensus.
In the good grade, results were valid without obvious major bias. The study 
provided a clear description of the population, settings, B vitamin measurement 
technique and status, and the appropriate outcome measurements used (e.g., diag-
nosis of osteoporosis) applying validated methods for BMD, fracture and B vitamins 
assessment criteria, appropriate statistical and analytical methods (including adjust-
ment for other risk factors such as gender, age and BMI), had less than 20% dropout, 
and clearly reported reasons for dropouts.
In the fair grade, the study had some defi ciencies or was susceptible to some bias 
but not major bias. The study might be missing information, making assessment of 
the limitations and potential problems diffi cult, but omissions were not suffi cient to 
invalidate the results. This category included studies that did not meet all the criteria 
in the good grade.
In the poor grade, a bias was present that could invalidate results. The study had 
serious errors in design, analysis, or reporting, or had large amounts of missing 
information or discrepancies in reporting.
Evidence synthesis
In homogeneous studies data were pooled and a meta-analysis was performed. 
For the meta-analysis we applied the Cochrane Review Manager (RevMan) version 
4.2.10 program, the Cochrane Collaboration, Oxford, UK). The association between 
elevated Hcy levels and fracture risk was assessed by defi ning highest quartile of 
Hcy levels versus the three remaining quartile within each study with 95% con-
fi dence intervals (95% CI). In contrast to all the other studies, that examined the 
upper quartile against the rest, the Hordaland study only presented cut-off point of 
greater than 15 μM. Heterogeneity between the studies was calculated by means of 
X2 – distributed Q statistic (with p-value considered signifi cant at a level of 0.10) 15, 
and the inconsistency index I2 (suggesting inconsistency among the studies’ results 
with values of 50%, or higher 16 estimated by RevMan program. Hazard ratios (HRs) 
with 95% CI were estimated by random effects model. Random effects assume that 
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there may be substantial diversity among different study groups, and assesses both 
within-study sampling error and between-study variance. Random effects are prefer-
able in the presence of signifi cant between-study heterogeneity.
In case of heterogeneity, we refrained from statistically pooling the data and 
performed a best-evidence synthesis. The studies were ranked according to the 
methodological scores described above, and then were graded using the levels of 
evidence shown in (Appendix II) 17.
Data extraction
One reviewer performed data extractions of each accepted article, and a second 
reviewer independently verifi ed the data. Discrepancies were resolved through con-
sensus. The characteristics covered the study design, study population, year, design, 
location, follow-up, baseline characteristics, mean age, total number of subjects, 
metric outcome, and the outcome of the studies.
Results
The search of Web of Science and PubMed yielded 409 abstracts and articles on hu-
man studies that examined the association between Hcy levels, B vitamins and bone 
health. Among those, 73 abstracts met the inclusion criteria by reading the titles. Of 
these, 30 studies, including 24 articles and 6 abstracts met the eligibility criteria (see 
fi gure 1).
73 Abstracts retrieved 
30 studies were retrieved of these: 
24were total articles  
6 were abstracts 
43 abstracts did not meet the inclusion criteria 
409 Abstracts found in Web of Science and Pub Med  
Figure 1. Flow diagram of the study selection process for this systematic review.
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Meta-analysis of the associations between Hcy, B vitamins and BMD or B vitamins 
and fracture risk could not be performed due to heterogeneity in Hcy and B vitamin 
thresholds and data analysis. Additional sources of heterogeneity in these studies 
included differences in biological sample (plasma/serum) sample type (fasting, non-
fasting), and differences in determination of B vitamin status (circulating levels, 
dietary intake). All the fi ndings of our systematic review are summarized in table 1.
Association between Hcy levels and fracture risk
Eight studies (all prospective cohorts), of which four were of good quality and four 
were graded fair, evaluated the association between Hcy levels and fracture risk 
2,3,7,11-13,18,19 (Table 2). Sample sizes ranged from 199 to 4766 subjects, and the number 
of fracture cases ranged from 44 to 348 per study. All eight studies investigated 
fracture risks among subjects with high Hcy levels compared to low levels, and the 
threshold for defi ning high Hcy levels ranged from 15 to 26.4 µmol/l. Three of these 
studies reported increased fracture risk per 1 SD increasing Hcy levels 2,11,19. Six of 
the eight studies reported an association between elevated Hcy levels and risk of 
fracture 2,3,7,11-13. In one study this association was diminished after correcting for 
age 19. In another study the association of Hcy levels with risk of fracture was partly 
dependent on folate levels 11. One study did not observe an association between 
elevated Hcy levels and risk of fracture 18. Four studies observed that Hcy was as-
sociated with fracture risk independent of BMD 2,13,18,19, while the remaining studies 
did not study this aspect.
There is strong evidence to support a positive association between Hcy levels and 
fracture risk. There is heterogeneity in the thresholds used to defi ne elevated Hcy 
Study  HR (random) (95% CI)  Weight %  HR (random) (95% CI)
The Rotterdam Study, The LASA Study 2 
             
 
 
 
  
 15.79      1.90 (1.39, 2.60)  
  4.24      3.82 ( 1.43, 10.18)
   
 11.37      1.99 ( 1.25, 3.19)
   
  9.62      2.41 ( 1.39, 4.17)  
  8.17      1.99 ( 1.06, 3.73)  
  5.78      1.40 ( 0.63, 3.14)  
 
   
 10.03      2.41 ( 1.42, 4.09)  
 18.88      1.20 ( 0.97, 1.49)  
  7.26      1.80 ( 0.91, 3.58)
 
   
  8.86      1.20 ( 0.66, 2.16)  
Total (95% CI) 100.00
     1.78 (1.43, 2.23)
Test for heterogeneity: Chi² = 18.02, df =9, p = 0.03, I² = 50.1%
Test for overall effect: Z = 5.07 (P < 0.00001) 
  0.1   0.2   0.5   1   2   5   10
The Framingham Study (men) 3 
 The Framingham Study (women)  3  
 
 
Sato et. al. (Parkinson case) 13
Sato et. al. (Stroke cases) 12
 
 
 
The OFELY Study 17
 
The Hordaland Study (men) 7
 The Hordaland Study (women) 7  
 
The OPRA Study 16
 
The CBSA Study 11
Figure 2. Meta-analysis of relationship between Hcy levels and fracture risk. Point estimates and 
95% confi dence intervals (CI) are shown for the hazards ratios (HR) in each study group. Summary 
estimates of HR and its 95% CI (diamonds), test for heterogeneity and effect are given by random 
effects model.
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levels. There is moderate evidence that the increased fracture risk is independent of 
BMD.
A meta-analysis on studies which examined an association between elevated Hcy 
levels and fracture shows 1.78 times an increased risk of fractures (95% CI: 1.43-2.23, 
p<0.0001) (Figure 2).There was a signifi cant heterogeneity between the studies ex-
amining risk of fractures and Hcy levels across studies I2 =50.1%, p=0.03. However 
Hordaland Study 7 considered a cut-off point of greater than 15 μM and not highest 
quartile of Hcy levels against the rest. Therefore, there is a need to perform this 
meta-analysis with including details of quartile analysis of Hcy levels especially for 
Hordaland Study in a more homogeneity manner.
Association between Hcy levels and BMD
Thirteen studies (all with a cross-sectional design) of variable quality investigated 
the relationship between Hcy levels and BMD 2,4,6,8,10,12,18-23 (Table 3). For two studies 
only an abstract was available, so we were unable to evaluate the quality. Sample 
sizes ranged from 143 to 5329 subjects. Across the studies, six different sites of BMD 
measures were examined. Five studies, found a signifi cant association between Hcy 
levels and BMD 6,8,20,21,23. Among those fi ve, in two studies the association disap-
peared after correction for folate and vitamin B12 8,20, while the other three studies 
did not adjust for B vitamin status. Eight studies, (one good, six fair, and one poor) 
with a sample size ranging from 143 to 2406 subjects found no association between 
Hcy levels and BMD 2,4,10,12,13,22,18,19. Taken together evidence for the association be-
tween Hcy and BMD appears confl icting. In addition, large heterogeneity exists 
across these studies in terms of BMD outcome (site of BMD) and statistical analysis, 
which makes it diffi cult to support any defi nite conclusion regarding the relationship 
between BMD and Hcy levels.
Association between B vitamin and fracture risk
Seven prospective cohort studies evaluated an association between B vitamin status 
and fracture risk (Table 4). Among the studies the examined B vitamin(s) varied, as 
well as the method of determination of B vitamin status (serum vs dietary intake). 
Two studies, (one graded fair and one abstract) examined only vitamin B12 in rela-
tion to risk of fracture, 5,24. One study (sample size of 1210 subjects and 55 fracture 
cases), observed a negative effect of vitamin B12 on fracture risk 5, while the other 
study (sample size 904 subjects, 91 fracture cases) found a similar relationship that 
failed to reach signifi cance.
Four studies, examined both folate and B12 in relation to risk of fracture7,11,18,25. 
Two studies with a total sample size of 5468 subjects (318 fracture cases), reported 
a negative association between folate and risk of fracture, independent of Hcy and 
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vitamin B12 status 7,11. Two studies (one fair and one abstract) with a sample size 
of 3012 subjects (627 fracture cases) found no association between either vitamin 
B12 or folate with risk of fracture 18,25. There is confl icting evidence regarding the 
negative relationship between folate status and fracture risk. Only a limited number 
of studies is available and there was large heterogeneity across the studies regarding 
measurement of folate status and statistical analysis.
Only one study, (with a sample size of 5304 subjects) explored dietary vitamin 
B2, B6, B12 and folate intake, and observed an effect of dietary vitamin B6 intake 
with risk of fracture independent of Hcy levels and other dietary B vitamin intake 
26. However, because this is a single study, there is limited evidence to support this 
association.
Association between B vitamins and BMD
Sixteen studies (14 cross-sectional, 4,6,8-10,20,21,25-31, and two prospective 14,25 (sample 
size ranging from 83 to 5304 subjects) evaluated the association between B vitamins 
and BMD (Table 5). Three studies examining an effect of vitamin B12 on BMD, (one 
good and two fair) found a positive association between vitamin B12 and BMD 
14,27,31. One of the three found this association independent of Hcy levels 31 while the 
others did not adjust for Hcy values. Taken together, there is moderate evidence for 
a positive association between vitamin B12 and BMD.
A single study, examined vitamin B6 in relation to BMD and reported a positive 
association between vitamin B6 and BMD at baseline, and during four years of 
follow-up 32. In conclusion, studying only vitamin B6, there is insuffi cient evidence 
for an association between vitamin B6 and BMD.
Seven studies with a sample size ranging from 161 to 5329 subjects, examined a 
possible effect of both vitamin B12 and folate on BMD 4,6,8,10,20,25,28. Six of the seven 
studies observed a positive effect of folate on BMD 4,6,8,20,25,28, but did not observe any 
association between vitamin B12 and BMD. In contrast, one study from the USA with 
a sample size of 1550 subjects and of good quality, reported an association between 
vitamin B12 and BMD 10. Overall, from the studies on vitamins B12 and folate, there 
is strong evidence for a positive association between folate and BMD.
In the studies examining vitamins B6, B12 and folate, there is insuffi cient evidence 
to draw any conclusion from the reported results because there were only two stud-
ies: one of which had insuffi cient data and the other was of poor quality.
Finally, two studies, (one fair and one good) assessed the effect of dietary intake 
of all four B vitamins in relation to BMD 9 26. One study found a positive association 
between vitamin B12 and BMD 9, but did not correct for other related B vitamins 
or Hcy levels, and the other study (with a sample size of 5304 subjects) found a 
positive association between vitamin B2 and B6, independently of each other with 
Nahid BW.indd   41 31-Oct-07   15:31:26 PM
Homocysteine, B vitamins and bone42
T
ab
le
 5
. 
C
h
ar
ac
te
ri
st
ic
s 
o
f 
o
b
se
rv
at
io
n
al
 s
tu
d
ie
s 
ev
al
u
at
in
g 
th
e 
as
so
ci
at
io
n
 b
et
w
ee
n
 B
 v
ita
m
in
s 
an
d
 B
M
D
Au
th
or
s, 
Ye
ar
D
es
ig
n
Lo
ca
tio
n
So
ur
ce
M
ea
n 
ag
e
(r
an
ge
) 
ye
ar
s
To
ta
l s
am
pl
e
N
o.
(W
%
)
B-
vi
ta
m
in
 
M
ea
su
re
Ef
fe
ct
 m
ea
su
re
Re
su
lts
Re
po
rt
ed
 
as
so
ci
at
io
n
St
ud
y 
qu
al
ity
Ad
ju
st
m
en
ts
Ag
e
O
th
er
s
Vi
ta
m
in
 B
12
D
ho
nu
sh
e-
Ru
tte
n 
et
 a
l. 
27
 2
00
3
CS
, T
he
 N
et
he
rla
nd
s
78 (7
5-
81
)
19
4
(7
4)
Pl
as
m
a 
B1
2,
Pl
as
m
a 
M
M
A
Re
gr
es
si
on
 
co
ef
fi c
ie
nt
β =
0.
12
, p
<0
.0
5
B1
2:
 Y
es
M
M
A:
 N
o
F
Ye
s
W
ei
gh
t
St
on
e 
et
 a
l. 
14
, 2
00
4
PC
, U
SA
Th
e 
SO
F 
St
ud
y
71 (6
9-
74
)
83 (1
00
)
Se
ru
m
 B
12
M
ea
n 
di
ffe
re
nc
e
in
 b
on
e 
lo
ss
1.
6%
 d
iff
er
en
ce
, 
p=
0.
00
3
< 
20
7.
2 
vs
 >
 2
07
.2
 
pM
 /
l
B1
2:
 Y
es
F
Ye
s
W
ei
gh
t
Tu
ck
er
 e
t a
l. 
31
, 2
00
5
CS
, U
SA
Th
e 
Fr
am
in
gh
am
 S
tu
dy
58
.9
(5
6-
62
)
25
76
(5
6)
Pl
as
m
a 
B1
2
M
ea
n 
± 
SD
FN
-B
M
D
: 6
%
 
di
ffe
re
nc
e 
LS
-B
M
D
: 
6%
 d
iff
er
en
ce
> 
25
9 
vs
 ≤ 
14
8 
pM
ol
/l
B1
2:
 Y
es
G
Ye
s
H
cy
, B
M
I
Fo
la
te
Sh
en
g 
et
 a
l. 
30
, 2
00
7
CS
, C
hi
na
N
.A
93 (1
00
)
Se
ru
m
 N
.A
Co
rr
el
at
io
n 
co
ef
fi c
ie
nt
H
ip
-B
M
D
: 
r=
0.
00
5,
p>
0.
05
FN
-B
M
D
 
r=
0.
02
1,
p>
0.
05
Fo
la
te
: N
o
Ab
st
ra
ct
N
.A
N
.A
Vi
ta
m
in
 B
6
M
cL
ea
n 
et
 a
l. 
32
, 2
00
6
PC
, U
SA
Th
e 
Fr
am
in
gh
am
 S
tu
dy
75
.1
 M
75
.6
 W
(7
3-
78
)
11
35
(5
0.
2)
Pl
as
m
a 
B6
M
ea
n 
± 
SD
W
: 0
.0
32
 g
/c
m
 lo
w
er
 
BM
D
 in
< 
20
 v
s 
≥30
 
(p
M
/l
)
M
: 4
%
hi
gh
er
 b
on
e 
lo
ss
 in
 <
20
 v
s 
≥30
 M
B6
:
M
:B
M
D
:, 
bo
ne
 
lo
ss
 Y
es
W
: B
M
D
 Y
es
, b
on
e 
lo
ss
 n
o
Ab
st
ra
ct
Ye
s
H
ei
gh
t, 
W
ei
gh
t
Nahid BW.indd   42 31-Oct-07   15:31:26 PM
C
h
ap
te
r 
2
43
T
ab
le
 5
. 
C
h
ar
ac
te
ri
st
ic
s 
o
f 
o
b
se
rv
at
io
n
al
 s
tu
d
ie
s 
ev
al
u
at
in
g 
th
e 
as
so
ci
at
io
n
 b
et
w
ee
n
 B
 v
ita
m
in
s 
an
d
 B
M
D
 (
co
n
t.)
Au
th
or
s, 
Ye
ar
D
es
ig
n
Lo
ca
tio
n
So
ur
ce
M
ea
n 
ag
e
(r
an
ge
) 
ye
ar
s
To
ta
l s
am
pl
e
N
o.
(W
%
)
B-
vi
ta
m
in
 
M
ea
su
re
Ef
fe
ct
 m
ea
su
re
Re
su
lts
Re
po
rt
ed
 
as
so
ci
at
io
n
St
ud
y 
qu
al
ity
Ad
ju
st
m
en
ts
Ag
e
O
th
er
s
Fo
la
te
 a
nd
 v
it
am
in
 B
12
Ca
gn
ac
ci
 e
t a
l. 
4 , 
20
03
CS
, I
ta
ly
53
.5
(5
0-
57
)
16
1
(1
00
)
Se
ru
m
 B
12
Se
ru
m
 F
ol
at
e
Co
rr
el
at
io
n 
co
ef
fi c
ie
nt
r=
0.
37
1,
 p
<0
.0
00
1
Fo
la
te
: Y
es
B1
2:
 N
o
F
Ye
s
BM
I
G
ol
ba
ha
r 
et
 a
l. 
8 , 
20
04
CS
, I
ra
n
60
.8
(5
8-
63
)
27
1
(1
00
)
Se
ru
m
 B
2
Fo
la
te
Re
gr
es
si
on
 
co
ef
fi c
ie
nt
FN
-B
M
D
: β 
=0
.1
2,
 
p=
0.
00
1
LS
-B
M
D
: β=
0.
12
, 
p=
0.
05
Fo
la
te
: Y
es
B1
2:
 N
o
F
Ye
s
BM
I
G
ol
ba
ha
r 
et
 a
l. 
28
, 2
00
5
CS
, I
ra
n
60
.8
(5
8-
63
)
36
6
(1
00
)
Pl
as
m
a 
B1
2
RB
C-
 M
TH
F
5-
M
TH
F
Co
rr
el
at
io
n 
co
ef
fi c
ie
nt
FN
-B
M
D
: r
 =
0.
19
,
p 
=0
.0
04
LS
-B
M
D
: r
 =
0.
21
, 
p=
0.
00
1
Fo
la
te
: Y
es
B1
2:
 N
o
P
Ye
s
BM
I, 
B1
2,
 
H
cy
M
or
ris
 e
t a
l. 
10
, 2
00
5
CS
, U
SA
N
H
AN
ES
68
.0
>5
5
15
50
(5
2)
Se
ru
m
 
M
M
A(
n=
72
5)
,B
12
Se
ru
m
 F
ol
at
e,
 
RB
C 
Fo
la
te
M
ea
n 
± 
SD
M
M
A:
0.
05
 g
/c
m
 
lo
w
er
 B
M
D
 in
 Q
4 
vs
 
Q
1,
 p
=0
.0
03
B1
2:
 lo
w
er
 B
M
D
, 
p=
0.
01
 <
22
0 
vs
 >
22
0 
(p
M
/l
)
M
M
A,
 B
12
: Y
es
Fo
la
te
, R
BC
 F
ol
at
e:
 
N
o
G
Ye
s
Se
x,
 B
M
I
G
je
sd
al
 e
t a
l. 
6 , 
20
06
CS
,
N
or
w
ay
Th
e 
H
or
da
la
nd
 S
tu
dy
47
-5
0
71
-7
5
30
94
 (
60
)
22
35
 (
54
)
Pl
as
m
a 
Fo
la
te
Pl
as
m
a 
B1
2
Re
gr
es
si
on
 
co
ef
fi c
ie
nt
W
: β 
=0
.0
01
,p
=0
.0
03
Fo
la
te
: Y
es
B1
2:
 N
o
G
Ye
s
BM
I, 
H
cy
Re
jn
m
ar
k 
et
 a
l.,
 25
, 2
00
7
CS
, P
C,
 D
an
is
h
Th
e 
D
O
PS
 S
tu
dy
N
.A
20
16
(1
00
)
D
ie
ta
ry
 in
ta
ke
 
(μg
/d
ay
)
B1
2
Fo
la
te
Re
gr
es
si
on
 
co
ef
fi c
ie
nt
Fo
la
te
: B
M
D
: 
β=0
.0
27
, p
=0
.0
05
Fo
la
te
: Y
es
 B
M
D
N
o 
as
so
ci
at
io
n 
w
ith
 
bo
ne
 –
lo
ss
B1
2:
 N
o 
as
so
ci
at
io
n
Ab
st
ra
ct
N
.A
N
.A
Nahid BW.indd   43 31-Oct-07   15:31:26 PM
Homocysteine, B vitamins and bone44
T
ab
le
 5
. 
C
h
ar
ac
te
ri
st
ic
s 
o
f 
o
b
se
rv
at
io
n
al
 s
tu
d
ie
s 
ev
al
u
at
in
g 
th
e 
as
so
ci
at
io
n
 b
et
w
ee
n
 B
 v
ita
m
in
s 
an
d
 B
M
D
 (
co
n
t.)
Au
th
or
s, 
Ye
ar
D
es
ig
n
Lo
ca
tio
n
So
ur
ce
M
ea
n 
ag
e
(r
an
ge
) 
ye
ar
s
To
ta
l s
am
pl
e
N
o.
(W
%
)
B-
vi
ta
m
in
 
M
ea
su
re
Ef
fe
ct
 m
ea
su
re
Re
su
lts
Re
po
rt
ed
 
as
so
ci
at
io
n
St
ud
y 
qu
al
ity
Ad
ju
st
m
en
ts
Ag
e
O
th
er
s
Ar
da
w
i e
t a
l. 
20
, 2
00
5
CC
, S
au
di
-A
ra
bi
a
5-
60
27
8
(1
00
)
Pl
as
m
a 
N
.A
.
Co
rr
el
at
io
n 
co
ef
fi c
ie
nt
Fo
la
te
:
FN
-B
M
D
: r
=0
.1
8,
 
p<
0.
01
LS
-B
M
D
: r
=0
.1
5,
 
p<
0.
02
Fo
la
te
: Y
es
B1
2:
 N
o
Ab
st
ra
ct
Ye
s
H
cy
, B
12
Fo
la
te
, v
it
am
in
 B
12
, B
6
M
ar
tin
ez
 e
t a
l. 
29
, 2
00
6
CS
, A
riz
on
a
60
11
9
Se
ru
m
 B
12
 S
er
um
 
Fo
la
te
Se
ru
m
 B
6
D
ie
ta
ry
 B
12
, B
6,
 
Fo
la
te
Be
ta
 c
oe
ffi 
ci
en
t
Fo
la
te
 W
β =
0.
03
1,
 p
=0
.0
7
B6
, B
12
, F
ol
at
e
Ye
s
Ab
st
ra
ct
N
.A
N
.A
Ba
in
es
 e
t a
l. 
21
, 2
00
7
CS
, U
K
68 (4
0-
86
)
32
8
(1
00
)
Se
ru
m
 B
12
 S
er
um
 
Fo
la
te
Pl
as
m
a 
B6
 (
PD
P)
Co
rr
el
at
io
n 
co
ef
fi c
ie
nt
Fo
la
te
:
r=
0.
14
, p
=0
.0
2
Fo
la
te
 Y
es
B1
2,
 B
6:
 N
o
P
Ye
s
W
ei
gh
t, 
H
ei
gh
t
Fo
la
te
, v
it
am
in
 B
12
, B
2,
 B
6
M
ac
do
na
ld
 e
t a
l. 
9 , 
20
04
,
PC
, C
S,
 U
K
AP
O
SS
 S
tu
dy
48 (4
5-
51
)
12
41
(1
00
)
D
ie
ta
ry
 in
ta
ke
 B
2,
 
B6
, B
12
, F
ol
at
e
Co
rr
el
at
io
n 
co
ef
fi c
ie
nt
B1
2:
LS
-B
M
D
: r
=0
.0
64
, 
p<
0.
05
B1
2:
 Y
es
B2
. B
6,
 F
ol
at
e:
 N
o
F
Ye
s
H
ei
gh
t, 
W
ei
gh
t
Ya
zd
an
pa
na
h 
et
 a
l.2
6 , 
20
07
PC
, C
S 
26
Th
e 
N
et
he
rla
nd
s
Th
e 
Ro
tte
rd
am
 S
tu
dy
68 (6
5-
71
)
53
04
(5
9)
D
ie
ta
ry
 in
ta
ke
B2
, B
6,
 F
ol
at
e,
 
B1
2
Re
gr
es
si
on
 
co
ef
fi c
ie
nt
β=0
.0
9,
 p
=1
*1
0-
8  B
6
β=0
.0
6,
 p
=0
.0
02
 B
2
B2
, B
6:
 Y
es
B1
2,
 F
ol
at
e:
 N
o
G
Ye
s
Se
x,
 B
12
, 
Fo
la
te
H
R
=
h
az
ar
d
 r
at
io
, 
O
R
=
 o
d
d
s 
ra
tio
, 
P
C
=
p
ro
sp
ec
tiv
e 
co
h
o
rt
, 
C
S=
cr
o
ss
 s
ec
tio
n
al
. 
W
=
w
o
m
en
, 
M
=
m
en
. 
N
.A
=
 n
o
t 
av
ai
la
b
le
Nahid BW.indd   44 31-Oct-07   15:31:27 PM
C
h
ap
te
r 
2
45
BMD 26. In summary, studies examining dietary intake of all four B vitamins (B2, 
B6, B12 and folate), produced confl icting results. This could be partly due to the 
heterogeneity in the statistical approach applied in these two studies while studying 
the same outcome.
Discussion
Our study highlights a substantial degree of heterogeneity in the literature evaluating 
the association of Hcy and related B vitamins with bone health. Notably, among the 
studies that examined the relationship between Hcy and bone health, different cut-
off points for higher Hcy levels were used. Association studies on serum levels of B 
vitamins consider a variety of cut off points for low or high B vitamins status.
Most of the studies did not examine all four B vitamins (B2, B6, B12 and folate) 
involved in Hcy metabolism. In addition, although all B vitamins are involved in 
Hcy metabolism (as co-factors or substrates) 33 there is a lack of studies that explore 
B vitamins and Hcy levels simultaneously. Furthermore, the studies used differ-
ent types of Hcy measurements (plasma/serum, or fasting/non-fasting) which may 
have affected the results. Moreover, there is considerable heterogeneity due to use 
of different statistical methods to express relationships and adjustments leading to 
methodological bias, which hinders drawing conclusions from a comparison of the 
studies.
Despite these limitations, 75% of studies reported a positive association between 
elevated Hcy levels and fracture risk 2,3,7,11-13. This association was consistent for Hcy 
levels in the highest population-specifi c quartile. Only two studies used a different 
cut-off point 7,11. Moreover, the result of the meta-analysis confi rms the association 
between elevated Hcy levels and risk of fracture. Nevertheless, we think there is a 
need to repeat this analysis with having similar cut-off points across all studies. We 
are now in the process of contacting the authors of the studies which this issue is 
needed to be addressed. The relationship between Hcy and fracture risk seems to be 
independent of BMD, because adjustment for BMD did not alter the association. The 
fracture risks that were observed, generally are about two times higher for the high-
est quartile versus the rest of the population and, therefore quite large 2,3,12,13. Thus, if 
these risks were caused by low BMD values, the difference between mean BMDs in 
high versus low Hcy must be relatively large given the fact that one SD difference in 
BMD will generally result in a two times higher fracture risk. The reports that studied 
only the relation between Hcy levels and BMD (and not fracture) gave confl icting 
results. The studies that did observe an association between Hcy and BMD reported 
a modest effect size (0.2 SD). Taken together, all this suggests that the association 
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between Hcy and fracture risk is probably not mediated through BMD. Nevertheless, 
still it could be that Hcy is associated with BMD-change rather than cross-sectional 
BMD measures. Up to now there is lack of studies addressed this issue, therefore, 
future studies are needed to clarify.
The evidence from B vitamin studies in relation to BMD suggests that there is a 
moderate evidence for an association between BMD and circulating levels of folate 
and vitamin B12. However, the studies used different cut-off points to distinguish 
low from high levels in their analysis which could have introduced some heteroge-
neity in the results. Interestingly, studies that examined both folate and vitamin B12 
status consistently reported folate to be associated with BMD and not vitamin B12, 
except one study from the USA which reported the opposite result. This apparent 
inconsistency can be explained by the mandatory fortifi cation of folate in USA, 
which results in a better folate status in the American population. This is supported 
by the observation that vitamin B12, and not folate, is the major determinant of Hcy 
levels in the American population after folic acid fortifi cation 34.
There are some limitations in studying the effects of B vitamins on bone health 
which require more attention. Since various B vitamins are often present in the 
same foods (see table 1, chapter1) simultaneous adjustment for the intake of other 
vitamins is required when studying associations with plasma Hcy concentrations. In 
addition, circulating B vitamin levels may not be the best marker for B vitamins status 
35, considering the fact that up to 50% of subjects with low intracellular vitamin B12 
status have normal plasma vitamin B12 levels 36. There is evidence that metabolites 
of B vitamins (such as methylmalonic acid for B12, and RBC-folate for folate) are 
more accurate indicators for assessing B vitamins status rather than studying solely 
circulating B vitamin levels 35,37. Therefore, for accuracy of assessing B vitamins status 
it might be more appropriate to measure circulating levels of B vitamin metabolites. 
Also, measuring vitamin levels only once may not refl ect the accurate and long-term 
amount of circulating B vitamin and/or Hcy levels.
Several biological mechanisms could explain how elevated Hcy levels are related 
to fracture risk, including: collagen cross-linking, bone remodelling and/ or DNA 
methylation. A mechanistic role of high Hcy concentrations in bone metabolism 
was fi rst suggested in patients with homocystinuria. This disease is characterised by 
extremely high Hcy levels and an increased prevalence of early osteoporosis 38 and 
in which a lower amount of collagen cross-links were found in the skin 39,40. It was 
suggested that high Hcy concentrations may interfere with collagen cross-linking, 
resulting in poor quality of bone and increased susceptibility to fracture 40. Because 
collagen cross-links are important for the stability and strength of the collagen net 
work, interference in the cross-linking may lead to higher bone fragility. Interest-
ingly, Paschalis et al. 41 observed altered cross-links in fragile bone specifi cally in 
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the micro-environment of the bone-forming surfaces, which would support this hy-
pothesis. In addition, Saito et al. 42 recently showed that bone tissue of fracture cases 
had a lower amount of collagen cross-links and increased Hcy levels as compared 
to controls.
Alternatively, Hcy may have a direct effect on bone homeostasis by stimulating 
osteoclast formation and osteoclast activity 22. This is corroborated by the fact that 
higher Hcy levels are associated with higher circulating concentrations of bone turn-
over markers 43 A higher bone turn-over could result in bone micro-damage, which 
in turn leads to more fragile bone 44.
On the other hand, Hcy is produced as a result of demethylation of methionine. 
During this reaction, a free methyl group is donated and available to methylate DNA 
and/or proteins in the cell. Higher Hcy levels could therefore, refl ect an impaired 
methylation status. Elevated Hcy levels may thus be an indirect indicator of elevated 
intracellular S-adenosylhomocysteine (SAH) and compromised cellular methylation 
capacity. It was indeed shown that higher circulating SAH levels are associated with 
decreased methylation of lymphocyte DNA 45,46. In addition, folate treatment was 
shown to lower Hcy levels and simultaneously restore DNA methylation to normal 
levels and correct the patterns of abnormal gene expression both in animal models 
47 and humans 48. Thus, the decreased methylation associated with high Hcy levels 
may alter gene regulation, which could eventually lead to disease. This hypothesis 
was supported by studying a gene, called Proliferation Associated SNF2-like Gene 
(PASG), which facilitates DNA methylation. They demonstrated that the disruption 
of PASG causes global hypomethylation, developmental growth retardation and a 
premature aging phenotype, including osteoporosis 49,50.
In conclusion, there are convincing data to support an association between Hcy 
levels and fracture risk. There are moderate evidence suggest a positive association 
between BMD and vitamin B12 and folate status It is diffi cult to draw fi rm con-
clusions on the relation between B vitamins and bone health. This is due to the 
heterogeneity in the assessment methodology, and a lack of standardized threshold 
levels for categorizing low B vitamins status.
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Appendix I. Key words.
#1 (BMD OR ”bone mineral” OR” bone density” OR”bone loss” OR Fracture OR osteopor*)
#2 (homocyst* OR folate OR folic acid OR cobalamin OR B11 OR B12 OR ribofl avin OR B2
OR “B vitamin” OR pyridoxine OR B6)
#2 AND #3
*denotes any extension for the key words to cover all the related topics.
Appendix II. Levels of evidence for interpretation of the study results 17.
Level of evidence Interpretation
Strong evidence Consistent fi ndings (>75%) in multiple high-quality studies
Moderate evidence Consistent fi ndings (>75%) in:
- one high-quality study and some other low-quality studies
- multiple low-quality studies
Limited evidence Only one high-quality study
Confl icting evidence Inconsistent fi ndings in several studies of equal quality
Insuffi cient evidence Less than 2 low-quality studies available
No evidence No studies could be found
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CHAPTER 3
Effect of dietary B vitamins on BMD 
and risk of fracture in elderly men and 
women The Rotterdam Study
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Abstract
A mildly elevated homocysteine (Hcy) level is a novel and potentially modifi able 
risk factor for age-related osteoporotic fractures. Elevated Hcy levels can have a 
nutritional cause, such as inadequate intake of folate, ribofl avin, pyridoxine or co-
balamin, which serve as cofactors or substrates for the enzymes involved in the Hcy 
metabolism. We examined the association between intake of Hcy-related B vitamin 
(ribofl avin, pyridoxine, folate and cobalamin) and femoral neck bone mineral den-
sity BMD (FN-BMD) and the risk of fracture in a large population-based cohort of 
elderly Caucasians.
We studied 5304 individuals aged 55 years and over from the Rotterdam Study. Di-
etary intake of nutrients was obtained from food frequency questionnaires. Incident 
non-vertebral fractures were recorded during a mean follow-up period of 7.4 years, 
and vertebral fractures were assessed by x-rays during a mean follow-up period of 
6.4 years. We observed a small but signifi cant positive association between dietary 
pyridoxine (β=0.09, p=1*10-8) and ribofl avin intake (β=0.06, p=0.002) and baseline 
FN-BMD. In addition, after controlling for gender, age and BMI, pyridoxine intake 
was inversely correlated to fracture risk. As compared to the three lowest quartiles, 
individuals in the highest quartile of age and energy-adjusted dietary pyridoxine 
intake had a decreased risk of non-vertebral fractures (HR=0.77, 95% CI; 0.65-0.92, 
p=0.005), and fragility fractures (HR=0.55, 95% CI; 0.40-0.77, p=0.0004). Further 
adjustments for other dietary B vitamins (ribofl avin, folate and cobalamin), dietary 
intake of calcium, vitamin D, A and K, protein and energy content, smoking and 
BMD did not essentially modify these results.
We conclude that increased dietary ribofl avin and pyridoxine intake was associ-
ated with higher FN-BMD. Furthermore, we found a reduction in risk of fracture in 
relation to dietary pyridoxine intake independent of BMD. These fi ndings highlight 
the importance of considering nutritional factors in epidemiological studies of osteo-
porosis and fracture.
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Introduction
Osteoporosis is defi ned as a skeletal disorder characterized by compromised bone 
strength predisposing a person to an increased risk of fracture. Several risk factors 
have been identifi ed for osteoporotic fracture, such as age, low body mass index 
(BMI) and low bone mineral density (BMD). More recently, mildly elevated homo-
cysteine (Hcy) concentrations were identifi ed as a novel and potentially modifi able 
risk factor for age-related osteoporotic fractures 1,2.
Hcy is a sulfur-containing amino acid formed from the essential amino acid methi-
onine. Defects in intracellular Hcy metabolism lead to an elevation of plasma Hcy 
concentrations. These metabolic defects can have a genetic cause, i.e., polymor-
phisms in genes involved in the Hcy metabolism. On the other hand, defects in 
the Hcy metabolism can also have a nutritional cause, such as inadequate intake of 
folate (vitamin B11), ribofl avin (vitamin B2), pyridoxine (vitamin B6) or cobalamin 
(vitamin B12) which serve as cofactors or substrates for the enzymes involved in 
the Hcy metabolism 3,4. It is well established that increased plasma Hcy concentra-
tions are associated with low dietary intake of ribofl avin, folate, cobalamin, and 
pyridoxine 5-7.
Several epidemiological studies have shown a positive association between folate 
and/or cobalamin status and bone end points. Some have found that higher serum 
concentrations of cobalamin 8-11 or folate 12 are associated with increased BMD, 
decreased bone loss 13, and decreased risk of fracture 9,14. In addition, a randomized, 
double-blinded study in Japanese patients, showed that combined serum cobalamin 
and folate supplementation was effective in preventing hip fracture presumably by 
decreasing Hcy concentrations 15. This indicates a possible effect of folate and co-
balamin on bone strength through effects on the Hcy metabolism. There are limited 
data available on the effect of Hcy-related B vitamins on bone end points, especially 
the risk of fracture.
We examined the relation between intake of the Hcy-related B vitamins (ribo-
fl avin, pyridoxine, folate and cobalamin) and BMD and risk of fracture in a large 
population-based cohort of individuals aged 55 years and over.
Materials and methods
Study population
This study was conducted within the framework of the Rotterdam Study, an ongoing 
prospective population-based cohort study among subjects aged 55 years and over, 
living in Ommoord, a suburb of Rotterdam, the Netherlands. The rationale and 
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design of the Rotterdam Study have been described elsewhere 16. Approval of the 
Medical Ethics Committee of the Erasmus University Rotterdam was obtained. From 
all participants written informed consent was acquired. We studied 5304 subjects 
who had data available on dietary intake.
Anthropometric measurements
Height (cm) and weight (kg) were measured at the initial examination, in standing 
position wearing indoor clothes without shoes. Body mass index (BMI) was calcu-
lated as weight in kilograms divided by height in centimeters squared (kg/cm2).
Dietary intake
Dietary intake of vitamins (including ribofl avin, pyridoxine, cobalamin folate, vi-
tamin A, vitamin K, vitamin D and calcium intake) and use of supplements were 
assessed using validated food intake data obtained from a food frequency question-
naire. A validation study comparing this questionnaire with a 2-week food diary 
demonstrated reproducible and valid estimates 17,18. For dietary vitamin B intake data 
were available for 5304 subjects. Dietary vitamin B intake was adjusted for age and 
energy intake as described elsewhere 19. Persons who reported taking supplements 
containing vitamins B2 (ribofl avin), B6 (pyridoxine), B12 (cobalamin) or B-complex, 
as well as multivitamins, were classifi ed as B vitamin supplement users (n=790).
Potential confounders
The presence of type 2 diabetes mellitus was defi ned by the current use of antidi-
abetic medication or by a non-fasting or post-load plasma glucose level above 11.1 
mmol per liter. Concentrations of serum creatinine were measured with the use of 
standard laboratory procedures. Prevalence of myocardial infarction was defi ned 
according to the international classifi cation of diseases, 10th revision (ICD-10) 20. 
Dementia was diagnosed with the use of the mini–mental state examination and 
the geriatric mental state schedule 20. The number of falls in the preceding year, and 
current smoking status were assessed with the use of a questionnaire. A lower limb 
disability index was obtained by calculating the mean score of answers to questions 
concerning rising, walking, bending, and getting in and out of a car. The index is 
represented by a continuous score, ranging from 0 to 3, where 0 indicates no impair-
ment and 3 indicates severe impairment 21.
Measurement of Hcy levels
Non-fasting blood samples from 738 subjects at baseline were immediately placed on 
ice and processed within 60 minutes. At baseline, serum samples were kept frozen 
until Hcy levels were measured. Total Hcy levels were determined as a fl uorescence 
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derivate with the use of high-pressure liquid chromatography and expressed as 
micro mol per liter (μM/L) 22,23.
Measurement of bone parameters
BMD (in grams per square centimeter) of the hip and lumbar spine (L2-L4) was 
measured by dual-energy x-ray absorptiometry (DXA) using a Lunar DPX- densitom-
etry apparatus (DPX-L, Lunar Corp. Madison, WI, USA), under standard protocols. 
Methods, quality, assurance, accuracy, and precision issues of the DXA measure-
ments have been described previously (n=4891) 24. To increase the accuracy of BMD 
measurements on follow-up, the search and template tools in the comparison mode 
were used to position the femoral neck region of interest in scans of the same 
individual. The rate of change in BMD was calculated as the differences between 
baseline and the second follow-up, with a mean follow-up period of 6.5 ± 0.6 (SD) 
years (n=2422).
Fracture follow-up
Fracture events were obtained from the computerized records of the general practi-
tioners (GPs) in the research area. Research physicians regularly followed participant 
information in the GP’s records outside the research area, and made an independent 
review and encoding of all reported events. Subsequently, a medical expert in the 
fi eld reviewed all coded events for the fi nal classifi cation of diseases, 10th revision 
(ICD-10)20. Additional information on hip fractures was gathered through the Dutch 
national hospital registration system. Information on incident non-vertebral fractures 
has been collected within an average follow-up period of 7.4 ± 3.3 (SD) years. For 
studying incident fractures, all fractures which were considered not osteoporotic 
(fractures caused by cancer and all hand, foot, skull, and face fractures) were ex-
cluded. We considered separately fragility fractures occurring at the hip, pelvis and 
proximal humerus 25.
Vertebral fracture assessment
Both at baseline (1990-1993) and at the second follow-up visit (between 1997 and 
1999) thoracolumbar radiographs of the spine were available for 3469 individuals 
in a mean follow-up of 6.4 years. All thoracolumbar radiographs of the follow-up 
visit were scored for the presence of vertebral fracture using the McCloskey/Kanis 
method, as described previously 26. If vertebral fractures were detected, the baseline 
radiograph was also evaluated. If the vertebral fracture was already present at base-
line, it was considered to be a baseline prevalent fracture. If it was not present at 
baseline, the fracture was defi ned to be incident.
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Statistical analysis
To examine a relation between dietary intake and BMD, a multivariable linear regres-
sion analysis was used. In this analysis femoral neck BMD (FN-BMD) and lumbar 
spine BMD (LS-BMD) were used as dependent variables and gender, age, BMI, 
dietary B (ribofl avin, pyridoxine, folate, cobalamin) vitamins intake, calcium, vitamin 
D, K, and A, protein and energy content energy and protein intake were used as 
covariates. We applied a stepwise multiple regression approach to identify the best 
predictors for baseline BMD. Analysis of variance (ANOVA) was used to examine the 
associations between baseline general characteristics across quartiles of pyridoxine 
intake. Analysis of covariance (ANCOVA) was performed to adjust for possible con-
founders such as BMI, age and important factors related to co-morbidity. Variables 
were log transformed if they did not meet normality assumptions, this was the 
case for Hcy levels and dietary intake of folate and cobalamin. Quartiles of dietary 
pyridoxine intake were created for each gender after adjustment for age and energy 
by using the residual method 19.
Incidence rates for all non-vertebral fractures were calculated by dividing the 
number of incident cases by the total number of fracture-free person-years, and 
95% confi dence intervals (CI) were calculated using the exact Poisson formula. 
The incidence rate of non-vertebral fractures was calculated for quartiles of dietary 
pyridoxine intake (age and energy-intake adjusted), taking the quartile with lowest 
pyridoxine intake as reference for the Cox proportional hazards analysis.
Cox’s proportional hazards regression was used to calculate the hazard ratio (HR) 
and the 95% CI to estimate the relative risk of non-vertebral fractures. Odds ratios 
(OR) and 95% CI to assess vertebral fracture risk were estimated using logistic regres-
sion. Cox proportional hazards analysis was used to evaluate the contribution of 
dietary pyridoxine intake to mortality, based on a proportional hazards model.
All analyses were adjusted for gender, age and BMI. Subsequently, additional 
adjustments were made for the following confounders: Dietary B vitamins other 
than pyridoxine (ribofl avin, cobalamin and folate), vitamin A and vitamin K intake, 
protein intake, current smoking, type 2 diabetes, serum creatinine, prevalence of 
myocardial infarction at baseline, history of recent falls, lower limb disability, and 
disability index.
All analyses were done using the SPSS package version 11 (SPSS, Chicago, IL, 
USA). P-values lower than 0.05 were considered signifi cant.
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Results
General characteristics of the study population are presented in Table 1. For each 
of the four B vitamins we found a signifi cant association with both FN-BMD and 
LS-BMD after correcting for intake of protein, energy, gender, age and BMI (Table 2). 
Furthermore, we observed that for baseline FN-BMD among the B-vitamins, ribo-
Table 1. Baseline characteristics of the study population
Characteristic Study population
n=5304
Age (years) 67.66 ± 7.75
Height (cm) 167.20 ± 9.20
Weight (kg) 73.63 ± 11.66
Body mass index (kg/m2) 26.33 ± 3.66
Dietary intakes
Ribofl avin (mg/day) 1.59 ± 0.56
Pyridoxine (mg/day) 1.63 ± 0.40
Folate (μg/day) 218.60 ± 77.99
Cobalamin (μg/day) 5.26 ± 4.55
Vitamin K (μg/day) 264. 7 ± 127.2
Vitamin A (μg/day) 1090.9 ± 781.6
Vitamin D (μg/day) 1.58 ± 1.01
Calcium (mg/day) 1127.0 ± 401.0
Protein intake (g/day) 81.33 ± 19.50
Energy intake (kJ/day) 8253.5 ± 2106.6
Current smoking (%) 23.2
Femoral neck BMD (g/cm2) 0.87 ± 0.14
Lumbar spine BMD (g/cm2) 1.09 ± 0.20
Data given as mean ± SD
Table 2. Single linear regression analysis between dietary B vitamin intakes and BMD in 5304 men 
and women in the Rotterdam Study
Dietary B 
vitamins intake
Model 1 Model 2
FN-BMD LS-BMD FN-BMD LS-BMD
β† p-value†† β p-value†† β p-value†† β p-value††
Ribofl avin 0.082 2.6*10-11 0.058 7*10-6 0.10 7*10-4 0.079 6*10-5
Pyridoxine 0.061 3*10-6 0.041 0.003 0.07 4*10-4 0.069 0.001
Folate 0.043 0.001 0.041 0.002 0.03 0.05 0.04 0.01
Cobalamin 0.039 0.001 0.026 0.049 0.01 0.55 0.01 0.51
Model 1: adjusted for gender, age and BMI.
Model 2: Model 1 plus adjustment for energy intake and protein intake.
† Standardized coeffi cients beta, FN: femoral neck; LS: lumbar spine.
†† Calculated by using linear regression.
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fl avin was the strongest predictor (β=0.09, p=1*10-8) and pyridoxine was a good 
predictor (β=0.06, p=0.002) (Table 3). Gender, age and BMI explained 24% of the 
variation in FN-BMD. Pyridoxine and ribofl avin together explained 1% extra varia-
tion (data not shown). For LS- BMD we found similar results for ribofl avin (β=0.06, 
p=1*10-5) and pyridoxine (β=0.06, p=0.002) (Table 3). At the lumbar spine, gender 
and BMI explained 16% of the variation in BMD, while pyridoxine and ribofl avin 
together also explained another 1% of the variation (data not shown). Age was not 
a predictor for LS-BMD. Furthermore, in a separate analysis we additionally adjusted 
for age at menopause and parity. These adjustments did not affect the results (data 
not shown).
We investigated whether B vitamin intake was associated with non-vertebral and 
fragility fractures. Only pyridoxine (as a continuous variable) was inversely associ-
ated with non-vertebral, fragility and vertebral fractures (Table 4). Further adjustment 
for other nutritional factors, (including four dietary B vitamins intake (ribofl avin, 
pyridoxine, cobalamin, folate) and dietary of :vitamin D, calcium, vitamin A and 
vitamin K intake) and baseline FN-BMD or co-morbidity, did not essentially change 
the result.
Table 3. Multivariable regression analysis of determinants of femoral neck and lumbar spine BMD in 
5304 men and women in the Rotterdam Study
Starting model Final Model
Variable FN-BMD LS-BMD FN-BMD LS-BMD
β† p-value†† β† p-value†† β† p-value†† β† p-value††
Female -0.33 10-112 -0.35 10-116 -0.33 10-112 -0.35 10-116
Age (years) -0.27 10-98 -0.004 0.75 -0.27 10-99 - -
Body mass index (kg/m2) 0.28 10-102 0.25 10-74 0.28 10-102 0.25 10-74
Ribofl avin (mg/day) 0.11 10-8 0.08 0.0002 0.09 10-8 0.06 10-5
Pyridoxine (mg/day) 0.07 0.002 0.06 0.01 -0.06 0.002 -0.06 0.002
Energy intake (kJ/day) -0.05 0.01 -0.07 0.002 -0.06 4*10-4 -0.08 10-5
Folate (μg/day) -0.02 0.46 0.01 0.73 - - - -
Vitamin D -0.01 0.88 -0.01 0.42 -
Calcium 0.01 0.68 -0.02 0.29 - - -
Vitamin A 0.003 0.88 0.003 0.90 - - -
Vitamin K -0.01 0.53 -0.03 0.07 - - -
Cobalamin (μg/day) -0.01 0.50 -0.01 0.51 - - - -
Protein intake (g/day) -0.03 0.29 -0.03 0.27 - - - -
† Standardized coeffi cients beta. †† calculated by using linear regression. FN: femoral neck; LS: lumbar 
spine. In the multivariable linear regression analysis FN-BMD or LS-BMD was used as the dependent 
variable and gender, age, BMI, dietary B (ribofl avin, pyridoxine, folate, cobalamin) vitamins intake, dietary 
intakes of: calcium, vitamin D, K, and A, protein and energy content were used as covariates. In the fi nal 
regression model, only variables signifi cantly and independently associated with FN-BMD (LS-BMD) were 
selected through a stepwise regression method. Adjusted R2 for fi nal model (SE); FN-BMD: (0.25 ± 0.12, 
p<0.001); LS-BMD: (0.17 ± 0.18, p<0.001).
Nahid BW.indd   60 31-Oct-07   15:31:30 PM
C
h
ap
te
r 
3
61
Table 5 shows the comparisons of general characteristics of the study population 
across quartiles of (age and energy adjusted) intake of pyridoxine. There was a sig-
nifi cant difference in weight, BMI, dietary intake of ribofl avin, folate and cobalamin 
across quartiles of dietary pyridoxine intake (p<10-4) (Table 5). Supplemental therapy 
did not differ across quartiles. To avoid confounding by supplement use, we also 
performed the analyses excluding users of supplements but the results remained 
unchanged (n = 790, 9.9%) (data not shown). FN-BMD and LS-BMD increased within 
quartiles of dietary pyridoxine intake (p=10-4). Moreover, we observed a signifi cantly 
reduced bone loss at the femoral neck; the latter result remained unchanged after 
adjustment for baseline FN-BMD.
Comparison of a number of important factors related to co-morbidity across quartiles 
of dietary pyridoxine intake are presented in Table 6. Subjects in the highest quartile 
of dietary pyridoxine intake had the lowest percentage of current smoking. The 
remainder of the factors related to co-morbidity did not differ across the quartiles. 
The results were not affected by adjustement for other nutritional factors.
Figure 1 shows the incidence rate of non-vertebral (A) and fragility (B) fractures, 
and percentage of vertebral fractures (C) by quartiles of dietary pyridoxine intake. 
Table 4. Association of dietary pyridoxine intake as a continuous variable with risk of fracture in 
5304 men and women in the Rotterdam Study
Types of fracture No. fracture/ Total no (%) β † Relative Risk (95% CI) p-value††
Non-vertebral
Model 1 744/5304 (14.0) -0.25 0.78 (0.60-1.00) 0.06
Model 2 -0.36 0.70 (0.49-1.00) 0.05
Model 3 -0.45 0.64 (0.42-0.98) 0.04
Fragility
Model 1 279/5304 (5.3) -0.54 0.58 (0.38-0.90) 0.02
Model 2 -0.85 0.43 (0.24-0.77) 0.004
Model 3 -1.09 0.34 (0.18-0.64) 0.001
Vertebral
Model 1 328/3003 (6.2) -0.44 0.64 (0.42-0.98) 0.04‡
Model 2 -0.63 0.46 (0.33-1.20) 0.16 ‡
Model 3 -0.64 0.53 (0.27-1.04) 0.06 ‡
Model 1: Adjustment for gender, age, BMI and energy intake
Model 2: Model 1 plus additional adjustments including: dietary intake of ribofl avin, cobalamin, folate, 
protein, calcium, vitamin D, vitamin K, vitamin A and co-morbidity status including; prevalence of 
myocardial infarction, type 2 diabetes, dementia, creatinine level, current smoking and recent falling
Model 3: Model 2 plus additional adjustment for FN-BMD for all non-vertebral and fragility fractures, For 
vertebral fractures adjustment for LS-BMD
† Indicates beta coeffi cient by unit of milligram per day
††Calculated by Cox’s proportional hazards regression, ‡Calculated by logistic regression
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The results suggest a possible threshold between the fourth and the three remaining 
quartiles of dietary pyridoxine intake. There was a decreased risk of fractures in 
the highest quartile of dietary pyridoxine intake compared with the three remaining 
quartiles (for incidence of non-vertebral fracture HR=0.77, 95%CI; 0.65-0.92, p=0.005, 
for fragility fracture HR=0.55, 95%CI; 0.40-0.77, p=4*10-4 and for vertebral fracture 
OR=0.86; 95%CI; 0.65-1.13, p=0.27) after controlling for gender, age and BMI. Further 
adjustment for other dietary B vitamins, protein, energy intake, calcium, vitamin D, 
Table 5. General characteristics of age and energy-adjusted pyridoxine quartiles in 5304 men and 
women in the Rotterdam Study
Quartile 1 Quartile 2 Quartile 3 Quartile 4 p-value†
n=1326 n=1325 n=1327 n=1326
Mean pyridoxine (mg/day) 1.30 1.50 1.67 2.03
Male (%) 40.8 40.8 40.8 40.8
Age (year) 67.64 ± 0.21 67.61 ± 0.21 67.96 ± 0.21 67.42 ± 0.21 0.34
Weight (kg) 72.52 ± 0.29 73.60 ± 0.29 74.27 ± 0.29 74.14 ± 0.29 10-7
Height (cm) 167.12 ± 0.17 167.09 ± 0.17 167.42 ± 0.17 167.17 ± 0.17 0.51
BMI (kg/m2) 25.95 ± 0.10 26.35 ± 0.10 26.50 ± 0.10 26.54 ± 0.10 10-7
Ribofl avin (mg/day) 1.41 ± 0.01 1.50 ± 0.01 1.61 ± 0.01 1.83 ± 0.01 10-94
Folate (μg/day) †† 177.83 ± 0.07 196.20 ± 0.07 214.42 ± 0.07 252.93 ± 0.07 10-256
Cobalamin (μg/day) †† 4.02 ± 0.07 4.27 ± 0.07 4.41 ± 0.07 5.05 ± 0.07 10-15
Protein intake (g/day) 74.56 ± 0.48 78.29 ± 0.48 81.94 ± 0.48 90.51 ± 0.48 10-126
Femoral neck BMD (g/cm2) 0.853 ± 0.004 0.861 ± 0.004 0.880 ± 0.004 0.879 ± 0.004 10-4
Lumbar spine BMD (g/cm2) 1.074 ± 0.005 1.076 ± 0.005 1.099 ± 0.005 1.106 ± 0.005 10-4
Rate of change FN-BMD 
(g/cm2 per yr)
-0.0067 ± 
0.0004
-0.0064 ± 
0.0004
-0.0052 ± 
0.0004
-0.0055 ± 
.0004
0.01
Data given as mean ± SE. Adjustment for gender and age.
† Calculated by Analysis of variance (ANCOVA) †† Back log transformed
Table 6. Comparison of co-morbidity markers by quartiles of dietary pyridoxine intake in 5304 men 
and women in the Rotterdam Study
Quartile 1 Quartile 2 Quartile 3 Quartile 4 p-value†
n=1326 n=1325 n=1327 n=1326
Mean pyridoxine (mg/day) 1.30 1.50 1.67 2.03
Co-morbidity
Dementia 3.5 (47) 3.7 (49) 4.2 (56) 3.2 (42) 0.55
Current smoking 31.0 (401) 23.9 (308) 21.0 (273) 17.7 (230) 0.01
Diabetes 9.5 (126) 10.0 (132) 10.8 (143) 12.1 (160) 0.15
Prevalent MI 13.0 (170) 11.6 (150) 12.3 (160) 12.0 (156) 0.69
Recent fall 14.8 (196) 15.0 (199) 13.1 (174) 13.1 (174) 0.32
Disability index >= 0.5 26.5 (351) 24.0 (318) 24.3 (322) 23.5 (311) 0.33
Data given as percentage (cases)
†Calculated by Analysis of variance (ANOVA)
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Figure 1. Incidence rate of A. non-vertebral fracture and B. fragility fracture and C. rate of vertebral 
fracture by quartiles of dietary pyridoxine intake.
HR: hazard ratio, CI: confi dence interval, Q: quartile
Quartiles of dietary pyridoxine intake were defi ned by gender, age and energy intake adjusted.
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A and K intake, co morbidity, and baseline FN-BMD did not alter the results. For the 
other three B vitamins we found no association with fractures (data not shown).
Since subjects with low vitamin intake might have increased mortality related to 
lifestyle or co-morbidity, we investigated the risk of mortality by quartiles of pyri-
doxine intake (Figure 2). Subjects in the lowest quartile had 1.24 times higher risk of 
mortality compared with the three remaining quartiles (95% CI; 1.09-1.40, p=0.001).
Table 7 shows the association between fractures and pyridoxine intake in the 
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Figure 2. Risk of mortality by quartiles of dietary pyridoxine intake (highest quartile is reference), 
Gender and age adjusted
Table 7. Association of fragility fracture and dietary pyridoxine intake in a subgroup of 738 subjects
with Hcy measurement
Fractures No.fracture/ Total no (%) Relative risk p-value†
Non-vertebral
Model 1 101/739 (13.7) 0.56 (0.30-1.06) 0.08
Model 2 0.59 (0.31-1.13) 0.11
Fragility
Model 1 42/739 (5.7) 0.37 (0.13-1.06) 0.06
Model 2 0.40 (0.13-1.16) 0.09
Vertebral
Model 1 45/428 (6.1) 0.60 (0.24-1.53) 0.29
Model 2 0.71 (0.28-1.79) 0.47
†Calculated by Cox’s proportional hazards regression
Model 1: Gender, age and BMI adjusted
Model 2: Model 1 plus adjustment for Hcy measurement
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subset (n=738) of subjects who had Hcy measurements in this subset. Adjustment for 
Hcy levels did not alter the association with fractures.
Discussion
In this population-based study in elderly individuals we observed a positive and 
independent relation between dietary intake of ribofl avin and pyridoxine with BMD. 
Furthermore, high intake of pyridoxine was associated with a signifi cantly decreased 
risk of fracture. This effect was not modifi ed either by factors related to co-morbidity 
or by dietary intake of other B vitamins (ribofl avin, folate, cobalamin), energy, pro-
tein, calcium and vitamin D. In addition, this effect appears to be independent of 
FN-BMD.
Pyridoxine and certain other B vitamins (ribofl avin, folate and cobalamin) function 
as cofactors for enzymes that maintain low Hcy levels 27. We hypothesized that high 
intakes of ribofl avin, folate, pyridoxine and cobalamin might be related to a lower 
risk of osteoporotic fracture by decreasing Hcy levels. Several biological mechanisms 
could explain how elevated Hcy levels are related to fracture risk. It has been sug-
gested that Hcy concentrations may interfere with collagen cross-linking, resulting 
in poor quality of bone and increased susceptibility to fracture 28. Alternatively, Hcy 
or related B-vitamins could affect the bone cells directly, something that has been 
suggested by recent studies of Herrmann et al., who observed direct effects of Hcy 
on osteoclasts 29.
Among the four studied B vitamins we observed that only higher dietary pyridoxine 
intake was associated with lower risk of fracture. After correcting for Hcy levels, the 
increased risk of fracture at low pyridoxine intake remained unchanged, suggesting 
that the effect of pyridoxine is independent of Hcy levels. However, since Hcy levels 
were available only for a small subgroup of our population and were measured only 
once, we cannot fully address the question whether or not the protective effect of 
dietary pyridoxine on fracture risk is mediated through lowering Hcy or not. The 
lack of a sizeable population in which both Hcys and B-vitamins are measured also 
makes it diffi cult to compare the effect-sizes and/or examine interaction between the 
two factors with respect to their effect on fracture risk.
The present study confi rms earlier fi ndings that gender and BMI are the main 
determinants of FN-BMD and LS-BMD. Among the four B vitamins, only pyridoxine 
and ribofl avin were independent predictors for BMD. This result is not consistent 
with previous studies which reported cobalamin 9,13 or folate 12 to be important 
determinants of BMD; however, these studies did not examine the status of ribofl avin 
and pyridoxine. In a study by Macdonald et al. 30 a weak but signifi cant association 
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was observed between intake of each single dietary B complex vitamins and BMD; 
however, most of these associations disappeared after adjustment for confounders 
such as age, height, weight and smoking. Because they did not consider all four B 
vitamins in a multivariate analysis, this, casts doubt on whether the associations of 
the B vitamins with BMD were independent of each other or not. In contrast, in the 
present study we examined contributions of all B vitamins in a multivariate approach 
in order to explain the variation in BMD and found the effects of both pyridoxine 
and ribofl avin to be independent of each other.
Little is known about an effect of pyridoxine on bone. However, some reports 
suggest a role for this vitamin in maintaining structural integrity of connective tis-
sue. Pyridoxine serves as an essential co-factor for lysyl oxidase, a key enzyme 
for the formation of enzymatic cross-links in bone 31. Mice studies showed that 
pyridoxine defi ciency results in a low (25.3%) amount of cross-link intermediates 
and impaired cross-link formation in bone 32. In addition, a correlation was found 
between decreased circulating pyridoxine concentrations and impaired cross-link 
formation in bone of human individuals with fracture 33. These observations suggest 
that pyridoxine defi ciency may lead to impaired cross-link formation, resulting in 
increased bone fragility.
It is known that pyridoxine acts not only as a cofactor for lysyl oxidase but also as 
cofactor for over 100 enzyme-catalysed reactions in the body, including many involved 
in the synthesis or catabolism of neurotransmitters including gamma-aminobutyrate 
(GABA) 34. Therefore, pyridoxine defi ciency could affect the locomotor system and 
thus, increase the risk of falling, and thereby increase fracture rates. However, we 
did not observe an effect of pyridoxine intake on the rate of falls, which makes this 
a less likely explanation.
Because low dietary intake of vitamins may refl ect bad dietary habits or compro-
mised health, we studied mortality rates across quartiles of dietary pyridoxine intake 
and found an increased risk of mortality in individuals in the lowest quartile. This 
selective mortality might have reduced the contrast in fracture risk between the low-
est quartile and the highest quartile. Thus, subjects in the lowest quartile of dietary 
pyridoxine intake may have died before a fracture could have occurred. Therefore, 
the real effect of low pyridoxine intake on fracture risk in the lowest quartile might 
be even larger than that observed in our study.
The main strengths of the present study are the size of our study population, 
and the validated dietary assessment. The study also has some limitations. Because 
we did not have serum levels of B vitamins available to study their relation with 
BMD and fractures, our fi ndings are likely to be biased by self-report. Furthermore, 
only baseline dietary intakes were available, and duration of any possible vitamin 
B defi ciency could not be assessed. Nevertheless, in Europe the dietary intakes 
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are relatively stable over time, especially among the elderly 35. The validated food 
frequency test is therefore a good measure for long-term assessment of nutrient 
intake. Using supplement therapy might dilute the relation between the quartile of 
pyridoxine intake with fracture. Nonetheless, our results were unchanged after either 
excluding supplement users at baseline (9.9%) from the analysis, or after controlling 
for B vitamin supplement use, suggesting that it is highly unlikely that residual 
confounding caused by intake of vitamin B supplements infl uenced our results. 
Although we adjusted for known confounders (such as important factors related 
to co-morbidity and using B vitamin supplements and dietary intake of vitamin K, 
A and, D), we cannot completely exclude that the effect of pyridoxine intake on 
fracture may be a refl ection of residual confounding by unknown factors.
In conclusion, we observed a reduction in the risk of fracture in relation to dietary 
pyridoxine intake. We cannot conclude whether the association between pyridox-
ine and fracture risk is causal. Therefore, performing placebo-controlled trials with 
pyridoxine supplements are needed to elucidate this association. The relative impact 
of pyridoxine intake and Hcy levels and the mechanisms through which these com-
pounds may affect the risk of fracture should also be further investigated.
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CHAPTER 4
The association between polymorphisms 
involved in homocysteine remethylation 
with bone phenotype
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CHAPTER 4.1
Low dietary ribofl avin but not folate 
predicts increased fracture risk in 
postmenopausal women homozygous for 
the MTHFR 677T allele
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Abstract
The MTHFR C677T polymorphism is associated with mildly elevated homocysteine 
(Hcy) levels in the presence of low folate and/or ribofl avin status. A mildly elevated 
Hcy level was recently identifi ed as a modifi able risk factor for osteoporotic fracture. 
We investigated whether dietary intake of ribofl avin and folate modifi es the effects of 
the MTHFR C677T polymorphism on bone mineral density (BMD) and fracture risk.
We studied 5035 individuals, from the Rotterdam Study aged 55 years and older, 
who had data available on the MTHFR, nutrient intake and fracture risk. We have 
performed analysis on Hcy levels in a total of 666 individuals while BMD-data was 
present for 4646 individuals (2692women).
In the total population, neither the MTHFR C677T polymorphism nor low ribo-
fl avin intake was associated with fracture risk and BMD. However, in the lowest 
quartile of ribofl avin intake female 677-TT homozygotes had a 1.8 (95% CI: 1.1-2.9, 
p=0.01) times higher risk for incident osteoporotic fractures and a 2.6 (95% CI: 
1.3-5.1, p=0.01) times higher risk for fragility fractures as compared to the 677-CC 
genotype (p-interaction=0.0002). This effect was not seen for baseline BMD in both 
men and women. No signifi cant infl uence was found of dietary folate intake on the 
association between the MTHFR C677T genotype and fracture risk or BMD. In the 
lowest quartile of dietary ribofl avin intake, T-homozygous individuals (men and 
women combined) had higher (22.5%) Hcy levels compared with C-homozygotes 
(mean difference=3.44 μmol/L, p=0.01) (p-trend=0.02).
In this cohort of elderly Caucasians, the MTHFR C677T variant interacts with di-
etary ribofl avin intake to infl uence fracture risk in women.
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Introduction
Osteoporosis is a condition characterized by low bone mineral density (BMD) and 
micro-architectural change in bone tissue, which leads to reduced bone strength 
and increased risk of fracture 1. Genetic and environmental risk factors interact to 
infl uence BMD, bone loss 2,3, and fracture risk 4. We and others have described that 
mildly elevated circulating homocysteine (Hcy) level is a potentially modifi able risk 
factor for osteoporotic fracture 5,6.
It is not yet clear whether the relationship between homocysteine and fracture risk 
is causal or not. A small placebo-controlled trial in stroke patients showed reduced 
fracture risk in response to lowering Hcy levels suggesting a causal link 7. However, 
this trial needs replication in the general elderly population using an appropriate 
design and suffi cient power to detect the differences in fracture risk 8. Another way 
to demonstrate a causal relationship between increased Hcy and fracture risk is by 
studying genetic variants that determine Hcy levels 9. The most well known genetic 
determinant of homocysteine levels in the general population is the common C677T 
polymorphism in the methylentetrahydrofolate reductase (MTHFR) gene 10.
MTHFR is required for the formation of 5, 10 methyltetrahydrofolate, which in turn 
is necessary to convert Hcy to methionine. The MTHFR C677T variant is associated 
with increased Hcy levels and has been implicated in increased risk of a wide range 
of adverse health conditions throughout life, from birth defects 11 to cardiovascular 
disease 12, cancer 13, pregnancy complications 14, psychiatry disorders 15, and osteo-
porosis 16 in the elderly.
The MTHFR C677T polymorphism results in an alanine (Ala) to valine (Val) sub-
stitution at position 222 of the protein, giving rise to a thermolabile enzyme with 
reduced activity 10. In order to be active MTHFR needs to bind to a cofactor, fl avin 
adenine dinucleotide (FAD), a derivative of ribofl avin. The Val222 (T677) allele af-
fects the binding site for FAD resulting in a lower affi nity for FAD than the C677 
allele 17,18. This binding can be stabilized by the addition of folate or ribofl avin 17,18. 
Therefore, low ribofl avin or folate status may reduce MTHFR activity, especially in 
individuals with the TT genotype, which results in increased Hcy levels. Indeed, 
ribofl avin and folate levels were shown to be predictors of Hcy levels in individuals 
homozygous for the MTHFR T677, and it is thought that higher ribofl avin and folate 
intake are required in T-homozygous individuals to maintain low Hcy levels 17,19,20.
A number of studies found a relationship between this polymorphism and BMD 
16,21,22 or fracture 16. Some studies have investigated the association of the MTHFR 
C677T variant with BMD in relation to the four B-vitamins (ribofl avin (B2), pyridoxine 
(B6), folate (B11), and cobalamin (B12)) involved in the homocysteine metabolism 
22-24 but results are inconsistent. These inconsistencies could be due to differences 
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in nutrient intake across the populations studied, since it is well known that the 
phenotypic expression of the MTHFR C677T variant is dependent on folate and 
ribofl avin status.
We have examined the infl uence of ribofl avin and/or folate status on the relation 
between the MTHFR C677T variant and risk of fracture and investigated whether 
the dietary ribofl avin and folate intake infl uence the relationship of MTHFR C677T 
variant with BMD, bone loss, and Hcy levels in a large population-based prospective 
cohort of elderly Caucasian of the Rotterdam Study.
Materials and Methods
Study population
This study was embedded in the Rotterdam Study, a population–based cohort study 
of men and women in which all residents of the Rotterdam suburb Ommoord aged 
55 years and older were invited to take part. The design of the study has been 
described elsewhere 25. Written informed consent was obtained from all participants 
and the Medical Ethics Committee of the Erasmus Medical Center approved the study. 
Baseline data collection was conducted between January 1990 until June 1993, while 
the follow-up assessment of BMD was performed between July 1996 and December 
1999. A total of 7983 men and women participated in the study (response rate 78%) 
and for the present analysis we studied 5035 men and women who were genotyped 
for the MTHFR C677T variant and had available data on nutrient intake and fracture 
data. We have performed analysis on Hcy levels in a total of 666 individuals and 
BMD data was present for 4646 individuals.
Dietary intake
At baseline participants completed a checklist at home that queried foods and drinks 
they had consumed at least twice a month during the preceding year as well as 
dietary habits, use of supplements, and prescribed diets. Next, during their visit to 
the research center, they underwent a standardized interview with a dietician based 
on the checklist, using a 170-item semi-quantitative food frequency questionnaire. 
A validation study comparing this questionnaire with a 2-week food diary demon-
strated reproducible and valid estimates 26. These dietary data were converted to 
total energy intake and nutrient intake per day with the computerized Dutch Food 
Composition (Dutch Food Composition Table (in Dutch). Rev ed. The Hague, the 
Netherlands: Voorlichtingsbureau voor de Voeding; 2001). Therefore, dietary habits 
were assessed using validated food intake data from a food frequency questionnaire 
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and were available for 5035 men and women who have been genotyped. Dietary 
vitamin B intake was adjusted for energy intake as described elsewhere 27.
Measurement of homocysteine levels
Non-fasting blood samples from 666 subjects at baseline (250 men and 416 women) 
were immediately placed on ice and processed within 60 minutes. Serum samples 
were kept frozen until Hcy levels were measured. Total Hcy levels were determined 
as a fl uorescence derivate with the use of high-pressure liquid chromatography and 
expressed as micro mol per liter (μmol/L) 28,29.
Fracture follow-up
Fracture events were obtained from the computerized records of the general practi-
tioners (GPs) in the research area. Research physicians regularly followed participant 
information in the GP’s records outside the research area, and made an independent 
review and encoding of all reported events. Subsequently, a medical expert in the 
fi eld reviewed all coded events for the fi nal classifi cation of diseases, 10th revi-
sion (ICD-10) 30. Additional information on hip fractures was gathered through the 
Dutch National Hospital Registration system. Information on incident osteoporotic 
fracture was available for an average follow-up period of 7.4 ± 3.3(SD) years (n=707 
fractures). For studying incident fractures all fractures which were considered not 
osteoporotic (fractures caused by cancer and all hand, foot, skull, and face fractures) 
were excluded. We considered separately fragility fractures occurring at the hip, 
pelvic, proximal humerus (n=269 fractures) 31.
Measurement of BMD
BMD (in grams per square centimeter) of the hip and lumbar spine (L2-L4) (LS) 
was measured by dual-energy x-ray absorptiometry (DXA) using a Lunar DPX- 
densitometry apparatus (DPX-L, Lunar Corp. Madison, Wisconsin), under standard 
protocols. To increase the accuracy of BMD measurements on follow-up, the search 
and template tools in the comparison mode were used to position the femoral neck 
region of interest in scans of the same individual using DPX-IQ software. The rate of 
change in BMD (mg/cm2 per year) was calculated as the difference between baseline 
and follow-up BMD divided by the time (in years) elapsed between measurements 
(and multiplied by a factor of 1000 for scale convenience) (mean 6.5 ± SD 0.6 years). 
The relative change of BMD from baseline was estimated as the difference in BMD 
between assessment periods divided by the BMD at baseline.
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Anthropometric measurements
Height (cm) and weight (kg) were measured at the initial examination, in standing 
position wearing indoor clothes without shoes. Body mass index (BMI) was com-
puted as weight in kilogram divided by height in meters squared (kg/m2).
Possible confounders
Possible confounders were taken from measures made at baseline. The presence of 
type II diabetes mellitus was defi ned by the current use of anti-diabetic medication 
or by a non-fasting or post-load plasma glucose levels above 11.1 mmol per liter 32. 
Dementia was diagnosed with the use of the Mini–Mental State Examination and 
the Geriatric Mental State Schedule 33. The presence of myocardial infarction was 
assessed by questionnaires and by analysis the ECG’s using the Modular Electrocar-
diogram Analysis System (MEANS) 34. The number of falls in the preceding year, and 
current smoking status were assessed with the use of a questionnaire.
Genotyping
Genomic DNA was extracted from samples of peripheral venous blood according 
to standard procedures. 1-2 ng genomic DNA was dispensed into 384-well plates 
using a Caliper Sciclone ALH3000 pipetting robot (Caliper LS, Mountain View, CA, 
USA). Genotypes were determined using the Taqman allelic discrimination assay. 
The Assay-by-Design service (www.appliedbio-systems.com) was used to set up a 
Taqman allelic discrimination assay for the MTHFR C677T polymorphism (Primers 
Fw: CCTCAAAGAAAAGCTGCGTGATG Rv: GCACTTGAAGGAGAAGGTGTCT Probes 
FAM-ATGAAATCGACTCCCGC, VIC-ATGAAATCGGCTCCCGC). The PCR reaction 
mixture included 1-2 ng of genomic DNA in a 2 μl volume and the following re-
agents: FAM and VIC probes (200 nM), primers (0.9 uM), 2x Taqman PCR master 
mix (ABgene, Epsom, UK). Reagents were dispensed in a 384-well plate using the 
Deerac Equator NS808 (Deerac Fluidics, Dublin, Ireland). PCR cycling reaction was 
performed in 384 well PCR plates in an ABI 9700 PCR system (Applied Biosystems 
Inc., Foster City, CA, USA) and consisted of initial denaturation for 15 minutes at 
95° C, and 40 cycles with denaturation of 15 seconds at 95° C, and annealing and 
extension for 60 seconds at 60° C. Results were analysed by the ABI Taqman 7900HT 
using the sequence detection system 2.22 software (Applied Biosystems Inc., Foster 
City, CA, USA). To confi rm the accuracy of genotyping results, 332 (5%) randomly 
selected samples were re-genotyped with the same method. No inconsistencies were 
observed.
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Statistical analysis
Allele and genotype frequencies of the MTHFR C677T variant were tested for Hardy-
Weinberg equilibrium proportions with χ2 test.
Analysis of variance (ANOVA) was used to examine the associations between the 
MTHFR C677T variant with Hcy levels and BMD measurements across genotypes 
and quartiles of vitamin intake. Analysis of covariance (ANCOVA) was performed 
to adjust for possible confounders such as BMI, age and co-morbidity. In case of a 
consistent trend, shown as an allele dose effect, we performed a linear regression 
analysis to quantify the association.
Variables were log transformed if they did not meet normality assumptions, this 
was the case for homocysteine levels and dietary folate intake. Ribofl avin and folate 
intake was analysed as a categorical variable with quartile cut-off points. Quartiles 
have been made in a gender specifi c manner and have been energy adjusted.
To estimate incident fracture risk we used Cox proportional hazard models, thereby 
taking potential differences in follow-up time into account with adjustment for age. 
Further adjustments were also made for possible confounders, i.e., type II diabetes 
mellitus, dementia, current smoking status and recent falls. We investigated possible 
interaction between dietary ribofl avin intake and the MTHFR C677T genotype in 
relation to fracture by including a product term of the two main effects in a Cox 
regression model with fracture as the dependent variable. Population attributable 
risks were calculated with the use of the formula {P (RR-1)÷(P (RR-1)+1)}*100, where 
P is the percentage of the population exposed and RR is the relative risk of fracture. 
P-values lower than 0.05 were considered signifi cant. All analyses were done using 
the SPSS package version 11.
Results
Allele and genotype frequencies were in Hardy Weinberg equilibrium proportions 
(p=0.2), with a T-allele frequency of 33%. The T-allele frequency was similar in men 
and women and did not change with age. Table 1 shows general characteristics of 
the study population across MTHFR C677T genotypes. No signifi cant differences in 
age, height, weight and BMI were seen across the MTHFR C677T genotype groups in 
both genders (Table 1). Serum plasma Hcy levels were 3.5 μmol/L (23.9%) higher in 
male TT carriers and 1.1 μmol/L (8.2%) higher in female TT carriers compared to the 
CC genotype with evidence of an allele dose effect (p for trend<0.001 in males and 
p for trend =0.03 in females respectively, Table 1). Overall, women were signifi cantly 
older and had signifi cantly lower dietary intake of nutrients compared with men.
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Hcy levels
In a subset of individuals with Hcy level measurements, we investigated the rela-
tionship between the MTHFR genotype and Hcy levels across quartiles of dietary 
ribofl avin and folate intake. In the lowest quartile of dietary ribofl avin intake, 
T-homozygous individuals (men and women combined) had 3.44 μmol/L higher 
(22.5%) Hcy levels compared with C-homozygotes (p=0.01) (p-interaction=0.05) 
(Figure 1). For dietary folate intake we found similar results, with Hcy levels being 
4.77 μmol/L higher in T-homozygous individuals compared with C-homozygotes 
(p=0.001), (p-interaction=0.1). The results suggested a possible threshold effect in 
the lowest quartile of dietary ribofl avin or folate intake. When we stratifi ed according 
to gender, we only observed a signifi cant effect in women, while in men a similar 
trend was seen, however not reaching signifi cance. Further adjustments for all pos-
sible confounders and factors related to co-morbidity did not alter the results.
Table 1. Baseline characteristics by MTHFR genotype (C677T) in 2093 men and 2942 women of the 
Rotterdam Study
CC CT TT ¶p
Men
N * (%) 961 (45.9) 923 (44.1) 209 (10.1)
Age (y) 67.0 ± 7.4 67.5 ± 7.3 67.4 ± 7.5 0.32
Height (cm) 175.0 ± 6.6 174.8 ± 6.7 175.2 ± 6.5 0.67
Weight (kg) 78.4 ± 10.6 78.7 ± 11.0 77.7 ± 9.9 0.14
Body mass index (kg/m2) 25.7 ± 2.9 26.0 ± 2.9 25.4 ± 2.9 0.03
Ribofl avin (B2) intake (mg/day) 1.68± 0.62 1.63 ± 0.57 1.70 ± 0.70 0.09
Folate (B11) intake (μg/day) (min-max) † 224.8 (75.0-1352.5) 218.2 (67.3-707.3) 222.3 (66.9-915.0) 0.08
N (%) ** 116 (46.4) 116 (.46.4) 18 (7.2)
Hcy level (μmol/L) (min-max) † 14.77 (9.20-37.10) 15.79 (8.30-27.20) 18.30 (10.60-41.40) ‡<0.001
Women
N * (%) 1318 (44.8) 1311 (44.6) 311 (10.6)
Age (y) 68.2± 8.0 67.8 ± 8.0 68.8 ± 8.4 0.12
Height (cm) 161.8 ± 6.4 162.0 ± 6.2 161.4 ± 6.9 0.23
Weight (kg) 69.4 ± 11.4 69.5 ± 11.4 69.6 ± 11.3 0.75
Body mass index (kg/m2) 26.8 ± 4.0 26.7 ± 4.1 26.7 ± 4.0 1.00
Ribofl avin (B2) intake (mg/day) 1.53 ± 0.51 1.54 ± 0.51 1.49 ± 0.49 0.31
Folate (B11) intake (μg/day) (min-max) † 197.8 (45.4-973.7) 199.8 (63.9-1012.7) 196. 9 (84.2-753.0) 0.50
N (%) ** 196 (47.1) 175 (42.1) 45 (10.8)
Hcy level (μmol/L) (min-max) † 13.96 (1.30-38.70) 14.44 (6.20-63.70) 15.10 (8.60-54.40) 0.03
Data are given as unadjusted mean ± SD for continuous variables
†Geometric mean (min-max), ‡P for trend after adjusting for age
* Number of individuals with nutrient intake data, ** Number of individuals with Hcy levels data, ¶ p ANOVA
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MTHFR, ribofl avin and bone82
BMD and BMD-loss
No association was observed in men or women between the MTHFR C677T variant 
and baseline BMD (femoral neck and lumbar spine), BMD-loss at the femoral neck 
and risk of fracture (Table 2).
We investigated the effect of dietary ribofl avin and folate intake on a possible 
relation between the MTHFR C677T genotype and baseline BMD. For this reason we 
grouped individuals by quartiles of dietary ribofl avin or folate intake, and examined 
the relationship between MTHFR genotype and baseline BMD (femoral neck and 
lumbar spine) and bone loss. We observed no effect of the MTHFR genotype on 
baseline BMD across quartiles of dietary ribofl avin or folate intake, neither in FN nor 
in LS (Table 3). However, in women an effect of ribofl avin on the relation between 
MTHFR genotype and BMD-loss was observed. Women with the TT genotype in the 
lowest quartile of dietary ribofl avin intake had higher rate of BMD-loss as compared 
to the CC genotype (1.4 vs 0.9% of baseline-year, p=0.05). Adjustment for age, height, 
weight did not affect the results. We were unable to study whether differences in Hcy 
levels explained the observed association with BMD-loss, because we had a small 
number of people available that had both baseline Hcy levels and bone loss data.
In men, no effect was observed of dietary ribofl avin intake on the relation between 
the C677T MTHFR genotype and baseline BMD (neither in FN nor in LS) or BMD-loss 
(Table 3.A).
Dietary folate intake did not infl uence the relationship between the MTHFR C677T 
genotype and bone parameters in both men and women (supplementary Table 1).
CC 
CT 
TT 
 
  Q1 (Low)                                                Q2                                                          Q3                                                           Q4 (High) 
5.0
7.0
9.0
11.0
13.0
15.0
17.0
19.0
21.0 
 
    Q1 (Low)                                               Q2                                                          Q3                                                            Q4 (high) 
N              66           68            18                            69            61           13                             73           68             7                             61            66           18 
p=0.01 
Figure 1. Homocysteine levels by MTHFR genotype (C677T) in quartiles of dietary ribofl avin intake 
in both men and women.
Bars represents back transformed means, with standard errors. Adjustments were done for gender, age and 
BMI. Hcy levels in TT homozygous subjects in the lowest quartile of dietary ribofl avin intake was compared 
to those with TT genotype in the three remaining quartiles. N denotes numbers of subjects.
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Fracture incidence
We analysed fracture risk according to quartiles of ribofl avin and folate intake, and 
we did not observe an association (data not shown). We next examined the as-
sociation between the MTHFR C677T genotype and incident fracture risk according 
to quartiles of energy-adjusted ribofl avin or folate intake. In the lowest quartile of 
dietary ribofl avin intake, T-homozygous women had an almost 2-fold higher risk for 
incident osteoporotic fracture compared to those with the CC genotype (RR=1.8, 95% 
CI; 1.2-2.9, p=0.01) (p-interaction=0.03) (Figure 2.A). In men we found no interaction 
between dietary ribofl avin intake and the MTHFR C677T genotype with fracture risk 
Figure 2.  
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Figure 2. Incident osteoporotic fracture by MTHFR genotype (C677T) in quartiles of dietary 
ribofl avin intake in women (2A) and in men (2B).
Bars represents hazard ratio’s, with 95% confi dence intervals. Adjustments were done for age and BMI
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(Figure 2.B). The effect of ribofl avin intake was even more pronounced for fragility 
fracture (Figure 3). TT homozygous women in the lowest quartile had a 2.6-fold 
higher risk of fragility fracture compared to those with the CC genotype (RR=2.6, 
95% CI; 1.3-5.1, p =0.01). Highly signifi cant interaction was observed between the 
MTHFR C677T polymorphism, dietary ribofl avin intake and fragility fracture risk 
(p=0.0002) (Figure 3). Adjustment for femoral neck BMD and femoral neck bone 
loss did not alter these results. Additional correction for co-morbidity factors (such 
as dementia, diabetes mellitus type II, prevalence of myocardial infarction, smoking 
status and recent falls) did not affect the results. Similarly, we examined the associa-
tion between the MTHFR C677T genotype and fracture risk according to quartiles of 
energy-adjusted dietary folate intake, but we did not observe any infl uence of dietary 
folate neither in women nor in men.
In the women who had Hcy values available (n=416) we tried to examine whether 
the ribofl avin-intake dependent association between the MTHFR C677T genotype 
and fracture risk was dependent on Hcys levels. In this small and selected group 
we observed an increased fracture risk for T-homozygous women in the lowest 
quartile of ribofl avin intake, which was not reaching signifi cance (RR: 4.03, 95% CI; 
0.61-26.60). Adjustment for baseline Hcy levels did not essentially change this risk 
estimate (RR: 3.75, 95% CI; 0.51-27.48).
Population attributable risk
For women in the lowest quartile of ribofl avin intake we calculated the popula-
tion attributable risk (PAR) for the TT-genotype. The risk of fragility fracture that 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.0 
0.5 
1.0 
1.5 
2.0 
2.5 
3.0 
3.5 
4.0 
CC 
CT 
TT 
 4.0  
 
 3.5  
 
 3.0  
 
 2.5 
 
 2.0 
 
 1.5 
 
 1.0 
 
 0.5 
 
 0.0 
Fr
ag
ili
ty
  r
is
k 
fr
ac
tu
re
 (9
5%
 C
I)
 
  
2.6 (1.3-5.1) 
p=0.01 
    No . Total            317           303           91                              317           328            65                               317          325             67                              319           313           78 
No of fracture          21             24             14                              17             17              3                                 26            19               5                                26             17             2 
                  %           6.6            7.9            15.4                            5.4           5.2             4.6                               8.2           5.8             7.5                              8.2           5.4            2.6 
 Q1 (Low)                                                   Q2                                                                 Q3                                                                 Q4 (High) 
                                       Quartiles of riboflavin intake (energy intake adjusted) 
Women 
Figure 3. Fragility fracture by MTHFR genotype (C677T) in quartiles of dietary ribofl avin intake in 
women.
Bars represents hazard ratio’s, with 95% confi dence interval. Adjustments were done for age and BMI
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was attributable to MTHFR TT-genotype was estimated 17% in women that had 
low ribofl avin intake. In the total population the PAR for the MTHFR TT-genotype 
in combination with low ribofl avin intake was 5%. For all incident osteoporotic 
fractures these PARs were 9% and 2.3% respectively. Therefore, based on our results 
one could argue that, 5% of fragility fractures (or 2.3% of all incident osteoporotic 
fractures) in our female population would potentially be prevented if all women are 
supplemented with ribofl avin. This is much higher in women with low ribofl avin 
intake, where 17% of fragility and 9% of all incident osteoporotic fractures might be 
prevented.
Discussion
This study shows that there is a relationship between the MTHFR C677T genotype 
and fracture risk depending on dietary ribofl avin (vitamin B2) intake. Women ho-
mozygous for the T allele had a higher Hcy level and increased risk for fracture than 
CC homozygotes but only when dietary ribofl avin intake was low.
We recently identifi ed elevated Hcy levels as a new risk factor for fracture 5. This 
risk was independent of known risk factors for fracture, such as BMD. In the present 
study, the increased fracture risk by MTHFR genotype was again independent of 
BMD or other known risk factors for fracture such as age, dementia, cardiovascular 
disease and other measures of co-morbidity. This suggests that an elevated Hcy level 
caused by the MTHFR 677TT genotype in combination with low dietary ribofl avin 
intake is a risk factor predicting fracture independently of other known risk factors 
and supports the initial results in our observational study 8.
Although we observed an effect on fracture, no association between the MTHFR 
C677T variant and BMD was seen. This is in line with one previous study 35, but 
is not consistent with other studies 16,21 that did show effects of this polymorphism 
on BMD. We cannot fully explain this difference, however, our study population is 
older than reported in previous studies. We, therefore, hypothesize that at older age 
perhaps other mechanisms than homocysteine are important in determining BMD.
We did not fi nd any effect of dietary folate intake on the relationship between the 
MTHFR and fracture risk in our cohort. It appears that in our population ribofl avin 
intake is a more important determinant compared to folate intake for increased 
fracture risk in T-homozygous individuals. Our results are consistent with an earlier 
study that reported a signifi cant effect of ribofl avin intake but not folate intake on 
the MTHFR genotype in determining BMD 22.
Previous research on the dietary regulation of increased Hcy concentrations has 
implicated both low folate and cobalamin intakes in elevated levels of homocysteine. 
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However, recent studies suggest that among individuals carrying the MTHFR 677 
TT genotype, ribofl avin status might be a more potent modulator of homocysteine 
levels than folate status 36. In the Framingham Study, an association between the TT 
genotype and Hcy was found to be dependent on low folate status 19. Thus, ribo-
fl avin did not seem to be the limiting nutrient. The most likely explanation for the 
inconsistencies in the aforementioned studies is that mandatory fortifi cation of fl our 
with ribofl avin has been in place since the 1940s in the United States. The impact 
of this policy in optimizing ribofl avin status in the general US population would 
reduce the extent to which ribofl avin is found to be a limiting nutrient in determining 
homocysteine levels in individuals with the TT genotype.
Several biological mechanisms could explain how elevated Hcy levels are related 
to fracture risk. It was suggested that Hcy concentrations may interfere with col-
lagen cross-linking, resulting in poor quality of bone and increased susceptibility 
to fracture 37. Recent evidence showed that higher levels of Hcy are correlated with 
excretion of higher levels of collagen cross-links 38. In a pilot study of 100 indi-
viduals, we also found that high Hcy levels are not associated with lower levels of 
collagen cross-links per excreted collagen molecule, but instead found a tendency 
towards a higher number of collagen cross-links (unpublished data). Yet, these are 
bone resorption markers, and one expects the Hcy effect on bone (if real) to affect 
the quality of newly formed bone, something that is not monitored effectively by any 
of the markers studied so far. In addition, no one knows the exact concentration of 
Hcy at the environment of the active osteoid, and whether it is suffi cient to interfere 
with collagen cross-links. Interestingly, Paschalis et al. 39 observed altered cross-links 
in fragile bone specifi cally in the micro-environment of the bone forming surfaces, 
which would support this hypothesis. In addition, Saito et al. 40 recently showed that 
bone tissue of fracture cases had a lower amount of cross-links and increased Hcy 
levels as compared to controls. An alternative hypotheses explaining the relationship 
between Hcy and fracture was recently suggested by showing that Hcy may have a 
direct effect on bone by stimulating osteoclast formation and osteoclast activity 41. 
This is in line with our observation that women with the TT genotype had higher 
BMD loss (possibly refl ecting higher osteoclast activity) when dietary ribofl avin 
intake was low. However, this effect was only borderline signifi cant and could not 
explain the increased risk of fracture seen in these same individuals. We cannot 
exclude that changes in BMD may occur after the initial fracture, making bone loss 
a secondary phenomenon rather than a causal factor.
Our results do not prove that elevated homocysteine is the cause of the observed 
associations. In a subgroup for whom homocysteine levels were available, adjustment 
of the increased fracture risk for homocysteine levels did not affect the risk estimates. 
However, since data on homocysteine levels was only available in a small number of 
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individuals, it is diffi cult to draw any conclusion from this analysis. Nevertheless, it 
is possible that the higher risk of fracture is not caused by higher Hcy levels, but by 
other factors related to a higher Hcy level such as impaired DNA methylation 42,43.
In men, no association was observed between the MTHFR C677T variant and risk 
of fracture by dietary ribofl avin intake. An explanation for this noticeable difference 
in effect by gender is not immediately apparent, however, due to the lower incidence 
of fracture in men, lack of power to detect an association in men might contribute to 
this. For studying the effect of low dietary ribofl avin intake together with the MTHFR 
genotype on risk of fracture, the sample size permitted us to detect a relative risk of 
2.3 with 80% power for fragility fracture in women. In men we had 80% power to 
detect a relative risk of 3.2 or more (For all incident fractures the required relative 
risks are 1.9 in women and 2.5 in men). In addition, men might have a different 
threshold for dietary ribofl avin intake, below which the effect of the MTHFR C677T 
genotype can become apparent, since in general ribofl avin intake was higher in men 
compared to women. Further studies are needed to elucidate the gender specifi city 
of our fi ndings.
Population stratifi cation might be a confounder in genetic association studies. 
However, because our study has a population-based cohort design and consists of 
ethnically homogenous elderly Dutch Caucasian living in a stable area with little 
emigration/immigration, we believe that stratifi cation is not a major concern in our 
study.
The strengths of the present study lies within the size of our study population 
and validated dietary assessment with high response rate. The study has also some 
limitations. Only baseline dietary intakes were available and not vitamin levels while 
combination of dietary intake and vitamin levels might provide a better predictive 
power for vitamin effects on bone health than dietary vitamin intake alone. Although 
our study is large, it represents a single observation concerning this interaction. 
Replication of this fi nding in different populations is necessary to establish its con-
sistency.
In conclusion, while the MTHFR C677T variant had no overall effect on fracture 
risk, it strongly interacts with dietary ribofl avin intake to determine fracture risk in 
our cohort of elderly Caucasian women. A low dietary ribofl avin status results in 
a higher fracture risk for TT genotype women. This suggests that ribofl avin intake 
modifi es the effect of the MTHFR C677T variant on fracture risk. This study highlights 
the importance of exploring gene-environment interaction in osteoporosis.
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Abstract
An elevated Homocysteine (Hcy) concentration has been identifi ed as a potentially 
modifi able risk factor for osteoporotic fractures. To gain more insight into the poten-
tial underlying mechanism, we studied a polymorphism involved in the remethylation 
of Hcy in relation to bone mineral density (BMD) and fracture risk. This enzymatic 
step is fully dependent on cobalamin (vitamin B12).
We examined 4744 men and women who were genotyped for the methionine syn-
thase (MTR) A2756G variant and had data available on nutrient intake and fracture 
risk. We performed analysis on Hcy levels in 878 individuals, and BMD data were 
available for 4347 individuals.
In women, the G allele of the MTR A2756G polymorphism was associated with 
lower femoral neck BMD (GG versus AA/AG; mean difference=0.03 mg/cm2, p=0.04), 
and with lower lumbar spine BMD (GG versus AA/AG; mean difference=0.05 mg/
cm2, p=0.01). Male individuals with the GG genotype had a higher rate of BMD loss 
compared with the AA genotype (0.4 vs 0.9% of baseline-year, p=0.01). A similar 
trend was observed in women, but this did not reach signifi cance. The MTR A2756G 
GG women had a more than 200% higher risk for fragility fracture compared to 
women with the AA genotype (RR: 2.16, 95% CI; 1.16-4.00, p=0.02). This increased 
risk of fracture seemed to be dependent on dietary B12 intake. Only in the presence 
of low dietary cobalamin intake did female MTR 2756-G homozygotes have a mark-
edly increased risk for fragility fracture (RR: 2.61, 95%CI; 1.25-5.49) and for vertebral 
fracture (OR: 3.16, 95% CI; 1.05-9.50).
In our cohort of elderly Caucasians the G allele of the MTR A2756G is associated 
with lower BMD in women and interacts with dietary cobalamin intake to determine 
fracture risk. These fi ndings need to be replicated in other large cohorts. This study 
highlights the importance of gene-environment interaction in osteoporosis.
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Introduction
Osteoporosis is a multifactorial disease and characterized by low bone mass and 
microarchitectural deterioration of bone tissue, with as a consequence an increase in 
bone fragility and susceptibility to fractures 1. Elevated homocysteine (Hcy) concen-
trations have been identifi ed as a potentially modifi able risk factor for osteoporotic 
fractures. The Hcy metabolism contains numerous enzymes that require nutritional 
cofactors, including vitamins B12 (cobalamin), B6 (pyridoxine), B2 (ribofl avin) and 
B11 (folate). Disruptions in the Hcy metabolism can be due to defi ciency of these B 
vitamins or genetic polymorphisms of the enzymes involved in the Hcy pathway, or 
a combination of the two.
Hcy is an intermediate metabolite of methionine and can be remethylated to 
methionine by methionine synthase (MTR) MTR uses cobalamin as a cofactor and 
5-methyltetrahydrofolate as a methyl donor to catalyze the remethylation of Hcy. 
Thus, reduced activity of MTR could reduce the remethylation of Hcy resulting in 
increasing Hcy levels.
One of the polymorphisms in the MTR gene is A2756G (rs1805087). This poly-
morphism consists of either an aspartic acid (Asp) or a glycine (Gly) at codon 919 
2. Although the direct functional impact of this polymorphism has not yet been 
established, there is some evidence that this polymorphism changes the activity of 
the enzyme. In some studies, individuals with the GG genotype have lower Hcy 
concentrations 3-5, but other studies failed to observe an effect of this polymorphism 
on Hcy levels 6,7.
The MTR A2756G variant has been implicated in increased risk of adverse health 
conditions including connective tissue disease 8,9, cardiovascular disease 10, and can-
cer 11; we found no publications on the relation between this polymorphisms and 
osteoporosis.
To gain more insight into the potential underlying mechanism relating Hcy to 
osteoporosis, we studied the MTR A2756G polymorphism in relation to BMD, bone 
loss and fracture risk in a large population-based cohort of elderly Caucasians.
Materials and Methods
Study population
This study was embedded in the Rotterdam Study, a population–based cohort study 
of men and women in which all residents of the Rotterdam suburb Ommoord aged 
55 years and older were invited to take part. The design of the study has been 
described elsewhere 12. Written informed consent was obtained from all participants 
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and the Medical Ethics Committee of the Erasmus Medical Center approved the 
study. Baseline data collection was conducted between January 1990 and June 1993, 
while the follow-up assessment of BMD was performed between July 1996 and 
December 1999. A total of 7983 men and women participated in the study (response 
rate 78%) and for the present analysis we studied 4744 men and women who were 
genotyped for the MTR A2756G variant and had available data on nutrient intake and 
fracture risk. Analysis of Hcy levels was performed in a total of 878 individuals and 
BMD data were available for 4347 individuals.
Dietary intake
Dietary habits were assessed using validated food intake data from a food frequency 
questionnaire and were available for 5542 men and women. A validation study 
comparing this questionnaire with a 2-week food diary demonstrated reproducible 
and valid estimates 13,14. Dietary vitamin B intake was adjusted for energy intake, as 
described elsewhere 15.
Measurement of Hcy levels
Non-fasting blood samples from 878 subjects at baseline were immediately placed 
on ice and processed within 60 minutes. Serum samples were kept frozen until Hcy 
levels were measured. Total Hcy levels were determined as a fl uorescence derivate 
with the use of high-pressure liquid chromatography and expressed as micro mol 
per liter (μmol/L) 16,17.
Non-vertebral fracture assessment
Fracture events were obtained from the computerized records of the general practi-
tioners (GPs) in the research area. Research physicians regularly followed participant 
information in the GP’s records outside the research area, and made an independent 
review and encoding of all reported events. Subsequently, a medical expert in the 
fi eld reviewed all coded events for the fi nal classifi cation of diseases, 10th revision 
(ICD-10) 18. Additional information on hip fractures was gathered through the Dutch 
National Hospital Registration system. Fracture follow-up started at baseline and for 
this study ended on January 1, 2002. Information on incident non-vertebral fractures 
was available for an average follow-up period of 7.4 ± 3.3 (SD) years (n=940 frac-
tures). We studied all incident fractures, while fractures that were considered not to 
be osteoporotic were excluded (i.e. fractures caused by cancer and all hand, foot, 
skull and face fractures). Fragility fractures, which are fractures occurring at the hip, 
pelvis, and proximal humerus (n=405) 19, were considered separately.
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Vertebral fracture assessment
Both at baseline and at follow-up visits between 1997 and 2001, thoracolumbar 
radiographs of the spine were obtained. The follow-up radiographs were available 
for 3469 individuals who survived an average of 6.4 (SD 0.4) years after the baseline 
visit to the center, and who were still able to come to our research center. All 
follow-up radiographs were scored for the presence of vertebral fracture by the 
McCloskey/Kanis method, as described earlier 20. If a vertebral fracture was detected, 
the baseline radiograph was also evaluated. If the vertebral fracture was already 
present at baseline, it was considered a baseline prevalent fracture. If it was not 
present at baseline, the fracture was defi ned as being incident.
Measurement of BMD
BMD (in grams per square centimeter) of the hip and lumbar spine (L2-L4) was mea-
sured by dual-energy x-ray absorptiometry (DXA) using a Lunar DPX densitometry 
apparatus (DPX-L, Lunar Corp. Madison, Wisconsin, USA), under standard protocols. 
BMD was measured at baseline (between 1990 and 1993) and at a follow-up (be-
tween 1996 and 1999). To increase the accuracy of BMD measurements at follow-up, 
the search and template tools in the comparison mode were used to position the 
femoral neck region of interest in scans of the same individual using DPX-IQ soft-
ware. The rate of change in BMD was calculated as the difference between baseline 
and follow-up, divided by the follow-up time (mean 6.5 ± SD 0.6 years). Within the 
population that had dietary information, BMD measurements were available for 4323 
individuals at baseline and 2211 individuals at follow-up.
Anthropometric measurements and potential confounders
Height (cm) and weight (kg) were measured at the initial examination, in standing 
position wearing indoor clothes without shoes. Body mass index (BMI) was com-
puted as weight in kilograms divided by height in meters squared (kg/m2).
The number of falls in the preceding year, and current smoking status were as-
sessed with the use of a questionnaire.
Genotyping
Genomic DNA was isolated from blood samples using standard methods 21. We 
utilized TaqMan allelic discrimination Assays-By-Design (Applied Biosystems, Foster 
City, CA, USA) for genotyping the MTR A2756G polymorphism. Primer and probes 
are available upon request.
The assays utilized 2 ng of genomic DNA and took place in 2 microliter reac-
tion volumes. The amplifi cation and extension protocol was as follows: an initial 
activation step of 10 minutes at 95 degrees preceded 40 cycles of denaturation at 95 
Nahid BW.indd   97 31-Oct-07   15:31:37 PM
MTR, cobalamin and bone98
degrees for 15 seconds, and annealing and extension at 50 degrees for 60 seconds. 
Allele-specifi c fl uorescence was then analyzed on an ABI prism 7900HT Sequence 
Detection System v2.1 (Applied Biosystems, Foster City, CA, USA).
Statistical analysis
Allele and genotype frequencies of the MTR A2756G polymorphism were tested 
for Hardy-Weinberg equilibrium proportions with the chi-square test. Analysis of 
variance (ANOVA) was used to examine the associations between the studied poly-
morphism and Hcy levels and BMD measurements across genotypes and median of 
dietary cobalamin intake. Analysis of covariance (ANCOVA) was performed to adjust 
for possible confounders such as BMI, age and co-morbidity. In case of a consistent 
trend, shown as an allele dose effect, we performed a linear regression analysis to 
quantify the association.
Variables were log transformed if they did not meet normality assumptions; this 
was the case for Hcy levels and dietary cobalamin intake. Dietary cobalamin intake 
as analysed as a categorical variable with quartile cut-off points. Quartiles and me-
dian of dietary cobalamin intake was made in a gender-specifi c manner and have 
been energy adjusted.
To estimate the risk for incident fracture risk by genotype we used the Cox pro-
portional hazard models, thereby taking potential differences in follow-up time into 
account. Adjustments were also made for possible confounders, i.e., age, BMI, cur-
rent smoking status and recent falls. We investigated possible interactions between 
dietary cobalamin intake and the MTR A2756G genotypes in relation to fracture by 
including a product term of the two main effects in a Cox regression model with 
fracture as the dependent variable.
All p-values less than 0.05 was considered signifi cant. All analyses were done 
using the SPSS package version 11.
Results
The genotype distributions for all studied polymorphisms were in Hardy-Weinberg 
proportions.
Table 1 presents data on the baseline characteristics of the study population.
We found a borderline signifi cant association of the MTR genotype with age in 
women in whom the GG group was two years older than either the GA or AA 
group. Hcy levels were 1.49 μmol/L higher in male AA carriers compared to the GG 
genotype with evidence of an allele dose effect (p for trend=0.02, Table 1). A similar 
trend was seen in women, but was far from signifi cant. When men and women were 
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combined, Hcy levels were 1.12 µmol/l higher in AA carriers compared to the GG 
genotype although did not reach signifi cance (p=0.17, adjusted for gender and age) 
(p for trend=0.06).
BMD and genotypes
Table 2 presents data on BMD across the MTR A2756G genotypes. In women, the 
MTR A2756G polymorphism was signifi cantly associated with both femoral neck 
BMD (FN-BMD) with evidence for a recessive effect (GG versus AA/AG; mean dif-
ference=0.03 mg/cm2, p=0.04) and with lumbar spine BMD (LS-BMD): (GG versus 
AA/AG; mean difference=0.05 mg/cm2, p=0.01). A similar pattern was seen in men, 
although this did not reach signifi cance. In addition, we observed an effect of the 
MTR genotype on BMD loss in men. Men with the GG genotype had 0.4 vs 0.9% 
of baseline-year higher rate of BMD loss compared with the AA genotype (p=0.01). 
Again we found the same trend in women, but this did not reach signifi cance. We 
then examined a potential effect of dietary cobalamin intake on the association 
between MTR genotypes and BMD and bone loss, by stratifying the population into 
two equal groups according to their dietary cobalamin intake. We observed no effect 
of dietary cobalamin intake on the association between the MTR A2756G genotypes 
in relation to BMD and bone loss in both genders (data not shown).
Fracture risk and genotypes
Table 3 gives data on fracture risk according to the MTR A2756G genotypes. In men, 
no evidence for an association was observed. There was a signifi cant association 
between the MTR A2756G genotype and risk of fracture in women with evidence 
Table 1. Baseline characteristics of the study population by the MTR A2756G genotypes in both 
genders in the Rotterdam Study
Men Women
AA AG GG P
ANOVA
AA AG GG P
ANOVA
Number * 1401 563 73 1963 843 80
Age (y) 67.1 ± 7.3 67.5 ± 7.5 67.6 ± 7.3 0.66 68.0 ± 8.1 67.9 ± 7.9 70.3 ± 7.8 0.04
Height (cm) 174.8 ± 6.6 175.2 ± 6.7 175.2 ± 6.8 0.50 161.9 ± 6.3 162.0 ± 6.5 160.9 ± 6.8 0.39
Weight (kg) 79.1 ± 10.4 79.0 ± 10.3 77.4 ± 9.3 0.40 70.0 ± 11.4 70.4 ± 10.4 69.7 ± 10.6 0.26
Body mass index 
(kg/m2)
25.8 ± 2.9 25.7 ± 2.9 25.2 ± 2.8 0.16 26.7 ± 4.1 26.8 ± 3.7 26.8 ± 5.4 0.75
Cobalamin intake 
(mg/day)
5.7 ± 6.6 5.8 ±3.8 4.9 ± 2.7 0.38 4.9 ± 4.0 5.0 ± 3.4 4.9 ± 3.5 0.97
Number ** 248 91 15 355 153 16
Hcy level (mmol/L) † 16.2 ± 0.3 15.0 ± 0.4 14.8 ± 1.0 ‡0.02 14.5 ± 0.2 14.3 ± 0.3 13.3 ± 1.0 0.50
Data are given as unadjusted mean ± SD for continuous variables
†Geometric mean (SE), adjustment for age and BMI, ‡ p-trend=0.01
* Number of individuals with nutrient intake data, ** Number of individuals with data on Hcy levels.
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for a recessive effect. Homozygous carriers of the G allele had a higher risk of fragil-
ity fracture compared with A-allele carriers (RR: 2.16, 95% CI; 1.16-4.00, p=0.02). 
Correcting for FN-BMD attenuated the risk slightly (RR: 1.90, 95% CI; 0.99-3.65, 
p=0.06).
To examine the potential effect of dietary cobalamin intake on the relationship be-
tween the MTR A2756G polymorphism and fracture risk, participants were grouped 
according to their dietary cobalamin intake into two equal groups: high versus low 
cobalamin intake (Table 4). We observed that in the low dietary cobalamin intake 
group, G homozygous women had a more than 250% increased risk for fragility 
fracture compared with the AA genotype (RR=2.61, 95% CI; 1.25-5.49, p=0.01). The 
p-value for the interaction was p =0.6 and there was a more than 3-fold risk for 
vertebral fracture compared with the AA genotype (OR=3.16, 95% CI; 1.05-9.50, 
p=0.04) (p-interaction=0.2). Further adjustment for FN-BMD did not change these 
results. In men we did not observe such an effect of dietary cobalamin intake on the 
association between fracture and the MTR A2756A polymorphism.
Hcy levels
In a subset of individuals with Hcy level measurements, we investigated whether 
there was a relationship between the MTR genotype and Hcy levels in two group: 
higher or lower than the median dietary cobalamin intake. No effect of cobalamin 
intake across the genotype groups was found (data not shown).
Table 3. Fracture risk according to MTR A2756G genotypes in both genders in the Rotterdam Study
Men Women
Types of fracture/ 
Genotype
No. of fractures/
Total no (%)
RR (95% CI) No. of fractures/
Total no (%)
RR (95% CI)
Osteoporotic
AA 98/1341 (7.3) 1 (reference) 354/1886 (18.8) 1 (reference)
AG 44/545 (8.1) 1.10 (0.77-1.57) 139/823 (16.9) 0.89 (0.73-1.08)
GG 5/72 (6.9) 0.89 (0.36-2.20) 19/77 (24.7) 1.26 (0.79-1.99)
Fragility
AA 42/1341 (3.1) 1 (reference) 117/1886 (6.2) 1 (reference)
AG 17/545 (3.1) 0.96 (0.54-1.68) 54/823 (6.6) 1.06 (0.76-1.47)
GG 3/72 (4.2) 1.19 (0.37-3.05) 11/77 (14.3) 2.16 (1.16-4.00)
All Vertebral
AA 79/802 (9.9) 1 (reference) 128/1052 (12.2) 1 (reference)
AG 34/323 (10.5) 1.08 (0.70-1.65) 53/482 (11.0) 0.87 (0.62-1.24)
GG 3/45 (6.7) 0.66 (0.20-2.18) 7/38 (18.4) 1.53 (0.65-3.59)
Age and BMI adjusted
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Discussion
In this study we observed that the MTR A2756G polymorphism is associated with 
BMD, bone loss and fracture risk in women. The genotype-dependent effect on frac-
ture was stronger in the presence of low dietary cobalamin (vitamin B12) intake.
We and others have suggested that elevated Hcy levels are a novel risk factor for 
osteoporotic fracture independent of BMD 22,23. In the present study, the increased 
fracture risk by G allele of MTR genotype was independent of BMD and was depen-
dent on dietary cobalamin intake. On the other hand, in women, the MTR genotype 
was not associated with Hcy levels. One explanation for this is that cobalamin may 
play a more dominant role in bone health compared with Hcy levels this suggests 
that the MTR 2756GG genotype in combination with low dietary cobalamin intake 
predicts fracture, independently of elevated Hcy levels.
Our study had limited statistical power because of the low frequency of the MTR 
GG genotype (3.1%), which is refl ected in the wide confi dence intervals for effect 
estimates. Hence, these fi ndings need to be confi rmed in larger populations. Our 
Table 4. Fracture risk according to MTR A2756G genotype by median of dietary cobalamin
Osteoporotic Fragility Vertebral
No. of 
fractures/
Total no. (%)
RR (95% CI) No. of 
fractures/
Total no. (%)
RR (95% CI) No. of 
fractures/
Total no. (%)
OR (95% CI)
Men
Low cobalamin
AA 44/678 (6.5) 1.0 18/678 (2.7) 1.0 46/415 (11.1) 1.0
AG 26/262 (9.9) 1.48 (0.91-2.41) 9/262 (3.4) 1.23 (0.55-2.79) 21/162 (13.0) 1.22 (0.70-2.12)
GG 3/41 (7.3) 1.05 (0.33-3.39) 2/41 (4.9) 1.71 (0.40-7.51) 1/30 (3.3) 0.29 (0.04-2.16)
High cobalamin
AA 54/663 (8.1) 1.34 (0.90-2.01) 24/663 (3.6) 1.62 (0.87-3.01) 33/387 (8.5) 0.77 (0.47-1.23)
AG 18/283 (6.4) 1.06 (0.61-1.83) 8/283 (2.8) 1.21 (0.53-2.80) 13/161 (8.1) 0.71 (0.37-1.36)
GG 2/31 (6.5) 1.02 (0.25-4.20) 1/31 (3.2) 1.22 (-.16-9.12) 2/15 (13.3) 1.25 (0.27-5.83)
Women
Low cobalamin
AA 184/944 (19.5) 1.0 60/944 (6.4) 1.0 65/535 (12.1) 1.0
AG 73/397 (18.4) 0.91 (0.69-1.19) 26/397 (6.6) 1.00 (0.63-1.59) 28/237 (11.8) 0.96 (0.60-1.55)
GG 11/43 (25.6) 1.22 (0.66-2.25) 8/43 (18.6) 2.61 (1.25-5.49) 5/17 (29.4) 3.16 (1.05-9.50)
High cobalamin
AA 170/942 (18.0) 0.92 (0.75-1.14) 57/942 (6.1) 0.93 (0.64-1.34) 63/517 (12.2) 1.03 (0.71-1.50)
AG 66/426 (15.5) 0.80 (0.60-1.07) 28/426 (6.6) 1.04 (0.66-1.64) 25/245 (10.2) 0.81 (0.49-1.35)
GG 8/34 (23.5) 1.19 (0.59-2.41) 3/34 (8.8) 1.33 (0.42-4.25) 2/21 (9.5) 0.68 (0.15-3.04)
Age and BMI adjusted
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population is relatively old, which is important given that cobalamin defi ciency is 
more prevalent in the elderly 24. Therefore, the real effect of low dietary cobalamin 
intake on fracture risk might be even larger than that observed in our study.
Little seems to be known about the relation of Hcy and cobalamin with bone 
health. Hcy levels are closely linked to cobalamin status, and cobalamin might be 
directly involved in the bone quality. Evidence for an association between cobalamin 
and bone emerges from in vivo studies. In a study by Carmel et al. 25 patients 
with cobalamin defi ciency were found to have low levels of serum osteocalcin, 
indicating a reduced osteoblast activity, and cobalamin treatment increased serum 
osteocalcin levels in these patients 25. Osteocalcin is one of the most abundant non-
collagenous proteins in bone, and cobalamin treatment increases serum osteocalcin 
levels in these patients. Osteocalcin is required to stimulate bone mineral maturation 
26. Furthermore, it is well documented that osteoblasts produce octeocalcin, which 
is used as a marker of bone formation. In addition, osteocalcin is released during 
bone resorption, refl ecting a higher bone turnover in these patients. A higher bone 
turnover indicates impaired bone remodelling resulting in fragile bone which is 
susceptible to fracture.
The strengths of the present study lie in the size of our study population and 
the validated dietary assessment with high response rate. The study also has some 
limitations. Only baseline dietary intakes were available and not vitamin levels. It 
has been suggested that serum cobalamin, specifi cally, methylmalonic acid (MMA) or 
holotranscobalamin (holo-TC) and concentrations are better predictors of cobalamin 
status than dietary cobalamin intake, particularly in elderly subjects 27. Nevertheless, 
in Europe the dietary intakes are relatively stable over time, especially among the 
elderly 28. The validated food frequency test is therefore a good measure for long-
term assessment of nutrient intake. Although our study is large, it represents a single 
observation concerning the effect of this polymorphism in relation to cobalamin 
intake. Replication of this fi nding in different populations is necessary to establish 
its consistency.
In conclusion, the MTR A2756G variant has an effect on fracture risk in women, 
and this effect is more pronounced in women with low dietary cobalamin intake. 
Moreover, the MTR A2756G is associated with BMD in women and bone loss in 
men. These results need to be replicated in other large cohorts, but highlight the 
importance of gene-environment interaction in osteoporosis.
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Abstract
Homocysteine (Hcy) is a sulfur amino acid formed by demethylation of methionine, 
which can be remethylated to methionine, and this requires B vitamins (ribofl avin, 
pyridoxine, folate and cobalamin) as cofactors. We investigated the association be-
tween Hcy levels and eight polymorphisms in enzymes involved in the Hcy metabo-
lism. In addition to the infl uence of dietary vitamin B intake on these associations.
We studied 2208 individuals aged 55 years and over who participated in four 
independent samples from the Rotterdam Study, and have been genotyped for 
polymorphisms involved in Hcy metabolism (MTHFR C677T, MTHFR A1298C, RFC 
G80A, THYMS 28 bp repeat 3R/2R, TCN C776G, MTR A2756G, MTRR A66G, CBS 
ins68bp). Dietary intake of nutrients was obtained from food frequency question-
naires at baseline.
The MTHFR 677T, MTR 2756A and RFC 80 G variants were associated with Hcy 
levels. In addition, a stepwise regression approach revealed that, besides the effect 
of age and gender, the variability in Hcy levels was attributed to the T allele of 
MTHFR 677 (1.3%, p=0.001), the A allele of MTR 2756 (0.2%, p=0.02), and the C 
allele of the MTHFR 1298 (0.2%, p=0.05). Furthermore, when nutrient factors were 
included in the model, the largest part of the variability in Hcy levels was explained 
by dietary folate intake (3.5%, p=0.001) and then the T allele of MTHFR 677 (1.8%, 
p=0.001) and dietary protein intake (0.9%, p=0.0002).
Moreover, the MTHFR C677T and RFC G80A polymorphisms separately interact 
with dietary folate intake to determine Hcy levels among all studied variants and 
nutrients based on the logic regression approach.
This study shows that MTHFR C677T, MTR A2756G and RFC G80A infl uence Hcy 
levels in our population. Furthermore, at baseline the MTHFR C677T polymorphism, 
dietary folate intake and dietary protein intake are the strongest independent predic-
tors of Hcy levels after age and gender in our cohort. Interestingly, we observed 
an interaction between the MTHFR C677T and RFC G80A polymorphisms with low 
dietary folate intake in determining Hcy levels among the other studied variants and 
dietary intakes in our population.
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Introduction
A mild elevation of homocysteine (Hcy) plasma level is an independent risk factor 
for a wide range of diseases from birth defects 1 to cardiovascular disease 2, cognitive 
dysfunction 3, osteoporosis and fracture in the elderly 4.
Hcy is formed by demethylation of methionine, and can be remethylated to methi-
onine by the enzyme methionine synthase (MTR). This enzyme requires vitamin B12 
(cobalamin) as a cofactor, and methionine synthase reductase (MTRR) is necessary 
to keep MTR active. The methyl group that is necessary for this reaction is derived 
from the folate (pool in the cell) by an essentially irreversible reaction catalyzed by 
the enzyme methylenetetrahydrofolate reductase (MTHFR). MTHFR needs vitamin 
B2 (ribofl avin) as a cofactor 5. The reduced folate carrier (RFC) plays a role in 
the transport of 5-methyltetrahydrofolate (5-THF) into cells 6. Thymidylate synthase 
(THYMS) catalyses the reductive methylation and competes with MTHFR for the 
one-carbon unit of 5,10-methyleneTHF 5. Hcy can be broken down in the transul-
furation pathway, in which the fi rst step is performed by the enzyme cystathionine 
β-synthase (CBS), which needs pyridoxine as a cofactor.
Hcy levels are determined by both genetic and environmental risk factors 7-10, heri-
tability estimates for Hcy levels range from 47 to 57% and there is an ongoing debate 
regarding the relative contribution of each. The main environmental determinants 
include nutritional defi ciencies in vitamin cofactors such as ribofl avin 4, pyridoxine, 
folate and cobalamin 11. These vitamins play a crucial role in the remethylation 
and transulfuration of Hcy, and the availability of which is determined by dietary 
intake.
There are several polymorphisms in the genes encoding the enzymes involved 
in the Hcy metabolism and these have been associated with abnormal Hcy levels. 
The most extensively studied polymorphism associated with Hcy variability is the 
MTHFR C677T (Ala 222 Val) 12. This polymorphism has been reported to explain 
4-9% of variations in plasma Hcy levels 7,9,13,14. Other common functional variants of 
the enzymes involved in Hcy metabolism include MTHFR A1298C (Glu429Ala) 15, 
MTR A2756G 16, CBS 844ins68 (an insertion variant) 17 and MTRR A66G 18. However, 
studies to date have considered only one or a few of these enzymes out of all 
those known to be involved in the metabolic pathway. Also, associations with Hcy 
levels on these genetic variants have not been consistent in all studies: some studies 
showed confl icting fi ndings for MTHFR A1298C 19,20 and the MTR A2756G 21, and 
THYMS 28bp repeat 3R/2R 22, and CBS ins68bp 23, MTRR A66G 18 and RFC G80A 6. 
This inconsistency in previous studies may in part be due to the small size of most 
of the studies, or to the unavailability of vitamin B status to examine potential gene-
nutrient interactions to determine Hcy levels.
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Therefore, in the current study, we investigated a possible association between the 
studied polymorphisms involved in the Hcy metabolism with Hcy levels in a large 
population. Moreover, we studied gene-nutrient interactions to address genetic and 
dietary determinants of Hcy levels in a several independent samples from a large 
population-based cohort of elderly Caucasian men and women.
Materials and Methods
Study population selection
We analyzed four independent samples from the Rotterdam Study. The Rotterdam 
Study is a prospective, ongoing population-based cohort study of individuals aged 
55 years or older resident in the Ommoord district of the city of Rotterdam, in the 
Netherlands. The study was designed to investigate chronic, disabling diseases. The 
rationale and design of the study have been described previously 24. The baseline 
examination included 7983 subjects. The medical ethics committee of the Erasmus 
Medical Center approved the Rotterdam Study. All the subjects in the Rotterdam 
Study gave written informed consent.
A random sample of 1028 subjects from the baseline examination (1991-1993) was 
selected (cohort 1). The sample did not differ in age, gender or education from the 
population from which it was selected. A second sample of 555 subjects was studied 
from the fi rst follow-up visit (1995-1996) (cohort 2). Cohort 2 was originally recruited 
for a study of age-related changes in the brains of elderly persons 25 and the exclusion 
criteria were dementia, blindness, and the presence of standard contraindications to 
the use of magnetic resonance imaging. The subjects in cohort 2 ranged in age from 
60 to 90 years and were randomly selected, with stratifi cation according to age (in 
fi ve-year age groups) and sex. A third sample of 1087 subjects was studied from the 
third follow-up visit (1996-1999) (cohort 3). At the same follow-up visit (1996-1999), 
a fourth sample of 505 women, aged 65 to 75 years was examined. This group had 
no history of using medication, absence of disorders such as dementia, stroke, hip 
fracture, and cancer (cohort 4).
To increase the statistical power, the baseline and three independent, non-
overlapping follow-up samples of subjects were included in the present study. The 
non-overlapping samples of these four cohorts included a total of 2015 persons.
Dietary intake
Dietary habits were assessed using validated food intake data from a food frequency 
questionnaire. A validation study comparing this questionnaire with a 2-week food 
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diary demonstrated reproducible and valid estimates 26. Dietary vitamin B intake was 
adjusted for energy intake as described elsewhere 26.
Measurement of homocysteine levels
Blood samples were immediately placed on ice and processed within 60 minutes, 
and kept frozen until Hcy levels were measured.
For cohort 1, non-fasting serum samples were obtained, and total Hcy levels 
were determined as a fl uorescence derivative with the use of high-pressure liquid 
chromatography 27,28. For cohort 2, non-fasting sodium citrate plasma samples were 
obtained. For cohort 3, fasting EDTA-treated plasma samples were obtained. For 
cohort 4, fasting sodium citrate plasma samples were obtained. For cohorts 2 and 
3 total Hcy levels were measured with the use of a fl uorescence polarization im-
munoassay on an IMx analyzer (Abbott Laboratories), which for cohort 4 Hcy levels 
were measured with LC/MS-MS.
Measurements
Height (cm) and weight (kg) were measured at the initial examination, in standing 
position wearing indoor clothes without shoes. Body mass index (BMI) was com-
puted as weight in kilograms divided by height in meters squared (kg/m2).
Genotyping
Genomic DNA was isolated from blood samples using standard methods 29 The 
33R, 23R, and 33R genotypes of the THYMS gene and 28 bp repeat and del-del, 
ins-del and ins-ins of 68bp in the CBS gene were detected using PCR products and 
were analysed by Gene Scan with some modifi cations. We utilized TaqMan allelic 
discrimination Assays-By-Design (Applied Biosystems ABI 3100, Foster City, CA) 
for genotyping the MTHFR C677T, and A1298C, the RFC G80A, the TCN C776G, the 
MTR A2756G and the MTRR A66G polymorphisms. Primer and probes are available 
upon request.
The assays utilized 2 ng of genomic DNA and 2 microliter reaction volumes. The 
amplifi cation and extension protocol was as follows: an initial activation step of 
10 minutes at 95 degrees preceded 40 cycles of denaturation at 95 degrees for 15 
seconds and annealing and extension at 50 degrees for 60 seconds. Allele-specifi c 
fl uorescence was then analyzed on an ABI prism 7900HT Sequence Detection System 
v2.1 (Applied Biosystems, Foster City, CA).
Statistical analysis
Allele and genotype frequencies of the studied polymorphisms were tested for 
Hardy-Weinberg equilibrium proportions with the χ2 test.
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Variables were log transformed if they did not meet normality assumptions, this 
was the case for Hcy levels and dietary folate intake.
Analysis of variance (ANOVA) was used to examine the associations between each 
variant and Hcy levels. Analysis of covariance (ANCOVA) was performed to adjust 
for possible confounders such as BMI, and age. In case of a consistent trend, shown 
as an allele dose effect, we performed a linear regression analysis to quantify the 
association.
Multivariable linear regression methodology was used to determine the signifi cant 
independent predictors that infl uence Hcy levels.
Intakes of B vitamins were adjusted for total energy intake using the linear residual 
regression method of Willett and Stampfer 30. Gender-specifi c tertiles of dietary B vi-
tamin intakes were calculated. Reference groups were those with the lowest vitamin 
B intake.
To explore the relation of Hcy levels with genotypes within a complete dataset, 
standard deviation scores were calculated separately for each subject in each cohort. 
Then the four cohorts were combined to increase statistical power. The standard 
deviation score was calculated with the formula (Hcy i- Hcy m)÷ SD, where Hcy i is 
the natural-log–transformed Hcy level in the individual subject, Hcy m is the mean 
natural-log–transformed Hcy level in the cohort, and the SD is the standard deviation 
of the natural-log–transformed Hcy level in the cohort. P-values lower than 0.05 were 
considered signifi cant. All analyses were done using the SPSS package version 11.
To explore possible interactions between polymorphisms and/or nutrient intake, 
we performed logic regression 31,32 that is available as an R package (version 1.4.0; 
http://bear.fhcrc.org/~ingor/logic/). The regression model was used to investigate 
the effect of multiple polymorphisms involved in Hcy metabolism. We set 100,000 it-
erations in the simulated annealing algorithm, therefore the number of acceptances/
rejections during the iteration process was optimal. Each polymorphism is coded 
into two binary covariates: X1d (dominant) = 1 if a person has at least one variant 
allele and X1r (recessive) = 1 if the person has two variant alleles; otherwise both 
are 0. Corresponding to the dominant and recessive effects of polymorphisms. In the 
logic regression we divided the intake of each dietary B vitamin (energy adjusted) to 
low and high with regard to the median intake.
Logic regression was successfully applied to select the best model as described 
else where 31,32.
Results
The baseline characteristics of our study populations are presented in Table 1.
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Genotype distributions for all polymorphisms were consistent with those predicted 
by Hardy-Weinberg equilibrium.
Table 2 shows the deviations from the population mean Hcy levels for each single 
polymorphism, when all subjects in the four independent samples were pooled. 
Subjects homozygous for the T allele of the C677T MTHFR polymorphism had 0.43 
μmol higher Hcy levels as compared with the CC genotype group with evidence for 
an allele dose effect (p-trend<0.0001). In addition, homozygotes for the G allele of 
the G80A RFC had 0.12 μmol higher Hcy levels compared with A homozygotes, with 
evidence for an allele dose effect (p-trend=0.03). Similarly, homozygotes for the A 
allele of the A2756G MTR gene, had 0.103 μmol higher Hcy levels than the 2756 MTR 
GG variant (p-trend=0.005).
Table 3 shows the Hcy levels according to the MTHFR C677T, RFC G80A, and the 
MTR A2756G polymorphisms in the four samples separately.
In a multi locus approach by logic regression, still the MTHFR C677T was signifi -
cantly associated with Hcy levels and the other polymorphisms add no more effect 
(data not shown).
Genetic factors modulating the variations in determining Hcy levels
Stepwise multiple linear regressions were performed to identify independent de-
terminants of Hcy levels (Table 4). First, we examined the effects of genotypes 
on Hcy levels. In the total study population 10.9% of the variability in Hcy levels 
was explained by this model. Of these age and gender explained 9.2%, (P<0.0001), 
Table 1. General characteristics of the study population
Characteristic Cohort 1 Cohort 2 Cohort 3 Cohort 4
Total number (n=1026) (n=555) (n=1087) (n=505)
Number of women (%) 602 (58.7) 279 (50.3) 692 (63.7) 500 (100)
Age (years) 70.51 ± 8.62 73.56 ± 7.90 73.86 ± 7.63 68.43 ± 3.84
Body mass index (kg/m2) 26.37 ± 3.74 26.33 ± 3.55 26.45 ± 12.07 27.32 ± 4.53
Dietary intakes
Ribofl avin (vitamin B2) (mg/day) 1.55 ± 0.54 - - -
Pyridoxine (vitamin B6) (mg/day) 1.60 ± 0.41 - - -
Folate (vitamin B11) (µg/day)
(min-max)
215.5 
(79.5-1352.5)
- - -
Cobalamin (vitamin B12) (µg/day) 
(min-max)
5.1 (0.99-105.6) - - -
Protein intake 79.72 ± 18.52 - - -
Energy intake (kj/day) 8189.88 ± 2038.41 - - -
Hcy levels (µMol/L) (max-min) 15.20 (0.26-60.9) 11.36 (5.2-40.0) 10.49 (3.4-54.6) 9.90 (3.50-23.50)
Values are unadjusted means ± standard deviations or numbers with percentages
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and the MTHFR C677T 1.3%, (p<0.0001), MTR A2756G 0.2%, (p=0.02), and MTHFR 
A1298C 0.2%, (p=0.05).
Then, we assessed the independent effects of genetic and nutrient factors in de-
termining Hcy levels in cohort 1. In this population, the variability in Hcy levels 
was attributed to age and gender 9.5%, (p<0.0001), to dietary folate intake 3.5%, 
(p=0.001), MTHFR C677T 1.8%, (p=0.0002), and to protein intake 0.9%, (p=0.01) and 
energy intake 0.9%, (p=0.0002, Table 4).
The same analysis could not be performed for cohorts 2, 3 and 4 of the Rotterdam 
Study, because data on dietary intake were not collected at the same time that Hcy 
levels were determined.
Table 2. Deviation of mean Hcy levels according to polymorphisms in genes in Hcy metabolism
Gene SNP Genotype N Deviation from mean (Hcy) p-ANOVA p-trend
MTHFR C677T CC 887 -0.05 ± 0.03 1.6*10-9 1.0 *10-9
CT 854 0.09 ± 0.03
TT 216 0.38 ± 0.06
A1298G AA 1064 0.07 ± 0.03 0.66
AG 906 0.06 ± 0.03
GG 252 0.003 ± 0.06
THYMS 2R/3R 2R2R 228 -0.02 ± 0.07 0.31 0.13
2R3R 494 0.01 ± 0.05
3R3R 293 0.11 ± 0.06
RFC G80A GG 794 0.10 ± 0.03 0.11 0.03
GA 1077 0.04 ± 0.03
AA 339 -0.02 ± 0.05
TCN C776G CC 670 0.01± 0.04 0.13
CG 1088 0.10 ± 0.03
GG 428 0.02 ± 0.05
MTR A2756G AA 1513 0.10 ± 0.02 0.008 0.005
AG 618 -0.04 ± 0.04
GG 74 -0.003 ± 0.11
MTRR A66G AA 704 0.08 ± 0.04 0.41
AG 1081 0.05 ± 0.03
GG 417 0.001 ± 0.05
CBS Ins68bp 0 1431 0.05 ± 0.03 0.48
1 281 -0.02 ± 0.06
2 20 0.14 ± 0.22
Values are means ± standard error
Adjusted for gender, age, and BMI.
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Effect of genetic factors and dietary B vitamin intake on Hcy levels
Since MTHFR C677T and dietary folate intake explained most variance in Hcy levels 
in the latest stepwise model, and they also mentioned in the biological pathway of 
Hcy metabolism, therefore, we tested possible interaction between these factors by 
performing a stratifi ed analysis. The association between the MTHFR C677T variant 
and Hcy levels were modifi ed by dietary folate intake at baseline. The genotype 
effect was larger in the low folate intake group with differences between the CC 
and TT group (mean difference=5.22 µmol/l, (35%), (p<0.0001). This difference was 
1.47 µmol/l, (11.0%) in the high folate intake group (p=0.1). In both groups an allele 
dose effect was observed and this only reached signifi cant for the low intake group 
(Figure 1A). In addition, an interaction between dietary folate intake and the RFC 
genotype was observed (p-interaction=0.04, Figure 2B). While the RFC G80A AA 
homozygotes had a 0.27µmol/l (2%) higher Hcy levels than GG genotype in the low 
folate group, the AA group had a 2.09 µmol/l, (16.6%) lower Hcy levels in higher 
folate group. Thus, the difference in Hcy level for the AA group between the low 
and high folate intake group was 2.64 µmol/l, (19.8%), (p=0.003).
Table 3. Hcy levels according to polymorphisms in genes in Hcy metabolism
Gene SNP Genotype
Cohort 1 Cohort 2 Cohort 3 Cohort 4
N Hcy levels N Hcy levels N Hcy levels N Hcy levels
MTHFR C677T CC 415 14.50 ± 0.21 226 11.00 ± 0.21 434 10.08 ±0.15 204 9.31 ± 0.17
CT 395 15.23 ± 0.22 225 11.27 ± 0.22 420 10.57 ± 0.16 236 9.62 ± 0.17
TT 86 16.79 ± 0.52 59 12.27 ± 0.47 115 11.76 ± 0.35 46 10.34 ± 0.41
p-ANOVA 2.0*10-6 0.04 1.5*10-7 0.05
p-trend 1.9*10-5 0.02 6.1*10-6 0.01
RFC G80A GG 322 15.24 ± 0.25 190 11.83 ± 0.25 339 10.64 ± 0.18 178 9.51 ± 0.19
GA 422 14.85 ± 0.21 230 11.01 ± 0.21 471 10.41 ± 0.15 230 9.68 ± 0.17
AA 142 14.87 ± 0.37 76 10.82 ± 0.37 137 10.11 ± 0.28 81 9.02 ± 0.27
p-ANOVA 0.45 0.02 0.26 0.1
p-trend 0.01 0.1
MTR A2756G AA 604 15.23 ± 0.18 335 11.46 ± 0.19 656 10.63 ± 0.13 320 9.72 ± 0.15
AG 244 14.57 ± 0.27 149 11.13 ± 0.27 256 9.93 ± 0.20 154 9.24 ± 0.20
GG 31 14.08 ± 0.74 19 9.84 ± 0.67 31 10.59 ± 0.60 15 9.93 ± 0.70
p-ANOVA 0.06 0.07 0.01 0.1
p-trend 0.02 0.05
Values are means ± standard error, Adjusted for gender, age, and BMI, * Values have been back log 
transformed.
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Effect of genetic factors and dietary B vitamin intake on Hcy levels by logic 
regression
To confi rm the observed interaction we performed a logic regression analysis within 
R statistical package on those individuals who had data available for all studied poly-
morphisms and nutrient intake (n=704). In this analysis the best model was a model 
in which both MTHFR and RFC interact with dietary intake of folate in determining 
Hcy levels (Figures 2).
Table 4. Independent contributors to variations in determining Hcy levels
Factors Total population
Percentage P-value
Polymorphisms
Age and gender 9.2 <0.0001
MTHFR C677T 1.3 <0.0001
TCN C776G - -
MTHFR A1298C 0.2 0.05
MTR A2756G 0.2 0.02
MTRR A66G - -
RFC G80A -
Total for this model 10.9
Baseline (Cohort 1)
Polymorphisms and nutrients
Age and gender 9.5 <0.0001
MTHFR C677T 1.8 0.0002
MTHFR A1298C - -
MTR A2756G - -
MTRR A66G - -
RFC G80A -
Protein intake 0.9 0.01
Energy intake 0.9 0.0002
Folate intake 3.5 0.001
Cobalamin intake - -
Ribofl avin - -
Pyridoxine intake - -
Total for this model 16.6
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Figure 2A, 2B. Association between dietary folate intake and the MTHFR C677T variant in relation to 
Hcy level
Adjusted for gender, age and BMI.
Low indicates below median of dietary folate intake and high indicates above median. The dietary folate 
intake adjusted for energy intake.
Bars represent means with standard errors.
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Discussion
In the present study populations, we described that Hcy levels were signifi cantly differ-
ent among subjects on the basis of genotypes for the MTHFR C677T, the MTR A2756G, 
and the RFC G80A polymorphisms. Furthermore, we observed a signifi cant interaction 
between dietary folate intake and the C677T MTHFR and G80A RFC variant.
In agreement with previous studies 14,33, we confi rmed that the 667T allele of the 
MTHFR gene is associated with higher levels of Hcy. While this is not so surprising, 
since MTHFR is a key regulatory enzyme in Hcy metabolism 34,35, we observed no 
difference in Hcy levels by the MTHFR 1298 genotypes. This variant alone may not 
signifi cantly affect the Hcy levels 15, but perhaps interacts with the 677 to determine 
Hcy levels. However, in our multi-locus approach within our population it not ap-
pears to interact with the MTHFR C677T polymorphism.
We observed that the MTR A2756G A allele was associated with elevated Hcy 
levels in an allele dose-dependent manner. This suggests that the MTR 2756A variant 
may diminish the MTR function, resulting in reduction of the conversion of Hcy to 
methionine and consequently a higher level of Hcy. The polymorphism results in 
the substitution of an aspartic acid (A2756), a moderate helix maker, by a glycine, a 
strong helix maker (2756G). The polymorphism lies close to the cobalamin binding 
domain of MTR 16, therefore functional consequences as a result of different protein 
structure is conceivable.
All of the studies with fewer than 500 subjects failed to see an association between 
MTR genotype and Hcy levels 21,36-39. However, two reports with larger numbers 
of subjects (>500) have noted a modest association between the presence of this 
variant and fasting Hcy concentrations 23,40,41.We confi rm this association in our large 
population-based sample of > 2000 individuals.
We observed an association between RFC G80A genotype and Hcy levels consis-
tent with the study of Chango et al. 6. RFC is the transporter for folate in the form 
of 5-methyl-tetrahydrofolate 42. The RFC-1 (G 80 A) polymorphism, at position 80, 
in exon 2, changes an arginine (G allele) into a histidine (A allele) 6. The RFC-1 A 
allele (histidine) is reported to have a higher affi nity for reduced folate than the G 
allele 6. Thus, in the presence of the G80 allele, the intestinal absorption of dietary 
folates might be impaired thereby increasing Hcy levels. In this light, our fi nding 
of the interaction of dietary folate intake with the RFC G80A in determining Hcy 
levels could be biologically plausible. The presence of the G80 allele impaired the 
intestinal absorption of dietary folate and resulted in increasing Hcy levels in sub-
jects who have low dietary folate intake (below median). This indicates that under 
biological stress condition (low folate intake) possible differences caused by these 
polymorphisms might became evident as slight increase in Hcy levels.
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The multivariate analysis showed that besides the effect of MTHFR 677, also MTR 
2756 plays a role in determining Hcy levels. Furthermore, a minor effect of the 
MTHFR 1298 was observed, for which the explanation is unknown.
Application of multi-locus analysis allowed us to identify interacting polymor-
phisms that contribute to the variation of increasing Hcy levels. The presence of 
interacting polymorphisms and the effect of identifi ed genetic variants were small, 
yet they confi rmed the complex character of elevated Hcy. This illustrates the ne-
cessity for considering not only one, but also all the genetic polymorphisms of 
the enzymes involved in the Hcy metabolism. Nevertheless, we note that we have 
limited power to pick up such associations, because this approach was feasible in 
70% of the individuals.
Several intervention studies have provided evidence for the importance of B vita-
mins in Hcy metabolism 43,44. In our study population, cohort 1, dietary folate intake 
was the most important dietary determinant of Hcy levels at baseline, consistent with 
previous studies 44. Folate is used as a substrate, where it donates a methyl group 
for the remethylation of Hcy to methionine. Consistent with our results, several 
lines of evidence indicate that there is an relation between protein and Hcy levels 
45. Unlikely, to some studies 46, we did not fi nd an effect of cobalamin on Hcy levels 
independent of the other dietary B vitamin intake. It is possible that the levels of 
cobalamin are not related to its intake. In the elderly, the uptake of cobalamin is 
impaired which could infl uence the relation between dietary intake of cobalamin 
and Hcy levels 47.
The strength of our study lies in the large study population. However, there are 
some limitations. Only baseline dietary intakes were available and no circulating 
vitamin B levels, while a combination of dietary intake and vitamin levels might pro-
vide a better predictive power for vitamin effects on Hcy levels than dietary vitamin 
intake alone. Moreover, there were considerable differences in the techniques used 
to assess Hcy levels in the four cohorts. These differences in method are known to 
infl uence the measurement of homocysteine levels 48.
In summary, we showed that MTHFR C677T, MTR A2756G and RFC G80A poly-
morphisms infl uence Hcy levels separately. Furthermore, our results indicate that the 
MTHFR C677T polymorphism, dietary folate intake and dietary protein intake are the 
strongest predictors of Hcy levels besides age and gender. Moreover, by applying 
a multi-locus approach, we identifi ed interactions between MTHFR C677T and RFC 
G80A with low folate intake in increasing Hcy levels. While our results require 
confi rmation in other cohorts, this suggests that genotype driven intervention could 
target those individuals most likely to benefi t by reducing Hcy levels.
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CHAPTER 6
Gene polymorphisms determining 
in bone phenotypes
The -1997 G/T and the Sp1 polymorphisms in 
the Collagen Type  I alpha 1 (COLIA1) gene in 
relation to changes in femoral neck BMD and the risk 
of fracture in the elderly: The Rotterdam Study
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Abstract
The COLIA1 Sp1 polymorphism has been found to be associated with bone mineral 
density (BMD) and fracture. A promoter polymorphism, the -1997 G/T has been as-
sociated with BMD. In this study, we examined whether these polymorphisms alone 
and in the form of haplotypes infl uence bone parameters and fracture risk in a large 
population-based cohort of elderly Caucasian.
We determined the COLIA1 -1997 G/T (promoter) and the Sp1 G/T (intron) poly-
morphisms in 6280 individuals and inferred haplotypes. Femoral neck BMD and 
BMD change were compared across the COLIA1 genotypes at baseline and at follow-
up (mean follow-up 6.5 years). We also investigated the relationship between the 
COLIA1 polymorphisms and incident non-vertebral fractures which were recorded 
during a mean follow-up period of 7.4 years. Vertebral fractures were assessed by 
radiographs on 3456 genotyped individuals.
Femoral neck BMD measured at baseline was 3.8% lower in women carrying two 
copies of the T-Sp1 allele (p for trend = 0.03). No genotype dependent differences 
in BMD-loss were observed. In women homozygous for the T allele of the Sp1 
polymorphism the risk of fragility fracture increased 2.3 times (95% CI: 1.4-3.9, p 
=0.001). No such association was observed with the promoter polymorphism. In 
men no association with either the Sp1 or the -1997 G/T promoter polymorphism 
was seen with BMD, or fracture. High linkage disequilibrium (LD) (D’=0.99, r2=0.03) 
exists between the two studied polymorphisms. We observed three haplotypes in 
our population: haplotype 1 (G promoter–G intron) frequency (f) = 69%, haplotype 
2 (G promoter–T intron) f = 17.6% and haplotype 3 (T promoter–G intron) f = 13.4%. 
Haplotype 2 was associated with increased risk of fragility fracture in women 2.1 
(95% CI: 1.2-3.7, p =0.001).
We confi rm that the COLIA1 Sp1 polymorphism infl uences BMD and the risk of 
fracture in postmenopausal Caucasian women. In contrast, we found no independent 
effect of the -1997 G/T promoter polymorphism on BMD, or fracture.
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Introduction
Osteoporosis is a multifactorial disease with both genetic and environmental de-
terminants. It is characterized by a reduction in bone mineral density (BMD) and 
microarchitectural deterioration of bone tissue which leads to an increased risk of 
fracture in later life 1,2. Being a predictor of bone fragility and susceptibility to frac-
ture, BMD is used for the diagnosis of osteoporosis 3,4. The risk of fracture is not 
only dependent on BMD but also on geometry, architecture, material properties and 
mass distribution 5.
The skeletal determinants of osteoporotic fracture risk such as BMD, bone loss and 
bone geometry are all subject to strong genetic infl uences 2,6,7. It has been estimated 
from twin studies that between 60-80% of the variance in BMD is attributable to 
genetic factors 8,9. Several genes are thought to be involved in the pathogenesis 
of osteoporosis. Collagen type I alpha 1 “(COLIA1)” is one of the most prominent 
candidate genes, which has been consistently associated with osteoporosis in differ-
ent populations 10-12. COLIA1 encodes the alpha 1 chain of collagen type I, which is 
the most abundant structural protein in the bone matrix, rare mutations in this gene 
cause osteogenesis imperfecta a mendelian disorder presenting with moderate to 
severe bone fragility 13,14.
Previously, Grant et al. 15 identifi ed a relatively common guanine to thymidine 
(G→T) polymorphism in the fi rst intron of COLIA1. This polymorphism affects one 
of the binding sites of the transcription factor Sp1 and results in increased expres-
sion of collagen type I alpha 1 in bone matrix in T carriers 11. We and others have 
shown that the T allele is associated with osteoporosis, lower BMD 10,15 and increased 
fracture risk 10,12,16,17. Moreover, in a very large prospective meta-analysis of individual 
data, we observed that the Sp1 polymorphism in the COLIA1 gene is associated with 
reduced BMD and incident vertebral fractures independent of BMD 18. In addition to 
the Sp1 polymorphism, Garcia-Giralt et al. 19 described two polymorphisms within 
the COLIA1 promoter region: the -1997 G/T and -1663 indelT. The study showed 
in a small cohort of postmenopausal Spanish women that the T-allele of the -1997 
G/T polymorphism was signifi cantly associated with 7.5% decreased lumbar spine 
BMD and 12% decreased femoral neck BMD. Furthermore, they analyzed compound 
genotypes including three polymorphic sites. However, this small study of the pro-
moter polymorphisms in women investigated the relation in form of compound 
genotypes and did not extend their study to examine haplotypes of promoter and 
Sp1 polymorphisms, and most importantly, did not analyze fractures, the clinically 
most relevant endpoint of osteoporosis.
Therefore, we investigated the infl uence of both COLIA1 polymorphisms inde-
pendently and in the form of haplotypes in relation to baseline femoral neck BMD, 
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change in BMD with follow-up and risk of vertebral and non-vertebral fractures in a 
large population-based cohort of elderly Caucasian men and women.
Materials and Methods
Study Population
This study was embedded in the Rotterdam Study, a population–based cohort study 
in which all residents of the Rotterdam suburb Ommoord aged 55 years and older 
were invited to take part in. The design of the study has been described elsewhere 20. 
Written informed consent was obtained from all participants and the Medical Ethics 
Committee of the Erasmus Medical Center approved the study. Baseline data collec-
tion was conducted in January 1990 and June 1993, while two follow-up assessments 
were performed between July 1993 and January 1996 and from July 1996 until De-
cember 1999. A total of 7983 subjects participated in the study (response rate 78%) 
and for the present study we examined 6280 individuals who were genotyped.
Study Design
This study was performed in three steps. In the fi rst step, we performed a cross-
sectional analysis where we examined the relation between the genotype and 
baseline BMD (n = 5737). In the second step, we performed a longitudinal analysis 
to study change in BMD between baseline and the second follow-up (mean 6.5 
± SD 0.6 years, n = 2670). In the third step we looked at the relation between 
COLIA1 polymorphisms and the risk of incident fracture. We studied incidence of 
non-vertebral fracture (mean follow-up 7.4 ± 3.3 SD years, n=6280) and vertebral 
fractures assessed by radiographs both at baseline (1990-1993) and at follow-up visit, 
between 1997 and 1999, thoracolumbar radiographs of the spine were available for 
3469 individuals in a mean follow-up of 6.4 years.
Measurements
Bone mineral density (g/cm2) of the hip and L2-L4 of the lumbar spine were mea-
sured by dual-energy x-ray absorptiometry (DXA) using a Lunar DPX- densitometry 
(DPX-L) (Lunar Radiation Corporation, Madison, WI, USA) and re-analysed with 
DPX-IQ software, under standard protocols. Methods, quality, assurance accuracy, 
and precision issues of the DXA measurements have been described previously 21. 
The relative change of BMD from baseline was estimated as the difference in BMD 
between assessment periods divided by the BMD at baseline.
Height (cm) and weight (kg) were measured with a stadiometer at the initial 
examination, in standing position wearing indoor clothes without shoes. Body mass 
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index (BMI) was computed as weight in kilograms divided by height in centimeters 
squared (kg/cm2).
Fracture Follow-up
Information on incident non-vertebral fractures was collected from baseline 
(1990-1993) until January 1, 2002 (mean follow-up 7.4 ± 3.3 SD years, n=6280).
Non-vertebral fracture events were retrieved from computerized records of the 
general practitioners (GPs) in the research area. Research physicians regularly fol-
lowed participant information in GPs records outside the research area and made an 
independent review, encoding all reported events. Subsequently, a medical expert 
in the fi eld reviewed all coded events for fi nal classifi cation. We excluded fractures 
that were considered non-osteoporotic fractures; caused by cancer and high trauma 
fractures, including fractures of the hand, foot, skull and face. Subsequently, we 
analysed separately “fragility” fractures, which were defi ned as any fracture of the 
hip, pelvic and proximal humerus that had occurred with minimal trauma at older 
age (mean age>75 years).
Vertebral fracture assessment
Both at baseline and at fi rst follow-up, between 1997 and 1999, thoracolumbar ra-
diographs of the spine were obtained. The follow-up radiographs were available for 
3456 individuals, who survived an average of 6.4 (SD 0.4) years after the baseline 
visit and who were still able to come to our research center. All follow-up radio-
graphs were scored for the presence of vertebral fracture by the McCloskey/Kanis 
method, as described previously 22.
Genotyping
Genomic DNA was extracted from samples of peripheral venous blood according 
to standard procedures. 1-2 ng genomic DNA was dispensed into 384-well plates 
using a Caliper Sciclone ALH3000 pipetting robot (Caliper LS, Mountain View, CA, 
USA). Genotypes were determined using the Taqman allelic discrimination assay. 
The Assay-by-Design service (www.appliedbio-systems.com) was used to set up a 
Taqman allelic discrimination assay for the COL1PR-1997 polymorphism (Primers 
Fw: GCCTCCGGAGGGTGTCA Rv: AAGGAGAGCAATTCTTACAGGTGTCT, Probes 
FAM-CCTGAGGGATGGAA-MGB, VIC-CCTGAAGGATGGAAG-MGB). The PCR reac-
tion mixture included 1-2 ng of genomic DNA in a 2 μl volume and the following 
reagents: FAM and VIC probes (200 nM), primers (0.9 μM), 2x Taqman PCR master 
mix (ABgene, Epsom, UK). Reagents were dispensed in a 384-well plate using the 
Deerac Equator NS808 (Deerac Fluidics, Dublin, Ireland). PCR cycling reaction was 
performed in 384 well PCR plates in an ABI 9700 PCR system (Applied Biosystems 
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Inc., Foster City, CA, USA) and consisted of initial denaturation for 15 minutes at 
95° C, and 40 cycles with denaturation of 15 seconds at 95° C, and annealing and 
extension for 60 seconds at 60° C. Results were analysed by the ABI Taqman 7900HT 
using the sequence detection system 2.22 software (Applied Biosystems Inc., Foster 
City, CA, USA). To confi rm the accuracy of genotyping results, 332 (5%) randomly 
selected samples were re-genotyped with the same method. No inconsistencies were 
observed. For Sp1 (intron1) an assay was set up using primer express software version 
2.0. Forward and reverse primer sequences were 5’-GTTGTCTAGGTGCTGGAGGTT-
3’and 5’-GGCGAGGGAGGAGAGAAGG-3’. The PCR reaction mixture included 5 ng 
of genomic DNA in a 4 µl volume and the following reagents: FAM-CCCGCCCA-
CATTCCCTGG-MGB probes (250 nM), TET-CCCGCCCCCATTCCCTGG-MGB probes 
(500 nM), primers :(300 nM), 2x Taqman PCR master mix (Applied biosystems Inc.). 
PCR cycling reaction were performed in 384 wells PCR plates in an ABI 9700 PCR 
system (Applied biosystems Inc.) and consisted of initial denaturation for 15 minutes 
at 95°C, and 40 cycles with denaturation of 15 seconds at 95°C and annealing and 
extension for 60 seconds at 60°C. Results were analysed by the ABI Taqman 7900HT 
using the sequence detection system 2.1 software (Applied biosystems). To confi rm 
the accuracy of the genotyping results 332 randomly selected samples were geno-
typed for a second time with the same method. All polymorphisms had an error rate 
lower than 1%.
Statistical Analysis
Hardy-Weinberg equilibrium of the COLIA1 polymorphisms genotypes was tested 
using the GENEPOP-package 23. Linkage disequilibrium between each pair of alleles 
at both polymorphic loci was calculated as D’ and r2 24.
We stratifi ed all analyses by gender considering peak bone mass, changes in BMD 
and fractures, follow age and sex -specifi c patterns. Baseline BMD and BMD rate of 
change were compared across COLIA1 polymorphisms using univariate analysis of 
variance (ANOVA). Corrections were made for age and BMI. Trend analysis assuming 
an underlying additive genetic model was done for the presence of zero, one, or two 
copies of the associated allele, incorporating the genotype variable as a continuous 
term in a general linear regression model. For the analysis of non-vertebral fracture 
follow-up data, we computed the incidence rates of fracture among genotypes and 
used Cox proportional hazards model adjusting for age and BMI to estimate risk of 
fracture. For vertebral fractures, odd ratios with 95% confi dence intervals (95% CI) 
were calculated using logistic regression models, since no data on the exact time of 
occurrence could be determined.
We used the HaploStats (available at http://cran.r-project.org/) to estimate the 
frequency of inferred haplotypes and investigate the association of haplotypes with 
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BMD and the risk of fractures. We restricted the analysis to haplotypes with an 
inferred frequency of more than 0.02. The fi rst haplotype, which was most frequent, 
was used as reference.
Signifi cant p-values were considered 0.05 or lower. Finally, model assumptions 
were verifi ed and model residuals were checked for goodness-of-fi t. SPSS 11.0 (SPSS, 
Chicago, IL, USA) was used for the analyses.
Results
Allele and genotype frequencies of the -1997 G/T and Sp1 polymorphisms were 
in Hardy-Weinberg equilibrium proportion (p=0.61 and p=0.10 respectively). Gen-
eral characteristics of the study population at baseline and follow-up are shown in 
Table 1.
Table 1. General characteristics of the study population at baseline and second follow-up
Women Men
Baseline 2nd follow up Baseline 2nd follow up
Number n=3374 n=1724 n=2452 n=1287
Age (years) 68.3 ± 8.2 72.7 ±6.8 67.6 ± 7.7 72.2 ± 6.5
Height (cm) 161.1 ± 6.8 160.6 ± 6.4 174.6 ± 6.8 174.0 ± 6.7
Weight (kg) 69.3 ± 11.4 70.3 ± 12.2 78.2 ± 10.8 79.5 ± 11.3
Body mass index (kg/m2) 26.7 ± 4.1 27.2 ± 4.4 25.6 ± 3.0 26.3 ± 3.2
Femoral neck BMD (g/cm2)* 0.83 ± 0.14 0.80 ± 0.13 0.92 ± 0.14 0.90 ± 0.14
Lumbar spine BMD (g/cm2) 1.03 ± 0.18 - 1.16 ± 0.20 -
FN- BMD change n=1527 n=1143
FN-BMD change (relative % of baseline year) † -0.84 ± 1.09 -0.45 ± 0.92
Values are means ± standard deviation
Anthropometric measurement based on 5826 individuals at baseline and 3011individuals at follow-up
*BMD measurements based on 5737 individual at baseline and 2670 individual at second follow-up
† Femoral neck (FN) BMD change has been measured between second follow-up and baseline
Second follow-up measurements were performed on average 6.5 (SD 0.6) years after baseline
Baseline BMD by COLIA1 genotypes
In both genders, age, height, weight, and BMI did not differ signifi cantly between 
genotypes for the -1997 G/T and Sp1 polymorphisms (data not shown). Table 2 
shows the BMD values according to COLIA1 genotypes in men and women. Femoral 
neck BMD was 3.8% lower (mean difference=0.03 g/cm2, p=0.09) in women ho-
mozygous carriers of the Sp1 T allele as compared to non-carriers, with evidence for 
an allele dose effect (p for trend=0.03) (Table 2). No association was found between 
the -1997 promoter polymorphism and lumbar spine BMD or femoral neck BMD in 
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men or women (Table 2). We did not observe any signifi cant association between 
the Sp1 and -1997 promoter polymorphisms with changes in BMD during follow-up 
in men or women (Table 2).
Risk of fracture by COLIA1 genotypes
The relation between risk of fracture and COLIA1 Sp1 polymorphism is shown in 
Table 3. Women with two copies of the T allele of the Sp1 polymorphism had 2.3 
times higher risk of fragility fracture (95% CI; 1.4-3.9, p=0.001). Adjustment for femo-
ral neck BMD did not essentially modify the association. A similar association was 
observed in men homozygous carriers of the Sp1 T allele, which was borderline sig-
nifi cant (RR=2.3, 95% CI; 0.9-5.8, p=0.07). For the -1997 promoter polymorphism no 
association was found with any type of fracture in either men or women (Table 3).
Haplotype analysis
High LD exists between the -1997 G/T and Sp1 polymorphisms as assessed by 
D’ measure (D`=0.99, r2=0.03). We observed in our population three -1997 G/T, 
Sp1 G/T haplotype alleles (Figure 1): haplotype 1 (G promoter–G Intron), 69.0%; 
haplotype 2 (G promoter–T Intron), 17.6%; and haplotype 3 (T promoter–G Intron), 
13.4%. Haplotype 4 (T promoter–T Intron) was not present (Figure 1). The strong 
Table 2. BMD measurements by COLIA1 genotypes at baseline and follow-up
Promoter -1997 G/T Intron 1 Sp1 G/T
GG GT TT †p GG GT TT †p
Men
BMD n=1663 n=494 n=37 n=1484 n=655 n=55
Femoral neck (g/cm2) 0.92 ± 0.13 0.92 ± 0.14 0.90 ± 0.14 1.00 0.92 ± 0.14 0.92 ± 0.14 0.90 ± 0.12 0.45
Lumbar spine (g/cm2) 1.16 ± 0.19 1.17 ± 0.20 1.15 ± 0.22 0.96 1.17 ± 0.19 1.16 ± 0.20 1.16 ± 0.20 0.91
Number n=668 n=233 n=16 n=606 n=293 18
FN-BMD change 
(relative % of baseline 
year)‡
-0.46 ± 0.91 -0.36 ± 0.93 -0.38 ± 0.60 0.62 -0.39 ± 0.93 -0.56 ± 0.87 -0.30 ± 0.82 0.01
Women n=2157 n=710 n=53 n=1971 n=858 n=91
BMD
Femoral neck (g/cm2) 0.83 ± 0.14 0.84 ± 0.13 0.85 ± 0.13 0.22 0.83 ± 0.13 0.82 ± 0.14 0.80 ± 0.14 ‡0.09
Lumbar spine (g/cm2) 1.03 ± 0.18 1.04 ± 0.18 1.01 ± 0.18 0.69 1.04 ± 0.18 1.04 ± 0.19 1.01 ± 0.20 0.52
Number n=820 n=298 n=24 n=773 n=340 n=29
FN-BMD change 
(relative % of baseline 
year)‡
-0.84 ± 1.11 -0.83 ± 1.01 -0.78 ± 1.03 0.85 -0.85 ± 1.08 -0.80 ± 1.04 -0.74± 1.49 0.55
Values are expressed as mean plus/minus standard deviation. Adjustments for age and BMI. † p for ANOVA.‡ 
For trend linear regression: p =0.03
Femoral neck (FN) BMD change has been measured between second follow-up and baseline
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linkage disequilibrium (LD) between the -1997 G/T and Sp1 G/T polymorphism 
and the virtual nonexistence of haplotype 4, suggests there is absence of ancestral 
recombination in the region. We observed a borderline association (p=0.06) between 
haplotype 2 (G promoter–T Intron) and femoral neck BMD in women. Women who 
carry haplotype 2 (G promoter–T Intron) had lower (-0.01 mg/cm2) femoral neck 
BMD compared with haplotype 1 (G promoter–G Intron).
The relation between risk of fracture and COLIA1 haplotypes is shown in Table 4.
Women with haplotype 2 (G
promoter
–T
Intron
) had 2.1 times higher relative risk of 
fragility fracture (p=0.03), in men the increase in risk is 2.0 (p=0.31). These results 
were essentially unchanged after adjustment for femoral neck BMD. For haplotype 
3 (T
promoter
–G
Intron
) we found no association with any type of fracture in either men 
or women.
Table 3. Risk of fractures by COLIA1 genotypes
COLIA1 
geno-
types
Event (%) Risk Ratio (95% CI)
Types of 
fracture
GG GT TT GG (Reference) GT vs Reference TT vs Reference
Men
Promoter -1997 G/T
Non-vertebral 147/1952 (7.5) 49/592 (8.3) 1/46 (2.2) 1.0 (Reference) 3.18 (0.45-22.74) 3.44 (0.47-29.94)
Fragility 72/1952 (3.7) 14/592 (2.4) 1/46 (1.8) 1.0 (Reference) 1.46 (0.20-10.55) 0.94 (0.12.7.14)
Vertebral 100/1056 (9.5) 35/340 (10.3) 3/28 (10.7) 1.0 (Reference) 1.07 (0.71-1.61) 1.23 (0.36-4.18)
Intron 1 Sp1 G/T
Non-vertebral 91/1254 (7.3) 39/574 (6.8) 4/44 (9.1) 1.0 (Reference) 0.97 (0.71-1.33) 1.40 (0.65-3.00)
Fragility 36/1254 (2.9) 14/574 (2.4) 2/44 (4.5) 1.0 (Reference) 0.94 (0.58-1.51) 2.34 (0.94-5.85)
Vertebral 68/719 (9.5) 31/350 (8.9) 2/22 (9.1) 1.0 (Reference) 0.83 (0.55-1.24) 1.59 (0.60-4.22)
Women
Promoter -1997 G/T
Non-vertebral 528/2721 (19.4) 182/879 (20.7) 8/63 (12.7) 1.0 (Reference) 1.53 (0.76-3.09) 1.66 (0.82-3.36)
Fragility 216/2721 (7.9) 73/879 (8.3) 4/63 (6.3) 1.0 (Reference) 1.13 (0.42-3.05) 1.19 (0.44-3.26)
Vertebral 159/1320 (12.0) 52/445 (11.7) 5/35 (14.3) 1.0 (Reference) 0.98 (0.70-1.37) 1.31 (0.49-3.45)
Intron 1 Sp1 G/T
Non-vertebral 279/1626 (17.2) 121/710 (17.0) 17/76 (22.4) 1.0 (Reference) 1.05 (0.90-1.23) 1.34 (0.92-1.23)
Fragility 98/1626 (6.0) 42/710 (5.9) 10/76 (13.2) 1.0 (Reference) 1.01 (0.78-1.31) 2.33 (1.39-3.87)
Vertebral 98/891 (11.0) 51/401 (12.7) 3/34 (8.8) 1.0 (Reference) 1.21 (0.88-1.65) 1.37 (0.56-3.35)
Adjustments for age and BMI
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Discussion
In this large population-based study we found that the Sp1 polymorphism infl uences 
the risk of fragility fracture in elderly women with a similar yet, not signifi cant effect 
in men. Similarly, women homozygous for the T-allele had 3.8% lower BMD at 
baseline. The -1997 G/T polymorphism showed no independent effect on fracture 
risk or BMD levels in both genders. The haplotype analysis showed an association 
with BMD and fracture in women, which appeared to be driven by the effect of the 
Sp1 polymorphism.
A study in Spain 19 showed that the -1997 G/T polymorphism located in the pro-
moter region of COLIA1 gene, was associated with BMD in postmenopausal women 
of Spanish origin. In addition, analysis of compound genotypes of the three studied 
polymorphisms (-1997 G/T, Sp1, and -1663 indelT) suggested that the lowest value 
for BMD corresponded to GG homozygous at -1997 and heterozygous at the other 
two loci. Furthermore, in another report by the same group they observed a possible 
functional mechanism for the -1997 G/T polymorphism 25. Our population-based 
study suggests there is no independent effect of the -1997 polymorphism on BMD 
and the risk of fractures.
Recently, in a study by Stewart et al. 26 examined the three polymorphisms of the 
COLIA1 gene in forms of haplotypes in postmenopausal women. In contrast with our 
study, they observed that there is an association between reduced BMD values and 
the promoter –1997G/T polymorphism. Since the promoter, -1997G/T polymorphism 
is in strong linkage disequilibrium with the Sp1 polymorphism, the observed associa-
tion of haplotype 2 deriven by the SP1 polymorphism.
We showed that the association between fragility fractures and Sp1 polymorphism 
is signifi cant only in women. We also found that the association between fragility 
fracture and the Sp1 polymorphism to be independent of femoral neck BMD. A 
Table 4. Risk of fracture by COLIA1 haplotypes
Types of 
Fracture
Men Women
OR (95 % CI) OR (95 % CI)
Haplotype 1 Haplotype 2 Haplotype 3 Haplotype 1 Haplotype 2 Haplotype 3
Non-
vertebral
1 (Reference) 1.29 (0.55-3.02) 0.00 (0.00-∞) 1 (Reference) 1.31 (0.83-2.07) 0.61 (0.29-1.29)
Fragility 1 (Reference) 2.01 (0.71-5.67) 0.00 (0.00-∞) 1 (Reference) 2.12 (1.23-3.66) 0.80 (0.29-2.23)
Vertebral 1 (Reference) 1.64 (0.62-4.31) 1.19 (0.35-4.00) 1 (Reference) 1.23 (0.51-2.95) 1.31 (0.50-3.42)
Adjustments for age and BMI
Haplotype1: (G
promoter
–G
Intron
)
Haplotype2: (G
promoter
–T
Intron
)
Haplotype3: (T
promoter
–G
Intron
)
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possible explanation for an increased risk of fracture is due to the different number 
of fracture between men and women. There are a higher number of fractures in 
women as compared to men (13.2% in women and 4.5% in men). This suggests 
that other underlying biological mechanisms beyond BMD levels such as the role of 
micro-architecture, and composition of mineral crystals in bone tissue which, might 
explain the increased fracture risk 11,27,28. Biomechanical testing of bone samples from 
heterozygous individuals with the GT genotype showed reduced bone strength com-
pared to homozygous GG genotype and a slight reduction in mineralization of bone 
11,29. Presence of the T allele in the COLIA1 Sp1 binding site leads to an abnormal 
relative level of COLIA1/COLIA2, which may reduce bone quality and quantity 11. 
Accordingly, we assume that a weaker network of abnormal collagen cross-linking 
may generate a three-dimensional unstable condition that may be responsible for 
its relatively greater risk of fragility fracture in the elderly women homozygous for 
the Sp1-T allele. Similarly, it is likely that the Sp1 polymorphism is driving these 
associations since evidence of functionality of this polymorphism has been reported 
previously.
In Genetic Markers for Osteoporosis (GENOMOS) Study, which is the largest study 
examining the Sp1 polymorphism (n=20,786) in relation to osteoporosis, an associa-
tion between the Sp1 polymorphism and 1.3 times incident risk of vertebral fractures 
was also observed. An effect of the -1997 promoter polymorphism due to power 
limitations cannot be fully excluded, and should be subject to study in the larger 
population like GENOMOS.
Our present study has some limitations. Survival bias may play a role in this study 
if individuals who were lost to follow-up were dependent to genotype. Consider-
ing this selection bias, a possible relationship of the COLIA1 polymorphisms with 
changes in BMD cannot be fully excluded.
In conclusion, we observed an increased risk of fragility fractures in women car-
riers of the COLIA1 Sp1 T-allele. In contrast, the -1997 G/T polymorphism by itself 
appears to have no infl uence on fracture, BMD in postmenopausal women. Though 
the role of power limitations cannot be excluded.
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The aim of this thesis was to determine the importance of genetic variability and 
dietary determinants of homocysteine (Hcy) metabolism in relation to osteoporosis 
in the elderly population. The current chapter will provide a more general discussion 
and includes the main fi ndings and background of this thesis. Finally, clinical impli-
cations of our studies are discussed and suggestions are made for future research.
Main fi ndings
First, we performed a systematic review on all published studies that investigated 
the relation between Hcy levels, B vitamin determinants of Hcy levels, and bone 
health. We found strong evidence that an elevated Hcy level predicts a higher risk 
for fracture, and moderate evidence that cobalamin (vitamin B12) and folate (vitamin 
B11) status is associated with bone mineral density (BMD) (chapter 2).
By investigating an effect of dietary B vitamins intake on bone phenotypes in the 
Rotterdam Study, we found that low dietary intake of both ribofl avin and pyridoxine 
was associated with low BMD. In addition, high intake of pyridoxine was associated 
with a decreased risk of fracture (chapter 3).
In chapter 4, we describe genetic association studies in the Rotterdam Study on 
the relation to BMD and fracture risk with two polymorphisms that affect the amino 
acid sequence of two key enzymes (MTHFR and MTR) in the Hcy metabolism. 
The MTHFR Ala222Val (C677T) was investigated together with dietary intake of two 
established co-factors of the MTHFR enzyme: i.e., folate and ribofl avin. We observed 
that MTHFR Ala222Val interacts with dietary ribofl avin intake to determine fracture 
risk in women. When dietary ribofl avin was low (fi rst quartile), TT-homozygous 
women had higher Hcy levels and also increased 2.6 times fracture risks. Compared 
to AA homozygotes GG genotype of the MTR A2756G polymorphism was associated 
with low 5.1% lower BMD and 2.2 times higher fracture risk in women. The effect 
of the GG genotype on fracture risk was stronger in the presence of low (below 
median) dietary cobalamin intake.
In chapter 5 we described analyses in the Rotterdam Study that showed that Hcy 
levels were associated with the MTHFR C677T, MTR A2756G, and the RFC G80A 
polymorphisms. Furthermore, by applying a multi-locus approach including the six 
studied polymorphisms (MTHFR C677T and A1298C, RFC G80A, TCN C776G, MTR 
A2756G, and MTRR A66G) and dietary intake of B vitamin co-factors (vitamin B2, B6, 
B11 and B12), an interaction was identifi ed between MTHFR C677T and RFC G80A 
with dietary folate intake in determining Hcy levels. In the low dietary folate intake 
(fi rst tertile) 222Val MTHFR homozygotes and 80G RFC carriers had higher Hcy 
levels. In the low folate intake group, homozygotes for the A allele of the RFC G80A 
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polymorphism had 2% higher Hcy levels than GG genotype and in the high folate 
intake group (third tertile) the RFC 80A homozygotes had 16.6%lower Hcy levels. In 
the low folate group (fi rst tertile) the T allele homozygotes (222ValVal)of the MTHFR 
C677T polymorphism had 35% higher Hcy levels compared with CC genotype.
Given the potential importance of the COLIA1 gene as a genetic marker of osteo-
porosis outcomes, we examined two polymorphisms in this gene (chapter 6). We 
observed an increased risk of fragility fractures in women that were homozygous 
carriers of the COLIA1 Sp1 T-allele. In contrast, the -1997 G/T polymorphism by itself 
appears to have no infl uence on fracture or BMD in postmenopausal women.
Methodological considerations
Study population: The Rotterdam Study
One of the major strengths of our approach was that we used a large population-
based cohort study with a long follow-up period. Yet, population stratifi cation could 
be a possible confounder when allele frequency of the studied polymorphism and 
disease frequency differ between two sub-populations which are treated as one 
homogenous population. However, 98% of our population is Caucasian, as was 
defi ned by questionnaires in which the ethnicity of the parents and grandparents of 
the subjects was documented. We therefore think this will not be a major problem 
in the analyses.
Study design
In this thesis several study designs were used. First, the studies on the relation 
between candidate genes and fracture risk had a longitudinal design. An important 
aspect of the longitudinal evaluation of fracture risk in time is the underlying cause 
for those associations. Also, a prospective design was used to examine the effect of 
dietary B vitamin intake on the association between candidate gene polymorphisms 
and incident fracture risk. Because of the prospective design, by assessing of the 
dietary B vitamin intake at baseline (which is before the fracture event) a causal 
effect relationship between B vitamin intake and fracture risk can be determined. 
We used a cross-sectional design only in studies that assessed the effect of polymor-
phisms on Hcy levels and BMD. Although technically this is a cross-sectional design, 
genetic studies in general can be considered prospective, since polymorphisms are 
stable and present in the individuals throughout life. Unlike circulating levels of Hcy, 
genetic markers do not essentially change during the lifetime of a person.
Some methodological issues should be considered in the interpretation of our 
fi ndings. In chapters 3, 4 and 5 of this thesis, food frequency questionnaires were 
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used to assess B vitamin status. One may argue that plasma B vitamins levels would 
refl ect B vitamin status better than food frequency questionnaires. However, in Eu-
rope the dietary intakes are relatively stable over time, especially among the elderly 
1.The validated food frequency questionnaires are therefore a good measure for 
long-term assessment of nutrient intake. Furthermore, in this thesis all dietary intake 
has been corrected for energy intake by using the residual method as described 
elsewhere 2. In addition, plasma B vitamins may not be the best functional marker 
for B vitamin status 3. For example studies have shown that up to 50% of subjects 
with low intracellular vitamin B12 status have normal plasma vitamin B12 levels 4. 
Also, measuring vitamin levels only once (for example, in our study at baseline) may 
not refl ect the accurate and long-term reservoir of B vitamins. Another method for 
accurate assessment of B vitamins status is to measure B vitamin metabolites, such as 
methylmalonic acid for B12 and RBC-folate for folate. This method might be a better 
indicator for assessing B vitamin status than studying solely dietary B vitamin intake, 
or plasma (vitamin B12 and folate) levels of the B vitamins.
In this thesis, we measured Hcy levels once at baseline, which can lead to a 
measurement error due to transient fl uctuations in Hcy levels caused by treatment, 
disease, age, or changes in the diet. Therefore, to determine the long term Hcy status, 
it might be useful to measure Hcy levels at different time points during follow-up 5.
Given the fact that BMD is a good predictor of bone fragility and susceptibility to 
fracture, and that the peak bone mass is strongly under genetic infl uences, BMD was 
used to study osteoporosis (chapters 3, 4 and 6). We determined BMD by applying 
dual-energy x-ray absorptiometry (DXA) using a Lunar DPX- densitometry (DPX-L). 
We applied an accurate technique and used standard protocols to minimize measure-
ment bias, especially in repeated measurement of BMD to examine BMD changes. 
We reanalysed with one uniform version (DPX-IQ) all scans the image acquisition of 
which had been done. Using a longitudinal measurement of BMD in a large prospec-
tive population-based cohort is an important tool to study bone health. Longitudinal 
measurements are helpful in establishing causality for the observed change and can 
be considered extensively for future study. However, the causes of bone loss are 
multifactorial and thus are also infl uenced by environmental factors (e.g., calcium 
intake, sun exposure for vitamin D status and physical activity), in addition to a 
variety of conditions and medications that may limit or accelerate bone loss. Thus, 
even longitudinal measurements still may not be an accurate marker for studying 
bone quality without taking these factors into consideration.
The assessment of incident events (i.e., fractures) is an important advantage of 
our study design. In the fracture studies in this thesis (chapters 3, 4, and 6) incident 
fracture data of the Rotterdam Study are well documented by the accurate register of 
general practitioners in the Dutch healthcare system. Furthermore, analysis of the in-
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cident non-vertebral fractures allows to investigate time-to-event and age-dependent 
relationships.
Association of Hcy and fracture risk with bone health
So far, it is not clear whether the association between Hcy and fracture risk is medi-
ated through BMD or not. To address this question, we explored the fi ndings from 
previously published studies in a systematic review (chapter 2) and found strong 
evidence that an elevated Hcy level predicts a higher risk for fracture in the elderly 
population. However, only a part of the observational studies (4 out of 8) have 
addressed the role of BMD.
The studies that did try to answer this question, observed that the Hcy levels were 
associated with fracture risk independent of BMD. However, the fracture risks ob-
served were generally about two times higher for the highest quartile of Hcy levels 
versus the lowest. So, if these risks were caused solely by low BMD, the difference 
between mean BMDs in high versus low Hcy must be fairly large (i.e., close to 1 SD 
difference), given the fact that one SD difference in BMD will generally result in a 
two times higher fracture risk 6. The reports that studied only the relation between 
Hcy levels and BMD (and not fracture) yield confl icting results. The studies that did 
observe an association between Hcy and BMD reported a modest (0.2 SD) between 
extreme groups. Taken together these studies suggest that the association between 
Hcy and fracture risk is most likely not mediated through BMD. It seems more 
plausible that differences in BMD, if any, might be a consequence of the relation 
between Hcy levels and fracture risk rather than a cause.
B vitamins involved in the Hcy pathway and bone health
In chapter 3, we studied the Hcy related B vitamin intake in relation to bone health. 
We studied the four major B vitamins involved in the Hcy metabolism (vitamin 
B2, B6, B12 and folate), in contrast to all previous studies which only examined 
one or two of these vitamins, (generally, vitamin B12 and folate). We observed a 
positive and independent relation between dietary intake of both ribofl avin (vitamin 
B2) as well as pyridoxine (vitamin B6) with BMD. Furthermore, we observed in 
the Rotterdam Study that high dietary intake of pyridoxine was associated with 
a signifi cantly decreased risk of fracture. This effect was not modifi ed by factors 
related to co-morbidity or by dietary intake of other B vitamins and this effect was 
independent of BMD.
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In addition, we observed that the decreased fracture risk by dietary intake of 
pyridoxine was independent of Hcy levels. However, since Hcy levels were available 
only for a small subgroup of our population and were measured only once, we 
cannot fully address the question as to whether or not the protective effect of dietary 
pyridoxine on fracture risk is mediated through lowering Hcy levels or not.
Although the mechanism underlying this association is still unclear, pyridoxine 
could have an effect on bone through the enzyme lysyl oxidase. Pyridoxine serves as 
an essential co-factor for lysyl oxidase, a key enzyme for the formation of enzymatic 
cross-links in collagen in bone 7,8. Mice studies showed that pyridoxine defi ciency 
results in a low amount of cross-link intermediates and impaired cross-link forma-
tion in bone 7. Yet, pyridoxine is also known to be an important co-factor in many 
enzymatic steps 9-12, which open the possibility that pyridoxine exerts its effects 
not directly on bone but through some enzymatic reactions in the body, includ-
ing many involved in the synthesis or catabolism of neurotransmitters including 
γ-aminobutyrate synthesis (GABA) 10. Therefore, pyridoxine defi ciency could affect 
neuromuscular control in the locomotor system and thus, increase the risk of falling, 
and thereby increase fracture rates. However, in our study we did not observe an 
effect of dietary pyridoxine intake on the rate of falls, which makes the latter less 
likely explanation for our observations.
Genetic studies on the association on Hcy and bone health
The observational studies reviewed in chapter 2, did not prove a causal relationship 
between Hcy and fracture risk. Observational epidemiological studies suffer from 
many potential biases, from confounding and reverse causation, and this limits their 
ability to robustly identify causal associations. Therefore, we have utilized the Men-
delian randomization approach to determine the magnitude of causal relationships 
between elevated Hcy levels and fracture risk. Mendelian randomisation provides a 
method to assess the causal nature of some environmental exposures, by studying an 
association between a disease and a DNA polymorphism that mimics the biological 
link between a proposed exposure and disease. To examine whether Hcy levels 
have a causal relation to fracture risk, we studied polymorphisms known to alter the 
biological availability of a dietary B vitamin or the activity of enzymes that affect the 
Hcy levels. We examined the effects of these polymorphisms on different aspects of 
bone health.
The most extensively studied polymorphism associated with variability in Hcy level 
is the MTHFR C677T polymorphism. This variant results in an alanine (Ala) to valine 
(Val) substitution at position 222 of the MTHFR protein, giving rise to a thermolabile 
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enzyme with reduced activity 13. The MTHFR C677T genotype has been associated 
with increased fracture risk 14, and weakly with reduced BMD, in some studies 15-17, 
while, other studies have identifi ed interactions with diet 14,16,18.
In order to be active, MTHFR needs to bind to a co-factor, fl avin adenine dinucle-
otide (FAD), a derivative of ribofl avin (vitamin B2) 19. The MTHFR enzyme converts 
5, 10-methylenetetrahydrofolate to 5-methyltetrahydrofolate (5MTHF), which is 
required for remethylation of Hcy to methionine (see Figure 1). The Val allele of 
the MTHFR Ala222Val polymorphism has less binding capacity for the FAD, thereby 
reducing the enzyme activity especially in case of shortage of ribofl avin. Previous 
studies have shown that the MTHFR 677 T allele is only associated with higher Hcy 
levels if folate and/or ribofl avin is low 20,21. Given this background it was reasonable 
to examine the association of MTHFR C677T in greater detail in relation to dietary 
intakes of B vitamins. Chapter 4 presents an examination in the Rotterdam Study 
in which we observed the MTHFR Ala222Val to interact with low dietary ribofl avin 
intake to increase fracture risk in women. This increased fracture risk was indepen-
dent of BMD or other known risk factors for fracture or potential confounders such 
as age, dementia, cardiovascular disease and other measures of co-morbidity. This 
Homocysteine5-methyl- THF -CH3 
Collagen 
Cross-linking
Gene 
expression
DNA 
methylation
 
Bone 
remodeling 
B11 B6
B12
B2 
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Figure 1. Possible biological mechanisms explain how elevated Hcy levels are related to fracture 
risk.
B2 (ribofl avin), B6 (pyridoxine), B11 (folate), B12 (cobalamin): B vitamins
THF=Tetrahydrofolate, SAM:S-adenosylmethionine, SAH: S-adenosyl-homocysteine, CH3: methyl
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suggests that an elevated Hcy level caused by the MTHFR 222ValVal homozygous 
genotype in combination with low dietary ribofl avin intake is a risk factor predicting 
fracture independently of other known risk factors.
Our results did not prove that elevated Hcy is the cause of the observed associa-
tions with increased fracture risk. In a small subgroup for whom Hcy levels were 
available, we found that adjustment of the increased fracture risk for Hcy levels did 
not affect the risk estimates.
In order to get more insight into the potential underlying mechanism relating el-
evated Hcy levels to fracture risk, we studied another gene, the MTR gene, involved 
in the remethylation of Hcy (chapter 4). The MTR gene is located on chromosome 
1q43 and uses both vitamin B12 as a co-factor and 5-methyltetrahydrofolate as a 
methyl donor to catalyze the remethylation of homocysteine. This enzymatic step is 
fully dependent on vitamin B12.
The MTR A2756G polymorphism results in an (Asp) to (Gly) substitution at position 
919 of the protein and has been reported to result in a small decrease in Hcy levels 
22-24. In our study the MTR 919GlyGly homozygous genotype was associated with 
5.1% lower BMD and 2.2 times higher fracture risk in women. The effect of the MTR 
919 Gly allele on fracture risk was stronger in the presence of low dietary cobalamin 
(below median) (vitamin B12) intake. This might suggest that the MTR 919GlyGly 
genotype in combination with low dietary cobalamin intake is a risk factor predicting 
fracture independently of an elevated Hcy level. One explanation is that cobalamin 
may play a more dominant role in bone health compared with Hcy levels. However, 
our study had limited statistical power because of the low frequency of the MTR 
919GlyGly genotype (3.1%). Hence, these fi ndings need to be confi rmed in other 
large populations, before a fi nal conclusion can be drawn.
Genetic and dietary determinants of Hcy level
From twin studies the heritability of Hcy levels has been estimated at 47-57% 25,26. 
Studies often have indicated that the MTHFR C677T polymorphism accounts for 4-9% 
of variations in plasma Hcy levels 26-29. Therefore, this leaves a major part of the ge-
netic contribution in the variation of Hcy levels unexplained, which is the rationale to 
continue the search for determinants of Hcy, as described in chapter 5 of this thesis. 
Based on the literature and biological background we selected the most promising 
potentially functional genetic variants involved in Hcy metabolism at the time the 
work on this thesis started. Our selection include MTHFR C677T (Ala222Val), MTHFR 
A1298C (Glu429Ala) 30, MTR A2756G (Asp919Gly) 24, CBS 844ins68 (68-bp insertion) 
31, MTRR A66G (Met22Ile) 32, TCN C776G (Pro259Arg) 33,34, RFC G80A (His27Arg) 35, 
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and the THYMS 28-bp repeat in the 5’ UTR 36. We show that variance in Hcy levels 
among subjects were signifi cantly associated with the MTHFR 677T, the MTR 2756G, 
and the RFC 80A variants. The Hcy metabolism is complex, and multiple genes are 
involved that encode several key enzymes involved in its pathway. In this light we 
applied a multi-locus analysis to identify interacting polymorphisms that contribute 
to explain variation in Hcy levels together with related B vitamin co-factors (chapter 
5). We identifi ed interactions between the MTHFR 677T and RFC 80 A variants with 
low folate intake determining Hcy levels.
Our study is limited because we analysed only eight DNA variants in seven genes. 
There are for example, other genetic variants located in the genes involved in Hcy 
transsulfuration or the remethylation pathway which also deserve more attention. 
Recently, in a large study population of approximately 10,000 subjects 13 polymor-
phisms involved in Hcy metabolism and related B vitamin co-factors or metabolites 
were examined 23. Among those, only four variants were associated with Hcy levels 
including the MTHFR 677T and MTR 2756G, which were also observed to be associ-
ated to Hcy levels in our study population (chapter 5).
In addition to the variants that are described in this thesis, which have been cho-
sen based on the most promising genetic variants in the Hcy metabolism at the time 
the work on this thesis was started, other variants may also affect Hcy levels. For 
example, betaine-homocysteine methyltransferase (BHMT) G716A (Arg 239 Gln) 37, 
and the nicotinamide N-methyltransferase gene (NNMT) 38 could be candidates for 
further studies.
Candidate genes involved in regulating the bone matrix
A large number of studies have explored the potential associations between candi-
date gene polymorphisms and various osteoporosis-related phenotypes. The MTHFR 
C677T is involved in bone metabolism (via infl uencing Hcy levels) and collagen 
type I alpha 1 (COL1A1) is the most abundant protein of bone matrix. Both have 
been considered as candidate genes for osteoporosis by infl uencing bone quality 
rather than quantity. Therefore, in this thesis, besides the polymorphisms involved in 
Hcy metabolism we examined COL1A1 polymorphisms to examine the relationship 
between each of the two polymorphisms in the COL1A1 with bone end points. The 
COLIA1 gene, which encodes the alpha I chain of type 1 collagen, is one of the most 
extensively studied candidate genes for susceptibility to osteoporosis 39,40. Rare muta-
tions in this gene cause osteogenesis imperfecta, a Mendelian disorder presenting 
with moderate to severe bone fragility 41,42. A polymorphism affecting an Sp1 binding 
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site within a key regulatory region of COLIA1 43 has been reported to be associated 
with BMD and susceptibility to osteoporotic fracture 44-47.
Studies have indicated that the COLIA1 Sp1 polymorphism, located in the fi rst 
intron of the gene, is a functional variant that affects bone quality rather than min-
eralization 39. In keeping with this, the association with fracture in many studies has 
been found to be independent of BMD 40. Yet, there are several other polymorphisms 
in the COLIA1 gene, including several in the promoter region that are potentially 
functional 48. This study showed that the -1997 G/T polymorphism located in the 
5’promoter region of COLIA1 gene was associated with BMD in postmenopausal 
women. However, fractures were not analyzed in this study 48. Given the potential 
importance of the COLIA1 gene as a genetic marker of osteoporosis outcomes, we 
investigated the infl uence of both COLIA1 polymorphisms independently and in the 
form of haplotypes in relation to femoral neck BMD, changes in BMD, and risk of 
fracture (chapter 6). We observed an increased risk of fragility fractures in female 
carriers of the COLIA1 Sp1 T-allele. In contrast, the -1997 G/T polymorphism by itself 
appears to have no infl uence on fracture or BMD in postmenopausal women. This 
suggest that the associations observed so far are explained by the Sp1 polymorphism 
and not by (LD with) the -1997 C/T polymorphism.
There is yet another polymorphism in the COLIA1 5’promoter region, the -1663 
indelT variant, which was found to be correlated to fracture risk 48,49. In a small 
case-control study of Scottish women this variant was found to be increased in 
frequency among hip fracture cases and was associated with a 27.5% reduction in 
bone strength compared with the common haplotype 50. However, this observation 
needs replication in larger studies in order to confi rm the results.
Possible biological mechanisms
Several biological mechanisms are available that could explain how elevated Hcy 
levels are related to fracture risk. Figure 1 shows these possible mechanisms, which 
include collagen cross-linking, DNA methylation, and bone remodeling.
Collagen cross-linking
A mechanistic role of high Hcy concentrations in a deteriorating bone metabolism 
was suggested early in patients with homocystinuria, a genetic disorder character-
ized by severely elevated Hcy levels and several clinical manifestations, including 
early onset of osteoporosis 51. It was suggested that high Hcy concentrations may 
interfere with collagen cross-linking, resulting in poor quality of bone and increased 
susceptibility to fracture 52.
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However, several studies showed that higher levels of Hcy are correlated with 
excretion of higher levels of collagen cross-links 7,53-55. In a pilot study of 100 elderly 
individuals from the Rotterdam Study (50 high and 50 low Hcy levels) we also found 
that high Hcy levels are not associated with lower levels of collagen cross-links per 
excreted collagen molecule. Instead, we found a tendency towards a higher number 
of collagen cross-links (presented in chapter 1). However, these are excreted bone 
resorption markers, and one expects the Hcy effect on bone (if real) to affect the 
quality of newly-formed bone, something that is not monitored effectively by any of 
the markers studied so far. In addition, we do not know the exact local concentration 
of Hcy at the environment of the active osteoid, and whether it is suffi cient to inter-
fere with collagen cross-links. Interestingly, Paschalis et al. 56 observed lower cross-
links in fragile bone of osteoporotic patients specifi cally in the micro-environment of 
the bone forming surfaces, which would support this hypothesis. In addition, Saito 
et al. 55recently showed that bone tissue of fracture cases had a lower amount of 
cross-links and increased Hcy levels as compared to controls 55.
Furthermore, there is a possible effect of pyridoxine on bone, as referred to earlier 
in this discussion. Some reports suggest that pyridoxine defi ciency may lead to 
impaired cross-link formation, because pyridoxine serves as an essential co-factor for 
lysyl oxidase, therefore resulting in increased bone fragility.
Bone remodelling
It has been suggested that Hcy may have a direct effect on bone by stimulating 
osteoclast formation and osteoclast activity in vitro. Thus, high Hcy levels might be 
associated with higher bone resorption 57 resulting in a disturbance of bone remodel-
ing which, in turn leads to more fragile bone. Accordingly, Koh et al.58 showed a 
direct activation of osteoclast formation and activity by elevated Hcy levels This is 
in line with our observation that women with the MTHFR 222 ValVal homozygous 
genotype had a higher BMD change (possibly refl ecting higher osteoclast activity) 
especially when dietary ribofl avin (vitamin B2) intake was low (chapter 4.2).
However, another in vitro study 59suggested that elevated Hcy levels decreases 
osteoblast activity. They studied Hcy at high doses (100 and 500 μMol) and dem-
onstrated that elevated Hcy levels inhibits production of osteocalcin, however it 
is questionable whether Hcy levels within normal or mildly elevated range (16-30 
μMol) has an effect on osteoblast function.
Hcy levels are also closely linked to cobalamin status, and cobalamin might be 
directly involved in bone remodeling 60. Evidence for such an association between 
cobalamin and bone remodelling emerges from in vivo studies. In a study by Carmel 
et al. patients with cobalamin defi ciency were found to have low levels of serum 
osteocalcin. Osteocalcin is one of the most abundant non-collagenous protein in 
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bone, and cobalamin treatment increases serum osteocalcin levels 60, refl ecting a 
higher bone turn over in these patients. Higher bone turn over indicates impaired 
bone remodelling resulting in fragile bone and susceptible to fracture.
Recently, experimental studies by Herrmann et al. 57,61 have been carried out to 
clarify the role of high Hcy level in bone. They suggested that Hcy may have a 
direct effect on bone by stimulating osteoclast formation and osteoclast activity in 
vitro. They support the hypothesis of a Hcy-induced stimulation of bone resorption 
and decreased bone formation by cell culture experiments. They reported that Hcy 
induced a dose-dependent increase in osteoclast activity and therefore, with higher 
bone resorption 57 resulting in disturbance of bone remodeling which in turn leads 
to more fragile bone. Moreover, in a recent study conducted by the same group the 
authors hypothesized that elevated Hcy levels might be associated with higher bone 
turnover marker. They reported that in the presence of high Hcy levels osteocalcin 
levels decrease (up to 34%), suggesting decreased osteoblast activity in the presence 
of an unchanged osteoclast activity. Their results suggest a mechanistic role of Hcy 
in bone metabolism. Since these studies are in vitro and we do not know whether 
the elevated Hcy levels created in these experimental studies are lethal for human 
bone cells or not, this issue needs to be investigated in vivo (human cells).
Additional biochemical data within larger sample sizes are needed to establish if 
Hcy truly interacts with extra-cellular matrix proteins leading to structural changes 
and a reduced bone stability. Therefore, studies on animal and cell culture experi-
ment are needed to clarify the mechanistic role of Hcy in bone metabolism.
DNA methylation
As is known from the Hcy metabolic pathway (Figure 1) Hcy is produced as a result of 
methylation reactions. Thus, higher Hcy levels in serum could refl ect the methylation 
status. In that respect elevated Hcy levels may be an indirect indicator of elevated S-
adenosylhomocysteine (SAH) and compromised cellular methylation capacity. It has 
been shown that higher circulating SAH levels associated with decreased methylation 
of lymphocyte DNA 62,63. In addition, folate treatment has been shown to restore DNA 
methylation to normal levels and correct the patterns of abnormal gene expression 
both in animal models 64 as well as in humans 65. Thus, the decreased methylation 
associated with high Hcy levels may alter gene regulation, which could eventually 
lead to disease. This hypothesis was supported by studying a gene, Proliferation As-
sociated SNF2-like Gene (PASG), showed that disruption of a protein that facilitates 
DNA methylation, causes global hypomethylation, developmental growth retardation 
and a premature aging phenotype, including osteoporosis 66,67.
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Clinical implications of the fi ndings in this thesis
Based on our results (chapter 4.1) one could argue that 5% of fragility fractures 
(or 2.3% of all incident osteoporotic fractures) in our female MTHFR 222 ValVal 
homozygous genotype population could be prevented by receiving supplementary 
ribofl avin. The proportion of subjects with a fracture that could be prevented is 
much higher in females with the MTHFR 222 ValVal homozygous genotype with low 
ribofl avin intake, where 17% of fragility and 9% of all incident osteoporotic fractures 
might be prevented by ribofl avin supplementation. Thus, our fi ndings provide novel 
options for the possible prevention of osteoporosis, and also suggest an intervention 
strategy.
The MTHFR 222ValVal homozygous genotype is quite frequent in the Caucasian 
population (10%) and our results on the gene-environment interaction suggest the 
possible importance of providing vitamin B2 (e. g., by fortifi cation of food or by 
supplementation) in the Netherlands. Thus, our fi ndings provide a clinical rational to 
consider the role of ribofl avin supplementation in the prevention of osteoporosis in 
the elderly. Randomized double-blind placebo-controlled trials are needed to con-
fi rm the suggested preventive effect of ribofl avin on fractures in elderly, in particular 
those with the MTHFR 222 ValVal genotype.
Moreover, the observed association between high dietary pyridoxine intake and 
low fracture risk suggests that pyridoxine may play a role in bone health. However, 
our data do not provide compelling evidence to support advice concerning the 
optimal overall pyridoxine intake in the elderly population. Therefore, it might be 
useful to perform a randomized double-blind placebo-controlled trials to confi rm the 
protective effect of pyridoxine in the elderly in relation to fracture risk.
Thus, the fi ndings of our studies (chapters 3 and 4) have some potential clini-
cal implications. The identifi cation of the polymorphisms that explain population 
variance in Hcy metabolism and their possible interaction with related B vitamin 
co-factors might lead to insights regarding the etiology of osteoporotic fracture, and 
may also provide preventive targets.
Future Studies
In this thesis we focused on variants in genes that are expected to be involved in 
Hcy metabolism. However, we studied only seven genes, and only a few variants per 
gene. Yet, for each gene many more (functional) variants exist and many more genes 
are likely to be involved in the Hcy metabolism. In future studies, the role of other 
polymorphisms regulating the enzymes and co-factors in this pathway should also 
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be investigated. In particular, studying a possible biologically plausible interaction 
of these polymorphisms with related co-factors for the relevant enzymes is certainly 
of interest.
Moreover, because most of our analyses were based on a single-center study 
and statistical power is limited to identify the contribution of all relevant candidate 
genes. Therefore, international multi-center studies collecting data on DNA and Hcy 
status are necessary. In addition, such large studies are necessary to reveal other 
polymorphic enzymes involved in Hcy metabolism but with (even) smaller effects. 
Finally, larger studies are required to obtain suffi cient interactions between these 
gene and dietary factors.
1- Genome wide association
Due to the rapid developments in the genotyping technology, we are now capable 
of assessing more than 500,000 single nucleotide polymorphisms (SNPs) in a single 
DNA sample. This SNP-chip technology will allow us to evaluate most of all existing 
variations in the human genome in relation to disease, or particular outcomes such 
as Hcy level. Interestingly, the Rotterdam Study will soon be screened with these 
high-density chips. This will allow to identify new pathways in relation to osteo-
porosis, and identifi cation of novel genes in the Hcy pathway that are involved in 
osteoporosis. Yet, a candidate gene approach still would be the next step to confi rm 
any novel region, including replication of association across several similar cohorts.
The candidate gene approach offers an important tool to assess genotype-pheno-
type relationships, and benefi ts from well-founded assumptions related to biological 
plausibility of the genes, comparatively low cost, and ease of analysis. Given the 
wealth of knowledge on the Hcy metabolic pathway this system offers excellent 
opportunities to study gene-environment interactions. The Hcy pathway is a well 
recognized and studied pathway and epidemiological and clinical studies have docu-
mented that nutrient intakes and their defi ciency are an important cause of increased 
Hcy levels. Therefore, another interesting line of research in the future would be to 
study gene-environment interaction especially for the Hcy pathway.
2- Randomized double-blind placebo-controlled trial
A randomized double-blind placebo-controlled trial is needed to further elucidate 
the role of the four B vitamins (B2, B6, B12, and folate) in bone health. Since a com-
mon cause of elevated Hcy levels is poor B vitamins status, most notably of vitamin 
B12 and folate, which together with Hcy are involved in the biological mechanism 
linking B vitamin status to fractures, we would suggest to examine fi rst vitamin B12 
and folate.
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Furthermore, the individuals who are at high risk of fracture (for example elderly 
≥ 70 years living at nursery home) with initial high Hcy levels (≥ 15 μmol/l), would 
be randomly selected in this trial to receive vitamin B12 and folate or placebo, after 
which Hcy levels, BMD and fracture will be systematically assessed.
3-System biology and Multi-locus approach
In complex phenotypes such as osteoporosis, fracture risk and Hcy level, multiple 
genes generally act through complex networks involving gene-gene and gene-
environment interaction. Accordingly, variants in each gene explain only a limited 
proportion of the phenotype thereby, making it diffi cult to defi ne to study which 
gene and how to assess such interaction. Therefore, multi-locus analysis is a logical 
approach to study the relation between Hcy pathway and bone health. Application 
of multi-locus analysis allows identifi cation and ranking of interacting polymor-
phisms and environmental factors that most prominently contribute to the variation 
of increasing Hcy levels.
System biology seeks to integrate different levels of information to understand 
how biological systems function by the study of the relationships and interactions 
between its various parts. It offers the potential to understand the complexity all 
factors determining Hcy levels in relation to osteoporosis. There is much knowledge 
about the Hcy metabolism which makes this approach possible. Especially, after the 
implementation of genome wide association to identify the most important genetic 
factors system biology in research on Hcy metabolism and bone health will be 
important. For example to help not only in the selection of suitable candidate genes 
that can be studied simultaneously, but also to evaluate and rank candidate genes in 
regions linked or associated to Hcy levels in relation to osteoporosis.
The complexity of the Hcy pathway illustrates the necessity for considering not 
only one gene, but multiple genetic polymorphisms of the enzymes and cofactors 
currently known to be involved in the Hcy metabolism. Finally, such combined 
genetic effects of the most prominent genes involved in the Hcy pathway should 
be studied in vitro and in vivo test systems to understand the underlying biological 
mechanism.
5- Recommendations
Several recommendations can be made based on the present thesis. First, more 
attention should be paid to the identifi cation of the most prominent genes involved 
in the complex Hcy pathway. Second, progress in this area can be expected from 
the genome wide association (GWA) studies (and replication effects) focussed on 
Hcy level and related endpoints. Third, there is a need to understand the underlying 
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biological mechanisms in order to implement targeted intervention by combining 
genetic information with requirements for specifi c co-factors.
Fourth, placebo controlled randomized trials are advised to evaluate possible 
cause-effect relationship between B vitamins and fracture risk. Such studies are likely 
to profi t from genotype-based patient selection based on the gene-environment 
interaction we have documented. Yet, given the relatively modest effect for each 
variant large confi rmation studies are mandatory. In the end personalized nutritional 
advice and the use of dietary supplements which are based on genetic information 
that is related to the requirements for specifi c co-factors, might help to reduce the 
incidence of osteoporotic fracture in the individual.
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SUMMARY
Osteoporosis is a skeletal disorder which predisposes a person to increased risk of 
fracture. Recently, a mildly elevated homocysteine (Hcy) levels has been found to 
predict fracture risk independent of bone mineral density (BMD) and other known 
risk factors. Since this fi nding, different nutritional determinants of Hcy, i.e. the vita-
mins B2 (ribofl avin), B6 (pyridoxine), B12 (cobalamin) and B11 (folate), have been 
investigated in relation to bone health. Despite these investigations, the pathogenesis 
underlying the association between Hcy and fracture risk is not fully understood.
The general aim of this thesis was to study the association between Hcy and 
osteoporosis by examining genetic and dietary determinants of Hcy status in rela-
tion to bone health. All the studies were performed within the Rotterdam Study, a 
population-based cohort study among 7,983 individuals aged 55 years and older.
Chapter 1 offers a general introduction to the studies and topics dealt within this 
thesis.
In chapter 2 we present a systematic review of the previously published studies on 
the relationship between Hcy levels, related B vitamins and bone phenotypes. Based 
on this systematic review it is still diffi cult to draw any defi nite conclusion due to 
heterogeneity in the methods of assessment and lack of a standardized threshold for 
categorizing low B-vitamin status. However, there are convincing data to support an 
association between Hcy levels and fracture, and also data were found that suggest 
an association between BMD and vitamin B12 and folate status.
In chapter 3 the relationship between dietary B vitamin intake and bone pheno-
types was investigated. It was shown that increased dietary ribofl avin and pyridoxine 
intake are associated with higher BMD. Furthermore, we reported that risk of fracture 
is reduced when dietary pyridoxine intake is high; this relationship was independent 
of BMD or co-morbidity.
Chapter 4 consists of two studies investigating the association between two poly-
morphisms involved in Hcy remethylation and bone phenotypes.
In chapter 4.1 we show that the MTHFR C677T variant interacts with dietary ribo-
fl avin intake to infl uence fracture risk in women. It was observed that neither the 
MTHFR C677T polymorphism nor low ribofl avin intake alone was associated with 
fracture risk or BMD. However, in the lowest quartile of ribofl avin intake, female 
677-T homozygotes had a higher risk for incident fractures. Furthermore, in the low-
est quartile of dietary ribofl avin intake, T-homozygous individuals (men and women 
combined) had higher Hcy levels compared with C-homozygotes. These results do 
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not, however, prove that elevated Hcy is the cause of the observed associations: In a 
subgroup for whom Hcy levels were available, adjustment of the increased fracture 
risk for homocysteine levels did not affect the risk estimates.
Chapter 4.2 describes the association between the MTR A2756G polymorphism, 
BMD, bone loss and fracture risk in women. We found that the G allele of the MTR 
A2756G polymorphism was associated with lower femoral neck BMD, and with lower 
lumbar spine BMD. Male individuals with the GG genotype had a higher rate of BMD 
loss compared with the AA genotype. A similar trend was observed in women, but 
did not reach signifi cance. The MTR A2756G GG women had a more than 200% 
higher risk for fragility fracture compared to women with the AA genotype. This 
increased risk of fracture seemed to be dependent on dietary B12 intake. Only in 
the presence of low dietary cobalamin intake did female MTR 2756-G homozygotes 
have a markedly increased risk for fragility fracture. Since this is a single center study 
and because the risk genotype has a low frequency in the population (3%), these 
fi ndings need to be replicated in other large cohorts.
The studies described in chapter 4 underline the infl uence of gene-environment 
interactions in the Hcy metabolism.
In chapter 5, we address the association between Hcy levels, eight polymorphisms 
in enzymes and proteins and dietary vitamin B intake involved in Hcy metabolism 
in a multivariate analysis model. It is shown that MTHFR C677T, MTR A2756G and 
RFC G80A infl uence Hcy levels in our study population. Furthermore, at baseline the 
MTHFR C677T polymorphism, dietary folate intake and dietary protein intake are the 
strongest independent predictors of Hcy levels after age and gender in our cohort. 
Interestingly, we observed an interaction between the MTHFR C677T and RFC G80A 
polymorphisms with low dietary folate intake in determining Hcy levels among the 
other studied variants and dietary intakes in our population. The study described 
in this chapter illustrates that Hcy metabolism is complex, resulting not only from 
underlying genetic variability and variability in environmental factors, but also from 
interaction between these factors.
Chapter 6 describes the effect of one of the most prominent candidate genes in 
osteoporosis, the COLIA1, which has been consistently associated with osteoporosis 
in different populations. We show that the COLIA1 Sp1 polymorphism is associated 
with BMD and fracture. However, in contrast to earlier reports from relatively small 
study populations, the -1997 G/T polymorphism showed no independent effect on 
fracture risk or BMD measures.
In the general discussion, chapter 7, the main fi ndings of the thesis are addressed. 
The results indicate that Hcy is associated with fracture. However, due to the 
generally modest effects of genetic variations on Hcy levels, in addition to limited 
knowledge on the pathogenetic mechanisms by which Hcy infl uences bone health, 
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additional research in the molecular fi eld is needed before one can draw any defi nite 
conclusion regarding causality. Nevertheless, our fi ndings provide a clinical rationale 
for a ribofl avin, pyridoxine, folate and B12 replete, if not supplemented, diet, in the 
aim to prevent osteoporosis in the elderly. Finally, our studies show that there is a 
need for better biological explanations in order to implement more targeted inter-
ventions. In the end personalized nutritional advice and the use of dietary supple-
ments which are based on genetic information that is related to the requirements 
for specifi c co-factors, might help to reduce the incidence of osteoporotic fracture 
in the individual.
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SAMENVATTING
Osteoporose (botontkalking) is een stoornis van het skelet dat iemand gevoeliger 
maakt voor het krijgen van fracturen. Recent is gebleken dat een mild verhoogde ho-
mocysteïne (Hcy) waarde een voorspellende waarde heeft voor de kans op fracturen, 
ongeacht de waarde van de botmineraal dichtheid (BMD) en andere bekende risi-
cofactoren. Sinds deze bevinding zijn verschillende voedingsdeterminanten van Hcy 
onderzocht in relatie tot de gezondheid van het bot. De onderzochte determinanten 
zijn de volgende B-vitamines: B2 (ribofl avine), B6 (pyridoxine), B12 (cobalamine) en 
B11 (foliumzuur). Ondanks deze studies wordt het onderliggende mechanisme van 
de associatie tussen Hcy en fractuurrisico nog onvolledig begrepen.
Het doel van dit proefschrift was de associatie tussen Hcy en osteoporose te 
bestuderen middels het bestuderen van de relatie tussen determinanten van Hcy 
(zowel genetische als voedings determinanten) en de gezondheid van het bot. Alle 
studies zijn uitgevoerd in de Rotterdam Studie, een groot bevolkingsonderzoek on-
der ongeveer 8000 mensen van 55 jaar en ouder die allen in de wijk Ommoord in 
Rotterdam woonden op het moment dat de studie begon.
Hoofdstuk 1 biedt een algemene introductie in de studies en onderwerpen die in 
dit proefschrift worden besproken.
In hoofdstuk 2 presenteren wij een systematische overzicht van de gepubliceerde 
studies over de relatie tussen Hcy waarden, gerelateerde B vitaminen en botfeno-
types. Gebaseerd op deze systematische review is het nog steeds moeilijk om een 
defi nitieve conclusie te trekken over de relatie tussen B-vitamines en gezondheid 
van het bot. Dit komt met name door de verschillende methodes die gebruikt zijn 
voor de statistische analyse en het bepalen van de B-vitamine status. Echter, er is 
overtuigende data beschikbaar die een associatie ondersteunt tussen de waarde van 
Hcy en fracturen en tevens is er data beschikbaar dat wijst op een verband tussen 
BMD en vitamine B12 en folaat status legt.
In hoofdstuk 3 werd de relatie tussen inname van vitamine B via het dieet en botfe-
notypes onderzocht. Hierin werd getoond dat een verhoogde inname van ribofl avine 
en een hogere inname van pyridoxine geassocieerd zijn met een hogere BMD. Daar-
naast rapporteerden wij dat het fractuurrisico gereduceerd is bij een hoge inname 
van pyridoxine; deze relatie was onafhankelijk van de BMD of co-morbiditeit.
Hoofdstuk 4 bestaat uit twee studies waarin de associatie tussen twee polymor-
fi smen, welke betrokken zijn bij remethylering van het Hcy, en botfenotypes werd 
onderzocht.
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In hoofdstuk 4.1 tonen wij dat de MTHFR C677T variant interactie vertoont met 
ribofl avine inname en zo het fractuurrisico in vrouwen beïnvloedt. Er werd ge-
zien dat zowel het MTHFR C677T polymorfi sme, als een lage ribofl avine inname 
niet geassocieerd was met het fractuurrisico of de BMD wanneer ze los van elkaar 
werden bestudeerd. Echter, in het laagste kwartiel van ribofl avine inname, hadden 
vrouwelijke 677-T homozygoten een hoger risico op incidente fracturen. Ook had-
den dezelfde vrouwen hogere Hcy waarden vergeleken met C-homozygoten. Deze 
resultaten bewijzen echter niet dat een verhoogd Hcy de oorzaak is van de geobser-
veerde associaties: in een subgroep van mensen voor wie Hcy waarden beschikbaar 
waren, beïnvloedde correctie van het verhoogde fractuurrisico voor verschillen in 
homocysteïne waarden de risicoschatting niet.
Hoofdstuk 4.2 beschrijft de associatie tussen een DNA variant in het gen wat 
codeert voor het enzyme methionine synthase (MTR A2756G) en gezondheidsken-
merken van het bot, zoals BMD, botverlies en fractuurrisico. Wij vonden dat het G 
allel van het MTR A2756G polymorfi sme geassocieerd was met een lagere BMD in de 
femurhals en in de lumbale wervelkolom. Mannen met het GG genotype hadden een 
hogere snelheid van BMD verlies vergeleken met het AA genotype. Een gelijksoortige 
trend werd geobserveerd in vrouwen, maar bereikte het signifi cantieniveau niet. De 
MTR A2756G GG vrouwen hadden een meer dan 200% hoger risico op een fractuur 
vergeleken met vrouwen met het AA genotype. Dit verhoogde fractuurrisico leek 
afhankelijk te zijn van diëtaire B12 inname. Alleen in de aanwezigheid van een lage 
diëtaire cobalamine inname hadden deze vrouwen een duidelijk verhoogd risico op 
fracturen. Aangezien het risico genotype een lage frequentie in de populatie heeft 
(3%), dienen deze bevindingen in andere grote cohorten gerepliceerd te worden. 
De studies die beschreven worden in hoofdstuk 4 onderstrepen het belang van 
gen-omgeving interacties in het Hcy metabolisme.
In hoofdstuk 5 bespreken wij de associatie tussen Hcy waarden, 8 polymorfi smen 
in enzymen en diëtaire inname van Hcy-gerelateerde B vitamines. Hierin wordt 
getoond dat 3 polymorfi smen Hcy waarden in onze studiepopulatie beïnvloeden: 
MTHFR C677T, MTR A2756G en RFC G80A. Verder zijn, na leeftijd en geslacht, het 
MTHFR C677T polymorfi sme, folaat inname en eiwit inname de sterkste onafhan-
kelijke voorspellers van Hcy waarden. Wij zagen bovendien een interactie tussen 
zowel MTHFR C677T als het RFC G80A polymorfi sme met een lage diëtaire folaat 
inname in het bepalen van Hcy waarden. De studie die in dit hoofdstuk wordt be-
schreven is illustratief voor de complexiteit van het Hcy metabolisme, wat niet enkel 
veroorzaakt wordt door de onderliggende genetische variabiliteit en verschillen in 
omgevingsfactoren, maar ook door interactie tussen deze factoren.
Hoofdstuk 6 beschrijft het effect van één van de meest prominente kandidaat-
genen in osteoporose, het COLIA1, welke consistent geassocieerd is met osteoporose 
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in verschillende populaties. Wij laten zien dat het COLIA1 Sp1 polymorfi sme geas-
socieerd is met BMD en fracturen. Maar, in tegenstelling tot eerdere bevindingen uit 
relatief kleine studiepopulaties, liet het –1997 G/T polymorfi sme geen onafhankelijk 
effect op fractuurrisico of BMD metingen zien.
In de algemene discussie, hoofdstuk 7, worden de hoofdbevindingen van dit proef-
schrift besproken. De resultaten wijzen erop dat Hcy geassocieerd is met fracturen. 
Echter, vanwege het over het algemeen bescheiden effect van genetische variaties 
op Hcy waarden, maar ook vanwege de beperkte kennis over het pathogenetisch 
mechanisme over de manier hoe Hcy de gezondheid van het bot beïnvloedt, is 
aanvullend onderzoek in het moleculaire vakgebied nodig voordat men conclusies 
kan trekken over causaliteit. Desalniettemin geven onze bevindingen een klinische 
rationale voor een aanvulling van ribofl avine en pyridoxine in het dieet, met als doel 
het voorkomen van osteoporose in ouderen. Tot slot laten onze studies zien dat 
betere biologische verklaringen nodig zijn om meer gerichte interventies te kunnen 
implementeren. Concluderend zouden persoonlijk voedingsadvies en het gebruik 
van voedingssupplementen, gebaseerd op genetische informatie die gerelateerd is 
aan de benodigdheden van specifi eke co-factoren, de incidentie van osteoporotische 
fracturen mogelijk
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